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ABSTRACT 
KRISTINE E. SHIELDS: The Participation of Pregnant Women in Clinical Research: 
Implications for Practice within the U.S. Pharmaceutical Industry 
(Under the direction of John E. Paul) 
 
Background: The treatment of medical conditions complicating pregnancy is 
challenged by a serious lack of information about the safety and effectiveness of the 
medications used by pregnant women. To improve our knowledge of what constitutes the 
most effective therapy, we conduct systematic research. Research for pregnant women, 
however, is challenging. The U.S. pharmaceutical industry is the leading conductor of 
clinical research, yet there is a dearth of published information from industry regarding 
pregnant women and drug studies. The extent of their exclusion has not been quantified, nor 
has its rationale been articulated. Industry input will be solicited when FDA releases its new 
guidance document on pregnant women in clinical research. 
Methods: To quantify the proportion of pharmaceutical company-sponsored studies 
that exclude pregnant women, we reviewed exclusion criteria from Phase IV trials posted on 
ClinicalTrials.gov from October 2011 – January 2012. To articulate the rationale for 
exclusion, we conducted key informant interviews (KIIs) with representatives from industry 
and related organizations.  
Results: Of 368 studies in which pregnant women could appropriately participate 
(drugs in FDA pregnancy categories A, B, or C and conditions that could occur during 
pregnancy), 94% excluded pregnant women. KIIs found that exclusion is primarily based on 
beneficence - the desire to avoid causing harm. Other issues include perceived risk of 
litigation, scientific validity, risk to drug approval and company reputation, and increased 
study complexity. Lack of advocacy, lack of regulatory requirement, and historic precedent 
are other barriers. However, KIIs also revealed that industry stakeholders agree with other 
advocates that pregnant women and their fetuses are at a higher risk of adverse medical 
consequences if they are not included in clinical trials than if they are included – and that 
opportunities exist within industry for more inclusive practices. 
Conclusion: We verified the perception that pregnant women are largely excluded 
from clinical studies and found that industry has both practical rationales for exclusion and 
recommendations to improve inclusion. This study adds industry's perspective to the 
dialogue on the barriers to, and opportunities for, a rational inclusion of pregnant women in 
clinical research to ultimately improve evidence-based treatment decisions for pregnant 
women.  
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PREFACE 
 
Introduction to the Principal Investigator: 
In October 2010, I participated on the organizing committee for the Drug Information 
Association's Maternal and Pediatric Drug Safety Conference held in Bethesda, MD.1 One of 
the invited speakers, Anne Drapkin Lyerly, presented a session entitled "How and When 
Should Pregnant Women Be Allowed to Participate in Clinical Trials?" She divulged that the 
pharmaceutical industry had not been included in recent meetings of thought leaders on this 
topic. She suggested that it was time for the industry to be brought into the dialogue.  
The pharmaceutical industry is uniquely positioned to play a meaningful role in this 
debate because of its influence on the conduct of clinical research in the U.S. where it funds 
more studies than any other organization including the National Institutes of Health.2 The 
industry is responsible for the research design, the research protocol, the inclusion and 
exclusion criteria, and the conduct of each of the studies they sponsor. Therefore, the 
pharmaceutical industry has a major influence on the extent to which pregnant women are 
included in clinical research studies.  
 
1Drug Information Association (DIA). (October 13-14, 2010.) Maternal and Pediatric Drug Safety Conference, 
Bethesda, MD.  
2 Pharmaceutical Research and Manufacturers of America. (2010). Press Release: R&D investment by U.S. 
biopharmaceutical companies reached record levels in 2010. Washington D.C. Retrieved on March 15, 
2011 from http://www.phrma.org/media/releases/rd-investment-us-biopharmaceutical-companies-
reached-record-levels-2010 
In my 10-year practice as an OB/GYN Nurse Practitioner, I cared for pregnant 
women in need of medical intervention. In my 12-year role as the director of a 
pharmaceutical company's pregnancy registry program, I worked in the industry and 
championed the collection and communication of safety information about drug exposures 
during pregnancy. I wrote and presented widely on the topic. With this background in 
obstetrical practice and pregnancy research in the pharmaceutical industry, I felt that I was 
uniquely positioned to raise and discuss the issue of pregnant women in clinical trials with 
my industry colleagues.  
Knowing many stakeholders involved in the issue - in industry, at FDA, in medical 
practice, and within academia - I would be able to access and articulate the issues involved 
from multiple perspectives. By raising the issue with industry colleagues, and by presenting 
this study's findings, I felt that I would be able to facilitate the dialogue and encourage 
industry's participation in the debate. I agree with the efforts being made to broaden pregnant 
women's access to clinical research and believe that progress will not be made without the 
participation of the pharmaceutical industry. This dissertation was conducted to contribute to 
these efforts and to promote multidisciplinary dialogue. 
 vii 
 
 TABLE OF CONTENTS 
 
List of Tables…………………………………………………...…………………………….xi 
List of Figures………………………………………………..………………………………xii 
List of Abbreviations……………………………………….……………………………….xiii 
Chapter 1. Background and Significance…………………………………………………..…1 
 A. Significance of the Issue and Problem Statement ………………………………...1 
B.  Background of the Issue…………………………………………………………..4 
C. Conceptual Framework……………………………………….…………………..17 
D.  Aims of the Study………………………………………………………………..20 
E. Plan for Change…………………………………………………………………...21 
Chapter 2. Literature Review………………………………………………………………...24 
 A.  Background and methodology…………………………………………………...24 
B.  Results……………………………………………………………………………26 
C.  Discussion………………………………………………………………………..27 
D.  Conclusion…………………………………………………...…………………..30 
E.  Presentation of findings…………………………………………………………..31 
Chapter 3. Ethical Framework……………………………………………………………….56 
A.  Theoretical approaches…………………………………………………………..57 
B.  Special considerations for pregnancy/maternal-fetal ethics………….…………..75 
C.  Conclusion: Application of the Ethical Framework to this Study……………….78 
 viii 
 
 Chapter 4. Study Design and Methods………………………………………………………82 
 A. Overall study purpose………………………………………………….…………82 
 B. Quantitative design & methods…………………………………………….……..83 
C. Qualitative design & methods………………………………………….…………90 
D. Plan for use of combined study results…………………………………………...95 
Chapter 5. Quantitative Results: Current practice…………………………………………...98 
A. Background……………………………………………………………….………98 
B. Results…………………………………………………………………………...100 
C. Discussion……………………………………………………………………….104 
D. Limitations………………………………………………………………………107 
E. Conclusion……………………………………………………………………….110 
Chapter 6. Qualitative Results and Discussion……………………………………………..113 
A. Background…………………………….………………………………………..113 
B. Study results and discussion……………………………………………………..115 
C. Ethical Considerations…………………………………………….……………..151 
D. Conclusion………………………………………………………………………152 
Chapter 7. The Plan for Change…………………………………………………………….155 
A.  Conceptual Framework…………………………………………………………155 
B.  Application of the Study Results to a Plan for Change…………………………157 
C.  Evaluation……………………………………………………………………….187 
D.  Conclusion……………………………………………………………………...191 
 
 ix 
 
 x 
 
Chapter 8. Discussion………………………………………………………………………192 
A.  The Impact of the Study on Public Health………………………….…………..192 
B.  Limitations……………………………………………………………………...196 
C. Ethical Considerations………………………………………………….………..198 
D. Conclusion.……………………………………………………………………...200 
E. Suggestions for further research…………………………………………………201 
Appendix I. The Ethical Principles Invoked For and Against the  
              Inclusion of Pregnant Women in Clinical Research………...………………...207 
Appendix II. The U.S. Drug Development Process…………………………………..….…208 
Appendix III. The Interview Guide……………………………………………………..….210 
Appendix IV. Qualitative Study Results: Key Findings from Key  
                       Informant Interviews……………………………………..…………………219 
Appendix V. The Plan for Change………………………………………………………....226 
Appendix VI. The White Paper………………………………………………………….…237 
Bibliography…………………………………………………………………………….….249 
 
LIST OF TABLES 
 
 
Table 1.1 Current federal policy on the inclusion of pregnant women in research…………..5 
Table 2.1 Results of literature review……………………………………………………….26 
Table 2.2 Rationales against the inclusion of pregnant women in clinical trials…………....32 
Table 2.3 Rationales for the inclusion of pregnant women in clinical research……………..42 
Table 3.1 Application of an ethical framework to this study………………………………..81 
Table 4.1 FDA Pregnancy Risk Categories………………………………………………….87 
Table 6.1 Participants' reasons why pregnant women are not included in clinical trials…..117 
Table 6.2 Factors that increase the risk of litigation by environment………..…………….135 
Table 6.3 Factors that decrease the risk of litigation by environment……………………...136 
Table 6.4 Key informants' reasons for including pregnant women in clinical trials……….141 
Table 6.5 Participants' observations, suggestions, and potential solutions…………………148 
Table 6.6 Barriers and solutions identified by key informants……………………………..154 
Table 7.1 Plan for Change in the Problem Stream: Understanding the Problem…………..161 
Table 7.2 Plan for Change in the Policy Stream: Proposing Solutions…………………….173 
Table 7.3 Contribution of this study in the policy cycle……………………………………177 
Table 7.4 Plan for Change in the Political Stream: Long-term advocacy………………….180 
Table 7.5 Evaluation of the Plan for Change……………………………………………….188 
Table 8.1 Ethical Guidance: Application of ethical principles to proposed solution………199 
 xi 
 
LIST OF FIGURES 
 
Figure 1.1 Influence and Interest of Stakeholders in Pregnant Women's  
      Participation in Clinical Research……………………...…………………………11 
 
Figure 5.1 Number of studies available for review on ClinicalTrials.gov between 
                 01Oct2011 and 31Jan2012 and their enrollment of pregnant women……….….102 
 xii 
 
LIST OF ABBREVIATIONS 
 
ACE – Angiotensin-converting-enzyme 
ACOG – American College of Obstetricians and Gynecologists 
BIO – Biotechnology Industry Organization 
CDC – U.S. Centers for Disease Control and Prevention 
CFR – Code of Federal Regulations 
CIOMS – Council for International Organizations for Medical Sciences 
COPD – chronic obstructive pulmonary disease 
DES – diethylstilbesterol 
EMA – European Medicines Agency 
FDA – U.S. Food and Drug Administration 
FDAMA – Food and Drug Modernization Act 
HIV – Human Immunodeficiency Virus 
IOM – Institute of Medicine 
IPA – International Pharmaceutical Abstracts 
IRB – Institutional Review Board 
KII – Key Informant Interview 
NIH - National Institutes of Health 
OB/GYN – Obstetrics and Gynecology 
OPRU – Obstetric-Fetal Pharmacology Research Unit 
PD - Pharmacodynamics 
PDUFA – Prescription Drug User Fee Act 
 xiii 
 
 xiv 
 
PhRMA – Pharmaceutical Research and Manufacturers' Association 
PI – Principal Investigator 
PK - Pharmacokinetics 
SPH – School of Public Health 
UNAIDS – Joint United Nations Programme on HIV/AIDS 
UNC – University of North Carolina 
WHO – World Health Organization
 Chapter 1 
Background & Significance 
 
 
A. Significance of the Issue and Problem Statement 
"The lack of drug studies in pregnancy constitutes a major public health problem."3 
"Each year over 400,000 women in the U.S. confront significant medical illness while 
pregnant."4 In addition to pregnancy-specific complications like gestational diabetes and pre-
term labor, medical conditions that occur in non-pregnant women occur in pregnant ones as 
well, including psychiatric illness, cancer, and infectious diseases. These conditions can have 
a devastating impact on the health of the pregnant woman and on the well-being of her fetus. 
The safe and effective treatment of medical conditions complicating pregnancy is challenged 
by a serious lack of information on the safety and effectiveness of medications used to treat 
illness.  Women's health care practitioners lament that the "current evidence base for the care 
of pregnant women facing illness is widely regarded as deplorable."5 
                                                 
3 Zajicek, A. & Giacoia, G.P. (2007). Clinical pharmacology: Coming of age. Clinical Pharmacology and 
Therapeutics, 81(4), 481-482. 
4Little, M.O., Faden, R., Lyerly, A.D., & Umas, J. (April, 2009). Workshop: The Second Wave: Toward the 
responsible inclusion of pregnant women in medical research. Georgetown University, Washington, 
D.C. Retrieved from http://kennedyinstitute.georgetown.edu/ secondwave/ 
5Lyerly, A.D., Little, M.O., & Faden, R.R. (2011). Reframing the Framework: Toward fair inclusion of 
pregnant women as participants in research. The American Journal of Bioethics, 11(5), 50-52, p. 51. 
 
The only way to improve our knowledge of what constitutes the most effective 
therapeutic interventions in these unfortunate circumstances is to conduct systematic 
research. Yet, despite the recommendations of subject matter experts like the U.S. Food and 
Drug Administration [FDA]6, the Institute of Medicine [IOM],7 the Council for International 
Organizations of Medical Sciences (CIOMS),8 and the American College of Obstetricians 
and Gynecologists (ACOG)9  to include pregnant women in drug research studies, exclusion 
is the norm.  Without information from research studies, clinicians, pregnant women and 
their supporters are left to make treatment decisions based on past practices, educated 
guesses, and gut feelings. We can and should do better than this. 
In the U.S., the pharmaceutical industry is the leading funder and conductor of 
clinical research studies.10 Yet there is a dearth of published information from the industry 
regarding pregnant women and drug studies. The extent of pregnant women's exclusion has 
not been quantified, nor has the industry's rationale for their exclusion been articulated.  
In order to improve the treatment of medically compromised pregnancies, proponents 
(such as ethicists, women's health advocates, and health care providers in academia, 
                                                 
6Feibus, K. & Goldkind, S.F. (May 17, 2011) Pregnant women and clinical trials: Scientific, regulatory, and 
ethical considerations. Oral presentation at the Pregnancy and Prescription Medication Use 
Symposium, Silver Springs, MD. 
7Mastroianni, A.C., Faden, R., & Federman, D. (Eds). (1994). Women and Health Research: Ethical and Legal 
Issues of Including Women in Clinical Studies. Institute of Medicine. Washington, DC: National 
Academy Press. 
8Council for International Organizations of Medical Sciences. (2002). International ethical guidelines for 
biomedical research involving human subjects. Retrieved on April 17, 2011 from www.cioms.ch. 
9American College of Obstetricians and Gynecologists. (2005) Maternal decision making, ethics, and the law. 
ACOG Committee Opinion No. 321. Obstetrics and Gynecology, 106, 1127-37. 
10Wendler, D. (Spring, 2009). Ethics of Clinical Research. In Zalta, E.N. (Ed.), The Stanford Encyclopedia of 
Philosophy. Retrieved April 26, 2011 from http://plato.stanford.edu/archives/spr2009/entries/ clinical-
research/ 
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government, and the health care system) want a change in practice towards a rational 
inclusion of pregnant women in clinical research. In order to accomplish this change, the 
current attitudes and practices of the pharmaceutical industry need to be better understood.  
The purpose of this concurrent mixed methods study was to better understand the 
U.S. pharmaceutical industry's practices and attitudes about the inclusion of pregnant women 
in clinical research. (To ensure focus and feasibility of completion, the study was limited to 
the U.S. pharmaceutical industry.) In this study, I quantified the proportion of pharmaceutical 
company-run studies that excluded pregnant women by reviewing relevant studies' exclusion 
criteria posted on ClinTrials.gov from October 2011 through January 2012. I also explored 
the attitudes of key opinion leaders in the U.S. pharmaceutical industry and related 
organizations, using qualitative interviews to identify key themes regarding the justification 
for exclusionary practices and the opportunities for inclusive ones.  
The results of the study will serve to inform the debate on proposals to change current 
practices in the U.S. pharmaceutical industry to broaden the inclusion of pregnant women in 
clinical studies when appropriate. The findings provide support for modifications of research 
protocols' inclusion/exclusion criteria, institutional review board (IRB) practices, and 
regulatory guidance. Alternative research designs and other legal, regulatory, and public 
policy solutions are addressed. Improved maternal-infant health outcomes resulting from 
improved knowledge of medication toxicities gained from clinical studies in human 
pregnancies are the ultimate goal. 
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 B. Background of the Issue 
"Pregnant women… are best protected through responsible inclusion in research, not broad-
based exclusion from it."11 
 
1. Federal Regulations 
As with research practices in general, guidelines regarding women's participation in 
research have evolved over time. Following the tragic outcomes related to the use of under-
studied but approved products by pregnant women in the 1960's, particularly 
diethylstilbesterol (DES) and thalidomide, federal regulations were changed to exclude 
women of childbearing potential from clinical trials. As the benefits of inclusion in research 
studies became more evident during the AIDS crisis in the 1980's, women began to advocate 
against their exclusion from studies. They began to question the accuracy of data derived 
from studies performed on men when applied to women. Through activism and advocacy, the 
regulations evolved until even pregnant women were permitted to participate in clinical 
trials. The current U.S. policy regarding the inclusion of pregnant women in federally funded 
research is codified in 45CFR46 Subpart B,12 also referred to as The Common Rule (see 
Table 1.1).   
 
                                                 
11Johns Hopkins Berman Institute of Bioethics. (Oct 5, 2009). Press Release, Research News: Second Wave 
Case Statement.  
12Code of Federal Regulations, Title 45, Vol. 1. (October 1, 2009). U.S. Government Printing Office via GPO 
Access [Cite: 45CFR46], 140-143. Retrieved from http://frwebgate.access.gpo.gov/ cgi-bin/get-cfr.cgi  
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    Table 1.1 Current Federal Policy on the Inclusion of Pregnant Women in Research13 
TITLE 45--PUBLIC WELFARE 
PART 46_PROTECTION OF HUMAN SUBJECTS  
Subpart B Additional Protections for Pregnant Women, Human Fetuses and Neonates 
Involved in Research 
 
Sec.  46.204  Research involving pregnant women or fetuses. 
 
    Pregnant women or fetuses may be involved in research if all of the following conditions 
are met: 
    (a) Where scientifically appropriate, preclinical studies, including studies on pregnant 
animals, and clinical studies, including studies on nonpregnant women, have been 
conducted and provide data for assessing potential risks to pregnant women and fetuses; 
    (b) The risk to the fetus is caused solely by interventions or procedures that hold out the 
prospect of direct benefit for the woman or the fetus; or, if there is no such prospect of 
benefit, the risk to the fetus is not greater than minimal and the purpose of the research is 
the development of important biomedical knowledge which cannot be obtained by any other 
means; 
    (c) Any risk is the least possible for achieving the objectives of the research; 
    (d) If the research holds out the prospect of direct benefit to the pregnant woman, the 
prospect of a direct benefit both to the pregnant woman and the fetus, or no prospect of 
benefit for the woman nor the fetus when risk to the fetus is not greater than minimal and 
the purpose of the research is the development of important biomedical knowledge that 
cannot be obtained by any other means, her consent is obtained in accord with the informed 
consent provisions of subpart A of this part; 
    (e) If the research holds out the prospect of direct benefit solely to the fetus then the 
consent of the pregnant woman and the father is obtained in accord with the informed 
consent provisions of subpart A of this part, except that the father's consent need not be 
obtained if he is unable to consent because of unavailability, incompetence, or temporary 
incapacity or the pregnancy resulted from rape or incest. 
    (f) Each individual providing consent under paragraph (d) or (e) of this section is fully 
informed regarding the reasonably foreseeable impact of the research on the fetus or 
neonate; 
    (g) For children as defined in Sec.  46.402(a) who are pregnant, assent and permission are 
obtained in accord with the provisions of subpart D of this part; 
    (h) No inducements, monetary or otherwise, will be offered to terminate a pregnancy; 
    (i) Individuals engaged in the research will have no part in any decisions as to the timing, 
method, or procedures used to terminate a pregnancy; and 
    (j) Individuals engaged in the research will have no part in determining the viability of a 
neonate. 
 
 
 
 
                                                 
13Code of Federal Regulations, Title 45, Vol. 1. (October 1, 2009). U.S. Government Printing Office via GPO 
Access [Cite: 45CFR46], 140-143. Retrieved from http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi. 
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 Essentially, the current regulations state that a pregnant woman may participate in a 
research study if: 
• Studies on animals and non-pregnant women have provided data that help define the 
potential risk to the mother/baby 
• AND the research will benefit either the mother or the babya  
• AND the study method provides the least possible risk to the mother/baby  
• AND the mother gives consentb  
• OR the mother and the father give consentc, d 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
a Studies that provide no direct benefit to the mother/baby may be conducted but the risk to the fetus must be 
minimal 
b For studies that benefit the mother, the mother/baby, or neither 
c For studies that only benefit the baby 
d The father's consent is not needed if he is unavailable, incompetent, incapacitated, or if the pregnancy resulted 
from rape or incest. 
 
While the Code of Federal Regulations now allows for the participation of pregnant 
women in research studies, it does not mandate their inclusion. Thus, the practice of 
including pregnant women in research studies remains uncommon.14 We know that many 
research protocols specifically exclude pregnant women15 but I have been unable to find any 
analysis on the extent to which they are excluded in the scientific literature. 
Of note to this research study, the FDA has on its 2011-2 docket of proposed 
guidance documents,16 one entitled, "Pregnant Women in Clinical Trials: Scientific and 
Ethical Considerations" on the inclusion of pregnant women in clinical trials. The guidance is 
                                                 
14Baylis, F. (2010). Opinion: Pregnant women deserve better. Nature, 465, 689-670, p. 689. 
15Hall, J.K. (1995). Exclusion of pregnant women from research protocols: Unethical and illegal. IRB: Ethics 
and Human Research, 17(2),1-3, p. 1. 
16FDA's Guidance Document To-Do List. (January 3, 2011). "The Pink Sheet".  
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currently in review at the agency. Although the period of review and the release of draft 
guidance documents is highly variable, particularly for potentially controversial topics such 
as this, it is slated for release in 2012.  
 
2. The Second Wave Consortium 
In October of 2007, Anne Drapkin Lyerly, an obstetrician/gynecologist and ethicist, 
then at the Trent Center for Bioethics at Duke University, along with colleagues Margaret 
Little (Kennedy Institute of Ethics, Georgetown University), Lisa Harris (University of 
Michigan) and Ruth Faden (Berman Institute of Bioethics, Johns Hopkins University) 
participated in a panel discussion at the American Society for Bioethics and Humanities 
annual meeting.17 The session was entitled, "The Second Wave: A Moral Framework for 
Clinical Research with Pregnant Women." The panel identified the "lack of an adequate 
moral framework for guideline development" to be a significant barrier to the inclusion of 
pregnant women in research – and one that sustains the near-universal presumption of 
exclusion – to the detriment of maternal and fetal health. (See Chap 3: The Ethical 
Framework of Clinical Research.) 
In 2008, Lyerly, Little, and Faden published a paper entitled, "The Second Wave: 
Toward Responsible Inclusion of Pregnant Women in Research."18  The paper highlighted 
the reasons that pregnant women should be included in research: to gain knowledge about 
                                                 
17American Society for Bioethics and Humanities Annual Meeting. (2007). Panel session: The Second Wave: A 
moral framework for clinical research with pregnant women. Retrieved Oct. 28, 2011 from 
http://www.asbh.org/uploads/files/meetings/annual/pdfs/broch07.pdf  
18Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22.  
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how to effectively treat pregnant women and keep the fetus safe, to prevent harm from 
withholding untested treatment that might be effective, for pregnant women to have the 
ability to decide for themselves whether to participate in studies, and to have access to the 
medicines available through research. The authors proposed that the exclusion of pregnant 
women from a research study should need to be justified – as opposed to the current practice 
of assuming exclusion unless inclusion can be justified. They proposed that the acceptance of 
inclusion and the justification for appropriate exclusion should be the norm and would 
benefit from an articulated ethical framework.  
In April of 2009, the three authors, joined by Jason Umans from Georgetown 
University Hospital, sponsored an invitation-only workshop to discuss the costs of excluding 
and the barriers to including pregnant women in medical research.  Various leaders in the 
field of women's health care research participated including those in academia (Georgetown, 
Johns Hopkins, Duke), government (National Institutes of Health [NIH], FDA), and other 
ethicists, women's health advocates, and health care providers.  The workshop sought to 
design actions to address priority issues and to discover what important information was still 
missing from the debate.  
Two key pieces of missing information related to the industry were identified by the 
workshop participants:  1) the perception of litigation risk [how influential is it and is it a real 
risk?] and 2) the role of the pharmaceutical industry [how influential is it in affecting the 
outcome of the debate?].19  This research study investigated both issues.  
It is worth noting that participation in the workshop was by invitation only and that 
no one from the pharmaceutical industry was invited. I recognize the need to limit the 
                                                 
19 Lyerly, A.D. (Nov. 12, 2010). Personal communication. 
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number of participants to those who were familiar with the issue. The participation of 
pregnant women in medical research is a sensitive topic that could be easily misunderstood 
and misconstrued by external audiences, particularly those with specific agendas regarding 
fetal protection. Describing the negative impact of non-participation is complex and is not 
easily captured in sound bites.  Workshop sponsors may have desired to limit the participants 
to those who understood the issues a priori and who could contribute to formulating actions 
that would further the agenda, including a plan to bring industry on board. However, I fear 
that the lack of an invitation to industry may be perceived as 1) a presumption of an 
adversarial position by industry and 2) a missed opportunity to acknowledge, educate, and 
involve a major stakeholder in the debate.   
The Second Wave Consortium is not the only group of stakeholders who promote the 
need to improve our capacity to perform research during pregnancy. A commentary 
addressed to the OB/GYN community in the British Journal of Obstetrics and Gynecology 
concluded that, "there needs to be a serious and ongoing debate about therapeutic research in 
the pregnant population and a consensus needs to be reached as to what levels of risk might 
be considered reasonable.20 
The debate is not limited to the U.S. but is currently being conducted globally. In fact, 
several documents from international agencies whose raison d'etre is the promulgation of 
                                                 
20Lupton, M.G.F., & Williams, D.J. (2004). The ethics of research in pregnant women: Is maternal consent 
sufficient? British  Journal of Obstetrics and Gynecology, 111, 1307-1312, p. 1308. 
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ethical standards for research activities, implicitly and explicitly promote the inclusion of 
pregnant women in clinical research.21  
Guideline 17 of the 2002 International Ethical Guidelines for Biomedical 
Research Involving Human Subjects of the Council for International 
Organizations of Medical Sciences (CIOMS)22 states: “Pregnant women 
should be presumed to be eligible for participation in biomedical research. 
Investigators and ethical review committees should ensure that prospective 
subjects who are pregnant are adequately informed about the risks and 
benefits to themselves, their pregnancies, the foetus and their subsequent 
offspring, and to their fertility."  
UNAIDS/WHO Guidance Point 923 states: “Researchers and trial sponsors 
should include women in clinical trials in order to verify safety and efficacy 
from their standpoint, including immunogenicity in the case of vaccine trials, 
since women throughout the life span, including those who are sexually active 
and may become pregnant, be pregnant or be breastfeeding, should be 
recipients of future safe and effective biomedical HIV prevention 
interventions. During such research, women’s autonomy should be respected 
and they should receive adequate information to make informed choices about 
risks to themselves, as well as to their foetus or breastfed infant, where 
applicable.” 
 
Stakeholders in the debate about pregnant women's expanded access to inclusion in 
clinical research are shown in Figure 1.1. I have illustrated what I believe to be their interests 
in, and influence on, the issue. Of course, pharmaceutical companies have their own 
stakeholders – stockholders, employees, product consumers, regulatory agencies worldwide, 
the U.S. tort system – many of whom have competing interests.  
                                                 
21Macklin, R. (2010). The art of medicine: Enrolling pregnant women in biomedical research. The Lancet, 375, 
632-633.  
22Council for International Organizations of Medical Sciences. (2002). International ethical guidelines for 
biomedical research involving human subjects. Retrieved on April 17, 2011 from www.cioms.ch. 
23UNAIDS/World Health Organization, Joint United Nations Programme on HIV/AIDS. (2007). Ethical 
considerations for biomedical HIV prevention trials: Guidance document. Geneva. Retrieved from 
http://data.unaids.org/pub/Report/2007/jc1399_ethical_ considerations_en.pdf 
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I don't believe that any individual stakeholder would disagree with the goal of 
providing health care providers and pregnant women with accurate information about the 
benefits and risks of treatment during pregnancy while minimizing research risks. But the 
self-interest of each group should be considered in the search for acceptable solutions. As 
proponents seek to create guidelines for the responsible inclusion of pregnant women in 
research, it is critical that the pharmaceutical industry articulate its perspective so that all 
issues and opinions are available for consideration and debate, fully illuminating 
opportunities for, and barriers to, better-informed decisions and policies. The evolution of 
safer and more inclusive research designs, regulations, and health care practices may result 
from this information sharing.  
 
Figure 1.1 Influence and Interest of Stakeholders in Pregnant Women's Participation in 
Clinical Research 
High 
Influence
Pharma
industry
Fetuses
IRBs
Healthy 
pregnant 
women
Low 
Influence
Low Interest High Interest
2nd Wave 
Consortium
FDA
Obstetricians
Health care 
providers
Sick 
pregnant 
women
CIOMS, 
WHO, EMA
 
 
*CIOMS = Council for International Organizations of Medical Sciences,  
   WHO = World Health Organization, EMA = European Medicines Agency 
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3. Consequences of the lack of information 
Studies indicate that over 60 percent of pregnant women are prescribed one or more 
drugs (not including vitamins) during their pregnancy.24,25 Inadvertent fetal exposure to acute 
or maintenance medication by women who do not yet realize that they are pregnant occurs 
frequently as about half of all U.S. pregnancies are unplanned.26  But we have little data on 
the safety and efficacy of most medications when they are used during pregnancy. A recent 
study found that safety in pregnancy was unknown for over 80% of the 468 drugs marketed 
in a recent 20-year period due to insufficient human data.27 This leaves the clinician and the 
patient not knowing how to interpret the little data that do exist - whether to take a potentially 
effective medication or not; the effect it may have on the woman, the fetus, or the pregnancy; 
or whether or not to terminate a pregnancy based on the exposure. Nor is it always apparent 
what the negative consequences will be if she doesn't take a medication, takes less of a 
medication, takes a different medication, or discontinues a medication. 
In my experience conducting pregnancy registries in a pharmaceutical company, I 
have spoken to women who had been advised by their physicians to consider terminating a 
pregnancy during which they had inadvertently used a medication or received a vaccine. 
None of the medications involved were suspected of causing birth defects. The desire to 
                                                 
24Andrade, S.E., Gurwitz, J.H. & Davis, R.L. (2004) Prescription drug use in pregnancy. American Journal of 
Obstetrics and Gynecology, 191, 398-407. 
25Glover, D.D., Amonkar, M., Rybeck, B.F. & Tracy, T.S. (2003). Prescription, over-the-counter, and herbal 
medicine use in a rural obstetric population. American Journal of Obstetrics & Gynecology, 188(4), 
1039-1045.  
26Henshaw, S.K. (1998). Unintended pregnancy in the United States. Family Planning Perspectives, 30:24-29. 
27Lo, W.Y. & Friedman, J.M. (2002). Teratogenicity of recently introduced medication in human pregnancy. 
Obstetrics & Gynecology, 100, 465-473. 
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decrease their liability risk if the infant was born with a birth defect is a potential motivation 
for such advice – but this is speculative. The number of women so advised and the number of 
pregnancy terminations resulting from inadvertent exposure to medication during pregnancy 
is unknown.  
Experimental drugs with unknown teratogenic potential would rarely be tested on 
pregnant women in the first trimester. “For humans, the teratogenic period is relatively short, 
lasting from implantation of the embryo in the uterus, which occurs 5 to 7 days after 
conception, until the 8th week of human development…”28  Unfortunately, however, this is 
the most common timing of inadvertent pregnancy exposures to marketed drugs  – prior to 
the mother’s suspicion of pregnancy at her first missed menstrual period.  
Overall there is an approximate 3 per cent risk of having a baby with a birth defect.29 
Most of the causes of these congenital anomalies are unknown  and medication exposures are 
known to induce a very small per cent.30 In fact, the vast majority of drugs and vaccines do 
not cause fetal harm.31 Preclinical animal testing has evolved greatly since the tragic impact 
of thalidomide and DES and, with one exception, all drugs that cause birth defects in humans 
have been shown to induce defects in animals as well. 32 However, it remains difficult to 
                                                 
28Frederiksen, M.C. (2008). Commentary: A needed information source. Clinical Pharmacology & 
Therapeutics, 83(1), 22-23. 
29Centers for Disease Control and Prevention. (2011). Birth defects. Washington, DC: Author. Retrieved Oct. 
28, 2011 from http://www.cdc.gov/ncbddd/birthdefects/data.html 
30Brent, R.L. (2004). Environmental causes of human congenital malformations: The pediatrician’s role in 
dealing with these complex clinical problems caused by a multiplicity of environmental and genetic 
factors. Pediatrics, 113(4), 957-968, p. 958. 
31Koren, G., Pastuszak, A., & Ito, S. (1998). Drugs in pregnancy. New England Journal of Medicine. 338, 1128-
1137, p. 1131. 
32Koren, G., Pastuszak, A., & Ito, S. (1998). Drugs in pregnancy. New England Journal of Medicine. 338, 1128-
1137, p. 1131. 
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identify rarely-occurring defects that are caused by drugs. For example, it was only recently 
ascertained that angiotensin-converting–enzyme (ACE) inhibitors, which have been on the 
market for over 20 years and were considered to be safe for use in the first trimester of 
pregnancy, increase the risk for cardiovascular and central nervous system defects.33 So, 
while the risk is small for most exposures, the uncertainty remains.  This situation leads to 
fear and potential overreaction by health care providers and pregnant women. Studies 
indicate that women and their health care providers tend to over-estimate the risk of 
medication-induced birth defects.34 
A tragic example of the consequences of such fears is the story told to me by a health 
care provider whose 7-months-pregnant patient discontinued her asthma medications so as to 
avoid exposing her baby in utero. She subsequently experienced an acute asthma 
exacerbation and died. The asthma medications she was taking are recommended to be 
continued during pregnancy because their risk to the fetus is less than the risk of poorly 
controlled asthma, as this tragic story illustrates.  
It is not only safety information that is lacking; there is a dearth of efficacy 
information as well. "Many physiological changes that women experience during pregnancy 
– such as increased plasma volume, body weight, body fat, metabolism and hormone levels – 
make it impossible to calculate dosage and efficacy information by extrapolating from data 
                                                 
33Cooper, W.O., Hernandez-Diaz, S., Arbogast, P.G., Dudley, J.A., Dyer, S., Gideon, P., …Ray, W.A. (2006). 
Major congenital malformations after first-trimester exposure to ACE inhibitors. New England Journal 
of Medicine, 354, 2443-2451. 
34Koren, G., Bologa, M., Long, D., Feldman, Y., & Shear, N.H. (1989). Perception of teratogenic risk by 
pregnant women exposed to drugs and chemicals during the first trimester. American Journal of 
Obstetrics & Gynecology, 160, 1190-1194. 
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on men and non-pregnant women."35 Only by conducting research on women in different 
trimesters of pregnancy can knowledge of dosing, timing, and efficacy be gained.  
The potential impact of a lack of data for drug efficacy during pregnancy is illustrated 
by the 2002 recommendation by the American College of Obstetricians and Gynecologists 
(ACOG) of the use of amoxicillin by pregnant women for anthrax post-exposure prophylaxis. 
Subsequent study, the results of which were published in 2007, showed that this dosage and 
frequency recommendation was ineffective for pregnant and post-partum women and no 
studies are available for ciprofloxacin or doxycycline, the alternative antibiotics.36 
Increased morbidity and mortality, inadequate treatment, the unnecessary termination 
of wanted pregnancies – these are the consequences of the lack of information about the 
safety and efficacy of medications used to treat illness during pregnancy.  
 
4. Ethical Issues 
"There is a tremendous reluctance to include pregnant women in research."37 
Concern about fetal safety is the primary motivation against researchers designing 
studies for pregnant women, against investigators including pregnant women, and against 
clinicians approaching pregnant women about participating in research studies – as well as 
the primary reason that pregnant women themselves decline to participate. 
                                                 
35Baylis, F. (2010). Opinion: Pregnant women deserve better. Nature, 465, 689-670, p. 689. 
36Andrew, M.A., Easterling, T.R., Carr, D.B., Shen, D. Buchanan, M., Rutherford, T., Bennet, R., Vicini, P., & 
Hebert, M.F. (2007) Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of 
dosage strategies. Clinical Pharmacology & Therapeutics, 81(4), 547-556.  
37Kennedy Institute of Ethics. (2010). The Second Wave workshop: Toward the responsible inclusion of 
pregnant women in medical research. Retrieved Oct. 28, 2010 from 
http://kennedyinstitute.georgetown.edu/ about/news/secondwave.cfm 
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Clinical trials have traditionally excluded pregnant women from participation due to 
this concern. But the ethics of this exclusion are subject to challenge due to the consequential 
lack of information on the safety and efficacy of medications to treat the multitude of 
medical conditions that occur during pregnancy.  
Which leaves us with an ethical conundrum – we want to improve the health of 
pregnant women and their babies, to do so we need to do research on pregnant women and 
their babies, to do so might harm pregnant women and their babies, therefore we can't do 
research to improve the health of pregnant women and their babies. Yet we do research with 
attendant risks on men and non-pregnant women. This begs the question, has too much 
emphasis on nonmaleficence in the pregnant population precluded us from achieving the 
health benefits of scientific research that have accrued to the non-pregnant population?  
The dilemma arises from a conceptual evolution in modern (i.e., developed nation's) 
obstetrical practice. With technological advances that allow health care providers to see, 
hear, and actually touch the fetus inside its mother's uterus, many have advanced the notion 
that the fetus is a patient in its own right. Prior to these individualizing capabilities, the 
mother-fetal dyad was widely considered to be a "patient package" – a unit. The fetus could 
only be evaluated indirectly - via palpation and measurement of the mother's abdomen, 
testing of the mother's blood, external fetal monitoring, etc. It wasn't until labor revealed the 
fetal scalp through the mother's dilating cervix that direct access to fetal blood was possible. 
The woman was considered to be somewhat of a barrier to be overcome in order to assess 
fetal status.38 In that milieau, the dependency of the fetus on the mother and the mother as the 
                                                 
38Rhoden, N.K. (1987). Informed consent in obstetrics: Some special problems. Western New England Law 
Review, 9(9)(1)/6, 67-88. 
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primary patient was obvious. With the advent of ultrasound, amniocentesis, umbilical cord 
blood testing, fetal surgery, and perinatology, however, many have advanced the notion of 
the fetus as a patient in its own right – sometimes as an individual, conceptually separable 
patient. Technological developments have led directly to the concepts of fetal rights and fetal 
'autonomy' in a clinical as well as a political sense.39,40  Our ethical conceptions evolve and 
adapt to encompass advances in technology.  
Nonmaleficence, the ethical dictate to avoid doing harm, may influence us to include 
or exclude pregnant women in studies. Beneficence, to do good, may influence us to include 
or exclude pregnant women in studies. But justice, the "equitable distribution of the burdens 
and benefits of research,"41 requires that we find a way to obtain evidence-based knowledge 
to formulate best practices to treat pregnant women and their fetuses.  [For further discussion, 
see Chapter 3. The Ethical Framework for Clinical Research.] 
 
C. Conceptual Framework 
In 1995, John Kingdon proposed a "Policy Window" theory of change in his book, 
Agendas, Alternatives, and Public Policies.42 In it, he identified three relatively independent 
issue workstreams whose interactions are required to advance social change. Kingdon called 
                                                 
39Rhoden, N.K. (1987). Informed consent in obstetrics: Some special problems. Western New England Law 
Review, 9(9)(1)/6, 67-88. 
40American College of Obstetricians and Gynecologists. (2005) Maternal decision making, ethics, and the law. 
ACOG Committee Opinion No. 321. Obstetrics and Gynecology, 106, 1127-37. 
41Levine, R.J. (1997). Ethics and Regulation of Clinical Research. New Haven, CT: Yale University Press, pp. 
67-93. In Weijer, C., Dickens, B., & Meslin, E.M. (1997). Bioethics for clinicians: 10. Research ethics. 
Canadian Medical Association Journal, 156(8), 1153-1157, p. 1154. 
42Kingdon, J. (1995). Agendas, Alternatives, and Public Policies, 2nd ed. New York: Harper Collins College. 
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the participants in the workstreams "policy entrepreneurs" – people who are "willing to 
invest their resources in return for future policies they favor." 
The three issue "streams," the Problem (recognition) stream, Policy (proposals) 
stream, and Political (influence) stream, can move along independently until a point in time 
when they "converge," often due to external forces. This convergence allows the issue and its 
potential solutions to be recognized across the workstreams. The "window of opportunity," if 
capitalized on by the entrepreneurs, can put the issue on the political agenda for resolution by 
the parties involved. The result is the advancement of social policy. 
Entrepreneurs in the problem recognition stream identify, describe, and frame an 
issue as a problem when it may not have been recognized as such before. Problem definitions 
often have an emotional values component which helps them to get on the agenda for change. 
Entrepreneurs in the policy stream contribute potential solutions to a "primeval soup" 
in which "ideas confront, compete, and combine with each other" and eventually result in 
policy formulation.43 The process relies on groups of interested and knowledgeable parties to 
propose multiple solutions that are both "technically feasible and consistent with policymaker 
and public values" and the policy entrepreneurs "must possess knowledge, time, 
relationships, and good reputations." 44 
The political stream is critical to getting the issue on the agenda for solution. The 
policy entrepreneur "recognizes the problem, attaches an appropriate policy proposal to it, 
                                                 
43Lieberman, J.M. (2002). Three streams and four policy entrepreneurs converge: A policy window opens. 
Education and Urban Society, 34(4), 445. 
44Stachowiak, S. (2009). Pathways for change: Theories about how policy change happens. Organizational 
Research Services. Retrieved from http://www.organizationalresearch.com/ 
publications_and_resources_featured.aspx 
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and floats the policy proposal in various forums"45 to bring it to the attention of the people 
with the power to place it on the agenda for change. Astute policy entrepreneurs can 
recognize the relationships among the event, the problem, and its proposed solutions and 
connect the streams. The result of the convergence of two or three of the streams is that "a 
compelling problem is linked to a plausible solution that meets the test of political 
feasibility."46  
Kingdon's Policy Window theory of change provides an appropriate framework with 
which to contextualize the compelling problem of pregnant women's exclusion from 
participation in clinical research. The release of the new FDA Guidance will initiate the 
convergence of a problem stream, a policy stream, and a political stream and provide the 
impetus that opens the "window of opportunity" for change. The issue and its potential 
solutions will be debated during the FDA call for public comment following its release. 
Kingdon recommended initiating special studies of social issues, providing indicators of the 
existence and magnitude of the problem, and promoting constituent feedback.47 This study 
provides indicators of the problem and policy options from constituents to the political 
debate.  
 
                                                 
45Lieberman, J.M. (2002). Three streams and four policy entrepreneurs converge: A policy window opens. 
Education and Urban Society, 34(4), 445. 
46Boussaguet, L., Jacquot, S., & Revinet, P. (2004). Dictionnaire des Politiques Publiques, Presses de la 
Fondation Nationale des Science Politiques, p. 217-225. Retrieved Oct. 12, 2011 from 
www.metagora.org/training/ encyclopedia/Kingdon.html 
47Stachowiak, S. (2009). Pathways for change: Theories about how policy change happens. Organizational 
Research Services. Retrieved from http://www.organizationalresearch.com/ 
publications_and_resources_featured.aspx 
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D. Aims of the Study 
"Alignment of vision among sponsors, caregivers, regulators, policy makers,  
and consumers is needed to ensure that pregnant women and their children  
are no longer 'therapeutic orphans.'"48 
 
This study sought to add research and scholarship to the debate about the inclusion of 
pregnant women in clinical trials – one of the aims of the Second Wave Consortium's effort 
to change the status quo. Another of its aims is to develop an advocacy agenda to raise 
awareness with lawmakers and influence legislation, which will be addressed in the Plan for 
Change (Chapter 7).49 
The study isolates, articulates, and communicates the opinions of selected 
pharmaceutical industry and related organization representatives about the inclusion and 
exclusion of pregnant women in clinical research studies. Attitudes and practices identified 
by speaking to experts who work in, or interact with, the industry, opportunities for, and 
barriers to, broadening the safe inclusion of pregnant women in clinical research.  
The aims of the study were to: 
1. Quantify the frequency of the participation of pregnant women in current 
pharmaceutical company-based studies by accessing the inclusion and exclusion 
criteria via ClinicalTrials.gov. (The Food and Drug Modernization Act of 2007 
mandates that all federally and privately funded clinical trials be posted on the NIH 
website, ClinicalTrials.gov.) 
2. Raise the issue to selected pharmaceutical industry representatives and related 
organizations to heighten their awareness of the issue and the debate. 
                                                 
48Zajicek, A. & Giacoia, G.P. (2007). Clinical pharmacology: Coming of age. Clinical Pharmacology and 
Therapeutics, 81(4), 481-482. 
49 Lyerly, A.D. (Nov. 12, 2010). Personal communication. 
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3. Isolate the concerns of the pharmaceutical industry representatives about including 
pregnant women in clinical trials to further our understanding of the reasons for, and 
potential barriers to, their inclusion. 
4. Isolate potential opportunities for inclusion of pregnant women in clinical trials from 
the pharmaceutical industry representatives' perspectives. 
5. Ascertain the selected pharmaceutical industry and related organization 
representatives' perspectives about the industry's role in shaping the debate. 
6. Describe the pharmaceutical industry and related organizations' representatives' 
perceptions of litigation risk.  
 
E. Plan for Change 
"Now is the time to make important changes to the rules and regulations governing research 
involving pregnant women…"50 
 
At the conclusion of the study, I will author a "White Paper" on the findings of my 
research and how they can be applied to the debate on the inclusion of pregnant women in 
clinical trials.  
A White Paper is an authoritative report or guide that helps solve a 
problem. White papers are used to educate readers and help people make 
decisions, and are often requested and used in politics, policy, business, 
and technical fields. Policy makers frequently request white papers from 
universities or academic personnel to assist policy developers with expert 
opinions or relevant research.51 
 
                                                 
50Kaposy, C. & Baylis, F. (2011). The Common Rule, pregnant women, and research: No need to "rescue" that 
which should be revised. The American Journal of Bioethics, 11(5), 60-62, p. 62. 
51Wikipedia contributors. (n.d.). White Paper. Retrieved July 15, 2011 from http://en.wikipedia.org/wiki/ 
White_Paper 
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 I will submit the paper to the biopharmaceutical industry's professional groups, 
PhRMA (Pharmaceutical Research and Manufacturers' Association) and BIO (the 
Biotechnology Industry Organization), to provide them with a better understanding of the 
issue, a prelude to what the FDA draft guidelines will likely contain, and – based on the 
results of this study – potential solutions to the problem. 
The paper may serve as an impetus to the creation of a PhRMA- or BIO-based 
guidance for industry practice and will assist PhRMA, BIO, and individual pharmaceutical 
companies respond to the call for public comment following the release of FDA's draft 
guidance, "Pregnant Women in Clinical Trials: Scientific and Ethical Considerations."  In 
addition, I plan to participate in the formulation of PhRMA's response by assisting my 
employer in the review of PhRMA's proposed response and/or the in the creation of a 
company-specific response to the FDA's call for comment.  
The White Paper will also be shared with the key informants who participated in the 
study so that they can share the results within their companies and organizations. In that way, 
the study results will contribute to debate in multiple settings and disciplines.  
In addition to the creation of a white paper for industry, I will publish the results of 
the quantitative study in the peer-reviewed scientific literature. The publication will not only 
share information to increase awareness and initiate discussion, it will also provide a measure 
of the prevalence of the exclusion of pregnant women from clinical trials. This measure can 
then serve as a baseline against which to evaluate the impact of efforts to improve the 
inclusion of pregnant women in clinical trials. 
I am also prepared to speak on the topic at workshops or conferences. Having 
established a reputation as an industry opinion leader on pregnancy registries, I receive 
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invitations to speak on the subject of drug safety in pregnancy. I will seek out opportunities 
to add my voice to the public debate in these forums. The information I gather from the 
process of conducting the study will also be shared with colleagues via my continued 
participation in industry groups and organizations that are concerned with maternal health.  
 Chapter 2 
Literature Review 
 
 
A. Background and methodology 
The Committee on the Ethical and Legal Issues Relating to the Inclusion of Women 
in Clinical Studies was convened by the Institute of Medicine in 1992 at the request of the 
NIH Office of Research on Women's Health. The committee was asked to investigate, report 
findings, and propose recommendations to improve the inclusion of women, women of 
childbearing potential, and pregnant women in clinical studies. Their 1994 report on women 
and health research made several recommendations52 including 
• that pregnant women be presumed to be eligible for participation in clinical studies 
and  
• that the decision about whether to participate or not should be made by the woman, 
following the provision and discussion of risk and benefit information by the 
investigator. 
Almost two decades later, these recommendations have not been fully implemented. What 
arguments support or inhibit the adoption of the IOM's recommendations? 
                                                 
52Mastroianni, A.C., Faden, R., & Federman, D. (Eds). (1994). Women and Health Research: Ethical and Legal 
Issues of Including Women in Clinical Studies. Institute of Medicine. Washington, DC: National 
Academy Press. 
 
Lit Review question: 
• Why should pregnant women be excluded from clinical trials? 
• Why should pregnant women be included in clinical trials? 
Constructs: 
1. Pregnant women 
2. Include/inclusion 
3. Exclude/exclusion 
4. Clinical studies (clinical trials, research studies, drug studies, medical research) 
 
Methods: 
To locate and obtain literature pertaining to the study constructs, a search for relevant 
papers was conducted through an electronic search of bibliographic databases available 
through the UNC Health Sciences Library. The electronic databases searched included 
Google Scholar, PubMed, and International Pharmaceutical Abstracts. These three data 
sources were chosen because they encompass the interdisciplinary, medical/clinical, and 
pharmaceutical domains. 
Searches were limited to papers in English about humans that were available from the 
UNC Health Sciences Library either electronically or in hard copy by request. Retrievals 
were initially screened by title and abstract for inclusion for further review. Excluded during 
review, were papers about studies evaluating the treatment of specific diseases or conditions 
in pregnancy - unless the paper also addressed the reasons for the inclusion or exclusion of 
pregnant women in the study. Final inclusion was based on a review of the full paper. 
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Constructs for the initial search included the following terms: pregnant or pregnancy 
(pregnan*), and include or inclusion (inclu*), and "clinical study." These terms were repeated 
substituting exclude or exclusion (exclu*) in place of inclusion.  Other search terms were 
tried including pregnan* and "inclusion criteria", "pregnant in clinical trials", and finally, 
"inclusion of pregnant" and "exclusion of pregnant" which achieved the best results. 
 
B. Results 
Results from the literature review were initially limited (see Table 2.1) The original 
concept was too broad and resulted in thousands of papers about clinical studies in pregnancy 
-- but few addressed the specific topic of why pregnant women should or should not be 
included in clinical studies. Most of these papers were on the results of clinical and non-
clinical studies pertinent to pregnancy. Because the initial searches resulted in thousands of 
"hits," I limited my review of those findings to the first 50 papers in each. If relevant papers 
were identified, I continued to search the next 50, and so on. Subsequently limiting the search 
to the more specific terms, "inclusion (or exclusion) of pregnant" resulted in a higher number 
of relevant returns. 
 
      Table 2.1 Results of literature review 
                          Databases: 
 Terms: Google Scholar PubMed (MedLine) 
International 
Pharmaceutical 
Abstracts 
Pregnan*, inclu*, "clinical 
trial" 0/1
st 50 of 18K 0/1st 50 of 3K 0/22 
Pregnan*, exclu*, "clinical 
trial" 1/1
st 50 of 16K 0/1st 50 of 751 0/2 
Pregnan*, "inclusion 
criteria" 0/ 1
st 50 of 19K 0/1st 50 of 1444 0/33 
Pregnant in clinical trials 2/1st 50 of 185K 9*/1
st 50 of 6614 
0/2nd 50 of 6614 0/1 
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"inclusion of pregnant" 49/1st 200 of 258 6/1st 200 of 907 0/1 
"exclusion of pregnant" 23/1st 200 of 686 5/1st 200 of 407 0/0 
       *All 9 were from the American Journal of Bioethics, May 2011, Issue 11(5).  
 
The references cited in the papers acquired via the review process were also evaluated 
for pertinent papers not otherwise identified. In addition, papers known to the author were 
searched for key words, themes, and citations of papers that addressed the literature review 
questions. These additional papers were included in the review results.  
 
C. Discussion 
Using the initial search parameters, I identified papers that were almost exclusively 
about the results of research studies on the treatment of diseases or conditions in pregnant 
women. I was at first heartened by the number of studies that involved pregnant women. But 
on closer look, I noted that relatively few were drug safety and efficacy studies for pregnant 
women with various disease states. For example, in a quick review of the first 100 papers 
retrieved from Medline, I noted that 39 were not interventional trials (this group included 
topics like diet, obesity, exercise, etc.), 26 were about infectious disease (mostly HIV, 
malaria, and sexually transmitted infections), 10 were about conditions specific to pregnancy, 
5 were about alternative therapies (moxibustion, acupuncture), 4 each on diabetes and 
tobacco or substance abuse, 2 on cancer, and 1 each on other conditions seen in the non-
pregnant population (cholesterol, mental health, hypothyroidism, etc.). While not conclusive 
by any means, this did seem to suggest that the common diseases in the population (heart 
disease, cancer, cerebrovascular disease, COPD, etc.) that could also affect pregnant women 
were not being studied in pregnant women. These papers, however, did not meet the goals of 
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the literature review as they did not discuss the inclusion or exclusion of pregnant women in 
the studies.  
Of note: No papers were identified whose topic was the 
evaluation of a subpopulation of pregnant women in a 
study that included both pregnant and non-pregnant 
subjects.  
 
One paper entitled "Eligibility criteria of randomized controlled trials published in 
high-impact general medical journals" listed "sex-specific conditions such as menstruation, 
pregnancy, or lactation" in a table under the title, "Poorly Justified Reasons for Excluding 
Individuals for a Trial."53  This classification, however, was not accompanied by a numeric 
value. The paper did not provide a count of the number or the proportion of published trials 
that excluded pregnant women from their eligibility criteria. 
Of note: No papers were identified that quantified the 
exclusion of pregnant women from clinical studies. 
 
The preponderance of papers identified that addressed the subject of the 
inclusion/exclusion of pregnant women in clinical studies were about the practical and ethical 
problems associated with their exclusion and the need for their inclusion. Papers defending 
their continued exclusion were not found.  I am speculating that, because exclusion is the 
accepted status quo, there is little perceived need to discuss, rationalize, explain, or defend it. 
Whereas interested parties who believe that pregnant women should be included feel the 
                                                 
53Van Spall, H.G.C., Toren, A., Kiss, A., & Fowler, R.A. (2007). Eligibility criteria of randomized controlled 
trials published in high-impact general medical journals. Journal of the American Medical Association, 
297, 1233-1240, p.1235.  
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need to provide their rationale to make their case and to build support for a change in the 
status quo. 
  Of note: No papers were identified on the topic of why 
pregnant women are or should continue to be excluded. 
  
Also of interest was the annual publication of the "FDA Guidance Document To-Do 
List" in the January 3, 2011 edition of "The Pink Sheet,"54 a weekly publication covering the 
prescription pharmaceutical industry. On its list of topics the Center for Drug Evaluation and 
Research is considering for the coming year is the "Responsible Inclusion of Pregnant 
Women in Clinical Trials." David Kessler, former FDA Commissioner, stated in 1993 that 
the FDA planned to "develop recommendations… that will facilitate the conduct of trials in 
pregnant women and result in more such trials."55 Seventeen years later the regulatory 
agency has the inclusion of pregnant women in clinical research on its to-do list.  
Guidance documents, while not binding, do provide standards and expectations and 
are closely adhered to by industry. Verified in an FDA presentation on the topic,56 the draft 
guidance document is currently in "internal review" at the agency. The length of a review 
period is variable, so it is not known when it will be released to the public. Once it is 
released, there is usually a 90-day comment period, where members of the public and other 
interested parties, including the pharmaceutical industry, can provide feedback to the agency 
                                                 
54FDA's Guidance Document To-Do List. (January 3, 2011). "The Pink Sheet".  
55 Kessler, D.A., Merkatz, R.B., & Temple, R. (1993). Authors response to Caschetta, M.B., Chavkin, W., & 
McGovern, T. Correspondence: FDA policy on women in drug trials. New England Journal of 
Medicine, 329(24), 1815-1816. 
56Feibus, K. & Goldkind, S.F. (May 17, 2011) Pregnant women and clinical trials: Scientific, regulatory, and 
ethical considerations. Oral presentation at the Pregnancy and Prescription Medication Use 
Symposium, Silver Springs, MD. 
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about the document. Stated Kessler, "The FDA believes that it is critical to obtain a broad 
range of views on these matters from the public as well as from experts in the fields of 
medicine, health care, ethics, and the law, and we are committed to facilitating that 
exchange."57 Following the comment period, the document is then re-reviewed and revised 
within FDA and ultimately, a final guidance document is published. The process can 
sometimes take several years to complete.   
 
D. Conclusion 
The findings of the literature review support the need for a better understanding of the 
practice of, and the rationales for, excluding pregnant women from clinical studies. Since no 
reference was found that quantifies the exclusion of pregnant women from research studies, 
the assumption that the practice is extensive should be verified. Because no papers were 
identified solely on the topic of why pregnant women should continue to be excluded from 
participation in clinical studies, there remains a gap in knowledge. Many of the rationales for 
excluding pregnant women from clinical trials (discussed below) were extracted from papers 
on the subject of why we need to include them. Therefore, these findings may be biased and 
may not reflect the actual thinking of the proponents of exclusion. The literature review 
supports the need to directly ask those responsible for the exclusion (such as pharmaceutical 
company sponsors and IRB members) for their reasoning to verify the rationales stated by 
proponents of inclusion and to make the justifications explicit. Because FDA is preparing a 
                                                 
57Kessler, D.A., Merkatz, R.B., & Temple, R. (1993). Authors response to Caschetta, M.B., Chavkin, W., & 
McGovern, T. Correspondence: FDA policy on women in drug trials. New England Journal of 
Medicine, 329(24), 1815-1816. 
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guidance document for industry on the inclusion of pregnant women in clinical trials, it is 
even more imperative to explore industry's practices and perspectives on the issue. Explicit 
information will be useful during the public debate on the topic. 
 
E. Presentation of Findings 
Findings from the electronic database review with the addition of supplemental 
papers acquired in the course of researching this topic resulted in the acquisition of many 
rationales both supporting the inclusion of pregnant women in clinical research and 
supporting the exclusion of pregnant women from clinical research. I have grouped these 
rationales into "buckets" to facilitate their presentation and discussion below. See Tables 2.2 
and 2.3.  
The reason for not including pregnant women in clinical trials is commonly stated as, 
"Of course, we can't ethically test drugs on pregnant women."58 Yet there are robust ethical 
principles that support the arguments both for and against the participation of pregnant 
women in clinical research. Similar rationales were sometimes cited to support both inclusion 
and exclusion (e.g., fetal safety, legal risk).  Because the topic of this study is laden with 
ethical issues, I have categorized each identified rationale for and against inclusion by the 
ethical principle that best applies to the reasoning therein.  (See Appendix I: Ethical 
Principles Invoked For and Against the Inclusion of Pregnant Women in Clinical Research).  
For further discussion on the ethical framework for pregnant women in clinical research see 
Chapter 3. Ethical Framework. 
                                                 
58Greenwood, K. (2010). The mysteries of pregnancy: The role of law in solving the problem of unknown but 
knowable maternal-fetal medication risk. University of Cincinnati Law Review, 79, 267-322, p. 274. 
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 1. Rationales against the inclusion of pregnant women in clinical research 
"Primum non nocere - First, do no harm"59 
 
Table 2.2 Rationales against the inclusion of pregnant women in clinical trials: 
1 The uncertain effect of new drugs on the mother and/or the fetus 
2 Litigation risk - Because birth defects are relatively common, they may occur unrelated to the experimental drug exposure, and result in spurious litigation 
3 The number of pregnant women needed to participate in the study in order to achieve statistical significance is unachievable 
4 Safer study designs are available 
5 Alternative treatments are often available 
6 Little return on investment 
7 Regulations do not require inclusion 
  
Rationale #1: The uncertain effect of new drugs on the mother and/or the fetus.60 [Ethical 
rationale: Non-maleficence] 
 
 The risk of unforeseen adverse effects on the woman, on the pregnancy, and on the 
fetus from exposure to the experimental compound is too uncertain to include pregnant 
women in clinical trials. This risk is one of the most frequently cited reasons for the 
exclusion of pregnant women from clinical research.61,62,63,64,65 
                                                 
59Gillon R. (1985). Primum non nocere and the principle of non-maleficence. British Medical Journal, 291, 
130. 
60Mohanna, K. & Tunna, K. (1999). Witholding consent to participate in clinical trials: Decisions of pregnant 
women. British Journal of Obstetrics and Gynaecology 1999, 106, 892-897, p.892. 
61Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22.  
62American College of Obstetricians and Gynecologists' Committee on Ethics. (2007). ACOG committee 
opinion: Research involving women. Obstetrics & Gynecology, 110(3), 731-736, p. 732. 
63Beran, R.G. (2006). The ethics of excluding women who become pregnant while participating in clinical trials 
of anti-epileptic medications. Seizure, 15, 563-570.  
64Weijer, C. (1999). Selecting subjects for participation in clinical research: One sphere of justice. Journal of 
Medical Ethics, 25, 31-36, p. 34. 
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The FDA acknowledges this issue. The "potential risks of fetal injury, the definition 
of circumstances under which such risks are justified, and the design of trials that will 
properly address the risks raise many challenging medical, scientific, legal, and ethical 
questions," stated David Kessler, former FDA Commissioner, in a 1993 editorial response.66 
Assurance of drug safety is dependent on the size and composition of the population 
studied in the clinical trials. (See Appendix II for a review of the U.S. drug development 
process.) The size of the studies is dependent upon a number of factors including the burden 
of the disease in the population which affects the number of subjects available to participate. 
Other considerations include cost and urgency – some studies of diseases for which there are 
few or ineffective treatments may require smaller sample sizes in order to get the product to 
patients more expeditiously. 
The results of animal studies do not always accurately predict the effects of treatment 
on human pregnancies.67,68 While animal reproductive studies are very important in 
identifying potential teratogenic effects in human gestation, they are not definitive. (A 
teratogen, from the Greek teras meaning monster,69 is any substance that causes congenital 
malformations.) Positive findings of teratogenicity in animals do not mean the drug will 
cause birth defects in humans, and conversely, the absence of teratogenic effects in animals 
                                                                                                                                                       
65 Zajicek A and Giacoia GP. Clinical pharmacology: Coming of age. Clinical Pharmacology and Therapeutics 
2007; 81(4):481-482.  
66 Kessler DA, Merkatz RB and Temple R. Authors response to Caschetta MB et al. Correspondence: FDA 
policy on women in drug trials. New England Journal of Medicine 1993; 329(24):1815-1816. 
67Macklin, R. (2010). The art of medicine: Enrolling pregnant women in biomedical research. The Lancet, 375, 
632-633. 
68Brent, R.L. (2004). Utilization of animal studies to determine the effects and human risks of environmental 
toxicants. Pediatrics, 113, 984–995. 
69 Wikipedia. "Teratology," available at http://en.wikipedia.org/wiki/Teratology, accessed 15 July 2011. 
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does not ensure safety for human fetuses.70 The number of unintended pregnancies that 
inadvertently occur in Phase II and III clinical trials is too few to provide accurate data and 
such subjects are usually disenrolled upon confirmation of the pregnancy. Therefore, we 
cannot rely on animal testing and preliminary clinical trials to know, or to reassure pregnant 
women, that it is safe to participate in clinical research.  
 
Rationale #2: Litigation risk - Because birth defects are relatively common, they may occur 
unrelated to the experimental drug exposure, and result in spurious litigation. [Ethical 
rationale: Financial stewardship] 
 
An increased risk of both warranted and spurious lawsuits against pharmaceutical 
companies and researchers is one of the reasons given for the exclusion of pregnant women 
from clinical studies that is cited by many authors.71,72 ,73,74 ,75 Merton calls this "tort 
phobia
                                                
."76 
 
70Brent, R.L. (2004). Utilization of animal studies to determine the effects and human risks of environmental 
toxicants. Pediatrics, 113, 984–995. 
71 Lyerly A, Little MO, & Faden R. Perspective: Pregnancy and clinical research. The Hastings Center Report 
2008; 38(6):[pages unnumbered]. 
72American College of Obstetricians and Gynecologists' Committee on Ethics. (2007). ACOG committee 
opinion: Research involving women. Obstetrics & Gynecology, 110(3), 731-736, p. 732. 
73Greenwood, K. (2010). The mysteries of pregnancy: The role of law in solving the problem of unknown but 
knowable maternal-fetal medication risk. University of Cincinnati Law Review, 79, 267-322, p. 274. 
74Charo, R.A. (1993). Protecting us to death: Women, pregnancy, and clinical research trials. Saint Louis 
University Law Journal, 38,135-187. 
75 Kaposy, C. & Baylis, F. (2011). The Common Rule, pregnant women, and research: No need to "rescue" that 
which should be revised. The American Journal of Bioethics, 11(5), 60-62, p. 62. 
76Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 400. 
 34 
 
According to population-based research studies, the risk of having a baby with a birth 
defect is about 3% for major congenital anomalies77 (structural defects with surgical, 
medical, or serious cosmetic consequences)  and up to 15% for minor anomalies78 (structur
defects that are usually of no surgical, medical, or serious cosmeti
al 
c consequences79).  The 
risk of 
 likely 
 the 
 
 
aracteristic 
                                                
having a baby with a specific birth defect varies widely – from 1 in 100 infants for 
heart defects to 1 in 5,000 for rare disorders like anencephaly.80   
Therefore, if 100 pregnant women were to participate in a clinical study, it is
that 2 to 4 babies in the study would be born with a major birth defect unrelated to their 
exposure to the experimental drug provided in the study. However, the mother, the 
researcher, reviewers of the study findings, and litigators could erroneously conclude that
defect was a result of the exposure. The drug could be incorrectly labeled as teratogenic and
the drug's sponsor could be subject to litigation. This misinterpretation could occur even 
though teratogenic agents are understood to produce specific phenotypic effects depending 
on the time in gestation of the exposure. In other words, it would be unlikely for a drug to
cause a cleft lip in one child and a club foot in another. The injury is usually a ch
 
77Correa, A., Cragan, J.D., Kucik, J.E., Alverson, C.J., Gilboa, S.M., Balakrishnan, R.,…Chitra, J. (2007). 
Metropolitan Atlanta Congenital Defects Program, 40th anniversary edition surveillance report.  Birth 
Defects Research, Part A:  Clinical and Molecular Teratology, 79(2), 1-120. 
78 Rasmussen, S., Olney, R., Holmes, L., Lin, A., Keppler-Noreuil, K., Moore, C., & the National Birth Defects 
Prevention Study. (2003). Guidelines for case classification for the National Birth Defects Prevention 
Study. Birth Defects Research (Part A), 67, 193-201. 
79 Rasmussen, S., Olney, R., Holmes, L., Lin, A., Keppler-Noreuil, K., Moore, C., & the National Birth Defects 
Prevention Study. (2003). Guidelines for case classification for the National Birth Defects Prevention 
Study. Birth Defects Research (Part A), 67, 193-201. 
80March of Dimes. (2011). Birth Defects. Retrieved on May 2, 2011 from http://www.marchofdimes.com/ 
Baby/birthdefects.html 
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l  have been approved for use in pregnancy since 1962 
pports the observation that U.S. pharmaceutical companies are reluctant to develop drugs 
r the litigious obstetrical market.84 
                                                
r cluster of effects that is readily identifiable and reproduceable. But lawyers a
juries do not always recognize the principles and complexities of teratogenesis. 
There is an actual and unfortunate example of this phenomenon. Bendectin, a 
combination of pyridoxine (vitamin B6) and doxylamine (an antihistamine), which are both 
available over the counter as separate medications, was approved and is effective for the 
treatment of nausea and vomiting during pregnancy. Despite having been extensively stud
in animal, clinical, and epidemiologic studies81 with no findings of measureable risk to the 
developing fetus,82 the product was withdrawn from the market in 1983 due solely to the 
burdens of litigation.83 The product remains on the market in the UK and Canada where it is 
widely used. In addition to the absence of an effective treatment for hyperemesis gravidarum 
on the U.S. market, an alleged consequence of this "litigation effect" is the reluctance of U.S
pharmaceutical companies to develop drugs for use during pregnancy. The fact that only two
medications – oxytocin and cervidi  –
su
fo
 
 
 
 
81Brent, R.L. (1995). Bendectin: Review of the medical literature of a comprehensively studied human 
nonteratogen and the most prevalent tortogen-litigen. Reproductive Toxicology Review, 9(4), 337-349. 
82Brent, R.L. (2007). How does a physician avoid prescribing drugs and medical procedures that have 
reproductive and developmental risks? Clinics in Perinatology 2007; 34:233-232, p. 252. 
83 Brody, J. (1983, June 19). Shadow of doubt wipes out Bendectin. New York Times.  
84Wing, D.A., Powers, B., & Hickok, D. (2010). U.S. Food and Drug Administration drug approval: Slow 
advances in obstetric care in the United States. Obstetrics & Gynecology, 115(4), 825-833.  
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Rationale #3: The number of pregnant women needed to participate in the study in order to 
show efficacy may be unachievable. [Ethical rationale: Non-maleficence] 
 
Clinical trials are conducted for two primary purposes – to measure efficacy and t
evaluate safety. In order to efficiently observe the clinical endpoints that confirm or refute 
efficacy, the characteristics of subjects permitted to enroll are usually narrowly define
People with renal impairment, children, and the elderly, for example, are populations that a
regularly excluded from initial trials in order to avoid added complexity. Sometimes 
additional trials for these specific subpopulations are conducted after initial studies on th
more homogeneous population have established efficacy. In addition to the safety concern
the complex physiologic changes associated with the advancing stages of gestation, can 
justify the exclusion of pregnant women from participation in early clinical trials. Blood 
volume, renal clearance, body mass index, and hormone levels fluctuate throughout the 
pregnancy. Trials specifically designed to evaluate efficacy in the pregnant population wo
be more likely to achieve results that advance evidence-based care, but di
o 
d. 
re 
e 
s, 
uld 
fficulty with the 
recruitm
 
                                                
ent and retention of pregnant women may be an obstacle.85 Baylis cautions that, 
"Persuading pregnant women to take part in research can be difficult."86  
Evaluating safety, specifically the potential for a new drug product to induce birth 
defects, would be even more difficult. “Populations of several thousand would be needed to
 
85Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 400, p.396. 
86Baylis, F. (2010). Opinion: Pregnant women deserve better. Nature, 465, 689-670, p. 689. 
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assess if the background risk produced by a particular treatment changes the rate of birth 
defects in general. If we are interested in a specific birth defect that occurs at a rate of 1 in 
1000 or fewer, then to demonstrate that a drug does not produce a specific birth defect wo
require treated and non-treated populations on the order of tens to hundreds of thousands 
pregnant women.”
uld 
of 
umbers are not feasible. Therefore, the evaluation of 
uman teratogenicity cannot rely upon clinical trials but requires accumulated data from 
 
87 Clearly these n
h
other sources (see Rationale #4).   
Rationale #4: Safer study designs are available. [Ethical rationale: Beneficence] 
One of the requirements of 45CFR46 to allow pregnant women to participate in 
research is that the study is designed to provide the least possible risk to the mother and the 
fetus.  Alternate methods of identifying drug-induced birth defects, including pregnancy 
registries, case studies, pharmacovigilance, and case-control studies,  though not definitive, 
do not subject pregnant women to the risks of clinical trials, including the risk of recei
placebo instead of a potentially effective medication.  These alternative study approaches are
performed after the drug has been approved and is on the market. States Greenwood, 
"epidemiological studies may be the only way to generate information about both rare b
88
ving a 
 
irth 
defects and long-term effects" and these can only be done after the drug is approved and 
                                                 
88Feibus, K. & Goldkind, S.F. (May 17, 2011) Pregnant women and clinical trials: Scientific, regulatory, and 
87Mattison, D. & Zajicek, A. (2006). Gaps in knowledge in treating pregnant women. Gender Medicine, 3(3), 
169-182, p. 180. 
ethical considerations. Oral presentation at the Pregnancy and Prescription Medication Use 
Symposium, Silver Springs, MD.  
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marketed.  Brent agrees that, "[w]ell performed epidemiology studies are still the best 
method for determining the human risk and the effects of environmental toxicants."  Once 
basic science, animal testing, and clinical study data have been collected and analyzed and 
have met FDA standards of benefit/risk analysis acceptable for license approval, then studies
of the safety of use in human pregnancy can be performed on marketed drugs. It is safer for
the mother and fetus if th
89
90
 
 
e safety of a product is as well-established as possible before it is 
sed during pregnancy.  
Ration
u
 
ale #5: Alternative treatments are often available. [Ethical rationale: Beneficence] 
In fact, we can never assure pregnant women that it is safe to participate in clinical
research, because we can never prove that a drug is safe in all women at all times. So it is 
prudent to err on the side of caution and not subject pregnant women and their fetuses to the 
risks of medical research. Instead, health care providers should continue to use best practice
guidelines and the medical literature to prescribe treatment that has been shown to be sa
and effective over time. Brent advises that the "obstetrician can avoid product lia
litigation by not prescribing drugs that have reproductive risks for the mother or 
developmental risks for the developing embryo or fetus."
 
 
fe 
bility 
                                                
91 Only in situations where the 
current treatment is not effective and significant morbidity or mortality to the mother or the 
fetus is likely should we resort to the use of an experimental medication. If the condition is 
 
89Greenwood, K. (2010). The mysteries of pregnancy: The role of law in solving the problem of unknown but 
knowable maternal-fetal medication risk. University of Cincinnati Law Review, 79, 267-322, p. 291. 
90Brent, R.L. (2004). Utilization of animal studies to determine the effects and human risks of environmental 
toxicants. Pediatrics, 113, 984–995. 
91Brent, R.L. (2007). How does a physician avoid prescribing drugs and medical procedures that have 
reproductive and developmental risks? Clinics in Perinatology 2007; 34:233-232, p. 252. 
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not life-threatening or medically significant, we can utilize palliative measures or encourage 
tolerance of short-term discomfort to ensure that we provide the safest prenatal environment 
ossible to protect the fetus from iatrogenic harm. 
Rationa
p
 
le #6: Little return on investment. [Ethical rationale: Financial stewardship] 
Pharmaceutical companies are publically held entities that have a responsibili
shareholders to increase profit and decrease loss. We have discussed the difficulties 
associated with conducting clinical trials on pregnant women. Recruiting, enrolling, and 
retaining a sufficient number of pregnant women to ensure that their participation will be 
statistically significant and generalizable to a larger population would be costly and has little 
hope of success. Even if the benefit of the product can be shown to be greater than the risk of 
adverse effects, the market of pregnant women is relatively minimal. Therefore, the com
may rationally decide that the actual cost of drug development and the potential cost of 
litigation exceed any potential financial gains.
ty to 
pany 
orces 
edical risk while also exposing the 
compan
.'"93  
The author of this statement admits, however, that "finding that a drug is unsafe for use 
                                                
92 The experience with Bendectin reinf
this case (see Rationale #2).  Enrolling pregnant women would expose the pregnant 
participants and their non-consenting fetuses to m
y to significant legal and financial risk. 
In addition, "a company that performs studies on one of its already-approved drugs 
risks 'generating results that could destroy the value of the product rather than enhance it
 
92Charo, R.A. (1993). Protecting us to death: Women, pregnancy, and clinical research trials. Saint Louis 
University Law Journal, 38,135-187. 
93Eisenberg, R.S. (2005). The problem of new uses. Yale Journal of Health Policy, Law, & Ethics, 5, 717-718. 
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during pregnancy could leave its broader market unaffected."94 But negative publicity 
generated by the correct or erroneous finding that a drug causes birth defects, could affect 
sales, particularly among women of childbearing potential. 
Also, limiting enrollment in research studies to non-pregnant women only is less 
complicated, less costly,95 and more efficient. The long-term result is that "therapies will 
become available sooner and cost less."96 
 
Rationale #7 – Regulations do not require inclusion. [Ethical rationale: Financial 
stewardship] 
 
The U.S. regulations (Code of Federal Regulations 45CFR46 Subpart B,97 or the 
Common Rule) state that pregnant women may participate in research studies under certain 
conditions. They do not state that pregnant women must be included in research studies or 
that pregnant women must be given the option to participate in research studies. The decision 
as to whether to include or exclude pregnant women from studies is left to the sponsor of the 
study or the IRB that approves the study. Until regulators make the inclusion of pregnant 
                                                 
94Eisenberg, R.S. (2005). The problem of new uses. Yale Journal of Health Policy, Law, & Ethics, 5, 717-718. 
95Kaposy, C. & Baylis, F. (2011). The Common Rule, pregnant women, and research: No need to "rescue" that 
which should be revised. The American Journal of Bioethics, 11(5), 60-62, p. 62. 
96Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 389. 
97Code of Federal Regulations, Title 45, Volume 1. (October 1, 2009). U.S. Government Printing Office via 
GPO Access [Cite: 45CFR46], 140-143. Retrieved from http://frwebgate.access.gpo.gov/ cgi-bin/get-
cfr.cgi 
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women mandatory, sponsors will continue to avoid the potential legal and financial risks by 
mandating exclusion.98,99 
 
2.  Rationales for the inclusion of pregnant women in clinical trials 
“Pregnant women get sick and sick women get pregnant” 100 
 
 
Table 2.3 Rationales for the inclusion of pregnant women in clinical research 
1 To acquire knowledge that improves the medical treatment of pregnant women (and their fetuses) 
2 To improve birth outcomes 
3 To improve pregnant women's access to the benefits of clinical research 
4 To improve the ethical acquisition of information about exposed pregnancies 
5 Because regulations do not require the exclusion of pregnant women 
6 Excluding pregnant women from participating in medical research is unethical and  illegal - and may increase litigation risk 
7 To follow the advice of experts in the field of women's health, law, and ethics 
 
Rationale #1 – To acquire knowledge that improves the medical treatment of pregnant 
women (and their fetuses). [Ethical rationale: Beneficence, Non-maleficence]  
 
Many authors agree that the primary reason to consider the inclusion of pregnant 
women in research studies is to provide evidence-based treatment guidelines to improve the 
health of pregnant women and their babies.101,102,103,104 The lack of information about how to 
                                                 
98Baylis, F. (2010). Opinion: Pregnant women deserve better. Nature, 465, 689-670, p. 689. 
99Kaposy, C. & Baylis, F. (2011). The Common Rule, pregnant women, and research: No need to "rescue" that 
which should be revised. The American Journal of Bioethics, 11(5), 60-62, p. 62. 
100Baylis, F. (2010). Opinion: Pregnant women deserve better. Nature, 465, 689-670, p. 689. 
101McCullough, L.B., Coverdale, J.H., & Chervenak, F.A. (2005). A comprehensive ethical framework for 
responsibly designing and conducting pharmacologic research that involves pregnant women. 
American Journal of Obstetrics and Gynecology, 193, 901-907. 
102American College of Obstetricians and Gynecologists' Committee on Ethics. (2007). ACOG committee 
opinion: Research involving women. Obstetrics & Gynecology, 110(3), 731-736, p. 732. 
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treat the more than 9 million pregnant women with chronic conditions and the millions more 
who develop new medical conditions during pregnancy is a significant problem.105 Because 
they have not been systematically evaluated in pregnant women, practically all medications 
used to treat illness during pregnancy are prescribed without FDA approval – essentially off-
label use.106  
Obstetricians, says Lyerly, "care for their patients without meaningful data regarding 
[drug] safety and efficacy..."107 "Many physiological changes that women experience during 
pregnancy – such as increased plasma volume, body weight, body fat, metabolism and 
hormone level – make it impossible to calculate dose and safety information by extrapolating 
from data on men and non-pregnant women."108,109   
Effective medical care is based upon trial and error – and the systematic collection 
and analysis of data from research conducted in vitro and in vivo over time.  Lyerly argues 
that the whole "purpose of the enterprise of clinical research is to take responsible, limited, 
                                                                                                                                                       
103Greenwood, K. (2010). The mysteries of pregnancy: The role of law in solving the problem of unknown but 
knowable maternal-fetal medication risk. University of Cincinnati Law Review, 79, 267-322, p. 274. 
104Feibus, K. & Goldkind, S.F. (May 17, 2011) Pregnant women and clinical trials: Scientific, regulatory, and 
ethical considerations. Oral presentation at the Pregnancy and Prescription Medication Use 
Symposium, Silver Springs, MD. 
105Greenwood, K. (2010). The mysteries of pregnancy: The role of law in solving the problem of unknown but 
knowable maternal-fetal medication risk. University of Cincinnati Law Review, 79, 267-322, p. 274-5. 
106Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22, p. 6. 
107Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22, p. 6. 
108Baylis, F. (2010). Opinion: Pregnant women deserve better. Nature, 465, 689-670, p. 689. 
109Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22, p. 5.  
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and calculated risks in order to garner evidence…"110 The results of these efforts inform and 
guide clinical practice. Excluding pregnant women from participation in research studies on 
new medication results in a lack of knowledge about the effectiveness, the appropriate 
dosage, and the potential side effects of medication when used during pregnancy – a time 
when the patient is most concerned about safe and effective treatment.  
This lack of knowledge can and does result in a number of adverse consequences for 
the medically compromised pregnancy. These include withholding treatment, under-
treatment, or overexposure of pregnant women and their fetuses.111  Pregnant women are 
prescribed medications with "no real basis for predicting their effects."112 Health care 
providers may be reluctant to prescribe and pregnant women themselves may discontinue 
medications – both of which may lead to the lack of effective management of medical 
conditions during pregnancy. They may lower the dose of the medication thinking that it will 
decrease the exposure to the fetus. However, this can result in the exposure of a fetus with no 
therapeutic benefit to the mother.  Conversely, standard dosages of some medications may 
result in overdosing of the pregnant woman due to physiologic changes during gestation.  
Sadly, lack of knowledge can and does lead to the elective termination of wanted pregnancies 
based on an unwarranted fear of birth defects following the exposure. I have been told first-
hand, and Kass et al. agree, that physicians have encouraged women to terminate pregnancies 
and pregnant women have terminated otherwise wanted pregnancies based on an inflated 
                                                 
110Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22, p. 8. 
111Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22, p. 5. 
112Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 400, p. 382. 
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perception of the risk of teratogenicity – "despite the fact that fewer that 30 drugs are proven 
human teratogens"113 and the percentage of birth defects caused by medication is very low.114  
Ironically, since women are excluded from much research in an effort to protect the 
fetus from harm, "significant harm to the child may result from not providing [maternal] 
treatments. The number of cases in which medications are given inappropriately during 
pregnancy constitutes a fraction of the number in which indicated therapy is inappropriately 
withheld."115  States Lott, "the benefits of barring pregnant women from participating in 
research may, in the end, harm expecting mothers and their foetuses more than their inclusion 
in clinical trials."116 
 
Rationale #2 – To improve birth outcomes. [Ethical rationale: Beneficence, Non-
maleficence] 
 
According to U.S. Department of Health and Human Services, the U.S. ranks 27th 
among industrialized nations in infant mortality.117 The infant mortality rate, the rate at which 
                                                 
113Kass, N.E., Taylor, H.A., & Anderson, J. (2000). Treatment of human immunodeficiency virus during 
pregnancy: The shift from an exclusive focus on fetal protection to a more balanced approach. 
American Journal of Obstetrics and Gynecology, 182(4), 1-5. 
114Brent, R.L. (2007). How does a physician avoid prescribing drugs and medical procedures that have 
reproductive and developmental risks? Clinics in Perinatology 2007; 34:233-232, p. 233. 
115Kass, N.E., Taylor, H.A., & Anderson, J. (2000). Treatment of human immunodeficiency virus during 
pregnancy: The shift from an exclusive focus on fetal protection to a more balanced approach. 
American Journal of Obstetrics and Gynecology, 182(4), 1-5. 
116 Lott, J.P. (2005). Module three: Vulnerable/special participant populations. Developing World Bioethics, 
5(1), 30-53, p. 48. 
117 U.S. Health & Human Services. (Jan. 13, 2006). Fact sheet: Preventing infant mortality. Washington D.C.: 
HHS Press Office. Retrieved from http://www.hhs.gov/news. 
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babies die before their first birthday, was 6.9 deaths per 1000 live births in 2003.118 
Contributing factors include disparities among racial and ethnic groups, congenital 
anomalies, prematurity, and maternal complications.119 Medical research is needed to prevent 
and treat these and other life-threatening conditions.  
Healthy babies are dependent upon healthy mothers and healthy pregnancies.  Fetal 
health can be compromised by conditions that affect women in general (e.g., lupus) or 
conditions specific to pregnancy (e.g., pre-eclampsia) or conditions of fetal origin (e.g., Rh 
incompatibility). Lack of knowledge about the efficacy or negative impact of various 
medications constrains treatment options and restricts the abilities of health care providers to 
provide the best care possible.  Birth outcomes are compromised. Therefore, improved fetal 
safety – often cited as a reason for the exclusion of pregnant women from research – can be 
just as effectively cited as a justification for the inclusion of pregnant women in research.120  
"Due to the underrepresentation of pregnant women in research, clinicians and women face 
treatment decisions in the context of a dearth of evidence about how drugs work in pregnant 
bodies, what doses are safe and effective,…and which drugs pose teratogenic risk for fetuses 
– a dearth that often leads to reticence to prescribe or take indicated drugs, to the detriment of 
maternal and fetal health."121 
                                                 
118U.S. Health & Human Services. (Jan. 13, 2006). Fact sheet: Preventing infant mortality. Washington D.C.: 
HHS Press Office. Retrieved from http://www.hhs.gov/news. 
119U.S. Health & Human Services. (Jan. 13, 2006). Fact sheet: Preventing infant mortality. Washington D.C.: 
HHS Press Office. Retrieved from http://www.hhs.gov/news.  
120Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22. 
121Lyerly, A.D., Little, M.O., & Faden, R.R. (2011). Reframing the Framework: Toward fair inclusion of 
pregnant women as participants in research. The American Journal of Bioethics, 11(5), 50-52,                
p. 51. 
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 Rationale #3 – To improve pregnant women's access to the benefits of clinical research. 
[Ethical rationale: Justice] 
 
"Restriction of trials to non-pregnant individuals excludes a class of potential 
beneficiaries and places them at an unfair disadvantage…" state Lyerly et al.122 Participating 
in a clinical trial can provide benefits such as "possible therapeutic advantage, better outcome 
of disease, closer monitoring than in routine practice, getting attention for other ailments, 
better physical and laboratory health checks, superior physicians, labs, and testing, more 
contact with the providers, access to contacts for future health information, remuneration, 
and contributions to society.123 
To Lupton and Williams, "pregnant women are often treated with drugs that have 
been superseded in every other branch of medicine…because newer drugs have not been 
fully investigated in the pregnant population."124 Clinical trials provide access to current 
potential advances in medicine and health care practice. Advocates for populations that have 
been excluded from participation in research studies (i.e., women, people living with 
HIV/AIDS, and children) have fought for, and succeeded in achieving, inclusion. "The 
former complete exclusion of fertile women led to more deaths of women with HIV than 
                                                 
122Lyerly, A.D., Little, M.O., Faden, R. (2008). The Second Wave: Toward responsible inclusion of pregnant 
women in research. International Journal of Feminist Approaches in Bioethics, 1(2), 5-22, p. 6. 
123Iber, F.L., Riley, W.A., & Murray, P.J. (1987). Conducting Clinical Trials, New York: Plenum Press. In 
Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) 
from biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 378. 
124Lupton, M.G.F., & Williams, D.J. (2004). The ethics of research in pregnant women: Is maternal consent 
sufficient? British  Journal of Obstetrics and Gynecology, 111, 1307-1312, p. 1308. 
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men and eventual revision of exclusionist policies."125,126  FDA has since revised its 
restrictions and now believes it is essential to include pregnant women when it is their only 
way to access potentially life-saving treatments that are under investigation.127 Including 
pregnant women in clinical studies would improve their access to new medications and better 
health care that could improve their health and health of the pregnancy.  
 
Rationale #4 – To improve the ethical acquisition of information about exposed pregnancies. 
[Ethical rationale: Non-maleficence, Autonomy] 
 
Ruth Macklin states that the most compelling reason for the inclusion of pregnant 
women in clinical research "is the need for evidence gathered under rigorous scientific 
conditions, in which fewer women and their fetuses would be placed at risk than the much 
larger number who are exposed to medication once they come to the market."128 
For the vast majority of pregnancies in which medications have been prescribed, the 
birth outcomes are never recorded. According to Berlin, "pregnant women who must take 
certain medications are essentially participating in an uncontrolled and unmonitored 
experiment for which the data will most likely never be assessed.129   
                                                 
125Cain, J., Lowell, J, Thorndyke, L, & Localio, A.R. (2000). Contraceptive requirements for clinical research. 
Obstetrics & Gynecology, 95(6), 861-866, p. 863. 
126Edgar, H., & Rothman, D.J. (1990). New rules for new drugs: The challenge of AIDS to the regulatory 
process. Milbank Quarterly, 68, 111-114. 
127Macklin, R. (2010). The art of medicine: Enrolling pregnant women in biomedical research. The Lancet, 375, 
632-633. 
128Macklin, R. (2010). The art of medicine: Enrolling pregnant women in biomedical research. The Lancet, 375, 
632-633. 
129Berlin, J.A. & Ellenberg, S.S. (2009). Commentary: Inclusion of women in clinical trials. BMC Medicine, 
7(56), 1-3. 
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Hall adds the additional point that "the quality of informed consent is better in a 
research setting than in the post-marketing environment where prescriptions are written with 
little instruction and little follow-up is done."130  "[T]he assumption seems to be that the 
researcher, or perhaps the IRB member, or perhaps a federal bureaucrat [or perhaps, I would 
add, the pharmaceutical company] is the best choice to judge the net harm and benefit, risk 
and advantage, that would result from a pregnant woman's participation in a protocol."131 
Rather, the well-informed pregnant woman, who, by being pregnant, has not lost her ability 
to evaluate information, judge risk, or make decisions for herself and her fetus, should be the 
one who decides.132 ,133   
Lack of knowledge about medication use during pregnancy has lead to efforts to 
collect information about pregnancy outcomes from women who take medications in the 
post-marketing environment – after the products have been approved. For example, 
pregnancy registries, studies that evaluate birth outcomes from women who have used 
approved medications during their pregnancies, have been established for some medical 
conditions and for some medications but they are usually not required by FDA for new drugs. 
                                                 
130Hall, J.K. (1995). Exclusion of pregnant women from research protocols: Unethical and illegal. IRB: Ethics 
and Human Research, 17(2):1-3, p. 2. 
131Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 399. 
132Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 399. 
133Beran, R.G. (2006). The ethics of excluding women who become pregnant while participating in clinical 
trials of anti-epileptic medications. Seizure, 15, 563-570. 
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But, warns Macklin, "surveillance activities…lack the rigor of the scientific gold standard: a 
prospective, randomized clinical trial in which pregnant women are enrolled."134 
 
Rationale #5 – Regulations do not require the exclusion of pregnant women. [Ethical 
rationale: Justice] 
 
The Declaration of Helsinki states, "Populations that are underrepresented in medical 
research should be provided appropriate access to participation in research."135 But the U.S. 
Common Rule "does little to promote research inclusion for pregnant women."136 
According to Hall, "there is no regulatory reason for excluding pregnant women from 
many studies."137 Historically, women of childbearing potential were excluded from 
participating in studies based on the study sponsor's overinterpretation of the regulations that 
had only excluded them from the first and earliest part of the second phase of studies.138 The 
exclusion of pregnant women from participation may be, in part, based on a similar 
misinterpretation.   
According to current regulation, pregnant women may be included in studies under 
certain circumstances. Various study designs have been proposed that can decrease the risk to 
                                                 
134Macklin, R. (2010). The art of medicine: Enrolling pregnant women in biomedical research. The Lancet, 375, 
632-633. 
135World Medical Association. (2008). Declaration of Helsinki. Retrieved on Aug. 25, 2011 from 
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and Human Research, 17(2):1-3, p. 2. 
138Merkatz, R. (1998). Inclusion of women in clinical trials: A historical overview of scientific, ethical, and 
legal issues. Journal of Obstetrical, Gynecologic, and Newborn Nursing, 27(1), 78-84, pp. 79-80. 
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the fetus while still providing for the inclusion of pregnant women. In fact, the IOM, in its 
2010 report, "Women's Health Research: Progress, Pitfalls, and Promise,"139 recommends 
that pregnant women be included unless there is a specific reason to exclude them.  
 
Rationale #6 - Excluding pregnant women from participating in medical research is unethical 
and  illegal - and may increase litigation risk. [Ethical rationale: Justice] 
 
Ethical conduct requires the inclusion of pregnant women in clinical trials, should 
they choose to participate. Lyerly (2011), citing Mastroianni et al., states that, "access to 
research, not just protection from its risks, is a constitutive part of the ethical mandates 
governing clinical research."140 "Issues of justice," they continue, "are perhaps the most 
pressing."141 "Women have the right – the same right as men – to decide for themselves (and, 
therefore, implicitly, for their potential offspring), whether it is prudent and morally right for 
them to participate in a given protocol, and women do not lose that right when they become 
pregnant," agrees Merton.142  
McCullough et al. question the ethics of treating pregnant in the absence of clinical 
study data. They state, "Until the risks and benefits of the different treatment options are 
                                                 
139Institute of Medicine Committee on Women's Health Research. (2010). Women's Health Research: Progress, 
Pitfalls, and Promise. Washington, DC: National Academies Press. Retrieved from www.nap.edu 
140Mastroianni, A.C., Faden, R., & Federman, D. (Eds). (1994). Women and Health Research: Ethical and Legal 
Issues of Including Women in Clinical Studies. Institute of Medicine. Washington, DC: National 
Academy Press.  
141Lyerly, A.D., Little, M.O., & Faden, R.R. (2011). Reframing the Framework: Toward fair inclusion of 
pregnant women as participants in research. The American Journal of Bioethics, 11(5), 50-52.                
p. 51. 
142Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p.388. 
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quantified and weighed against each other, the continued use of…drugs in these women 
without a sound evidence-base raises major clinical and ethical concerns."143  
Writing in IRB: A Review of Human Subjects Research, Jacqulyn Kay Hall 
concluded that "excluding women from publicly paid benefits on the basis of their sex is 
illegal."144 "There is no regulatory reason for excluding pregnant women from many studies" 
she writes, therefore "to exclude all pregnant women from the potential benefits of some 
protocols is illegal."145 Vanessa Merton concurs, "[R]esearch sponsors in fact have more to 
fear in the way of potential liability from the exclusion of…pregnant women…than from 
their inclusion."146 
While some view "the automatic exclusion of pregnant subjects as possibly more 
related to protecting the institution and investigator (from liability) than the subject or her 
unborn fetus (from possible harm),"147 an alternative view is that it is the inadequate testing 
of a drug prior to marketing that increases a company's risk of liability for adverse effects. 
While there are few reported cases of damages awarded due to injury from inclusion in 
research, there are a number of cases where damages were awarded for claims of inadequate 
                                                 
143McCullough, L.B., Coverdale, J.H., & Chervenak, F.A. (2005). A comprehensive ethical framework for 
responsibly designing and conducting pharmacologic research that involves pregnant women. 
American Journal of Obstetrics and Gynecology, 193, 901-907, p. 902. 
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and Human Research, 17(2):1-3, p. 1. 
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testing.148 One can imagine the liability claims for thalidomide were it released onto the 
market today with inadequate evaluation of its teratogenic potential. Had animal testing been 
performed to today's standards, the teratogenic potential of the drug would likely have been 
identified. But it is of interest to consider that if pregnant women had been included in the 
clinical trials for thalidomide, as tragic as the initial cases of birth defects would have been, 
thousands of cases of the severe limb defects that occurred in exposed children would have 
been prevented worldwide.149 Macklin says this "is a simple utilitarian calculation, an 
appropriate method for decision making when the intention is to decrease the number of 
individuals exposed to potential harm."150  
 
Rationale #7 – To follow the advice of experts in the field of women's health, law, and ethics. 
[Ethical rationale: Justice, Non-maleficence] 
 
The ACOG Committee on Ethics,151 the IOM,152 the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects of CIOMS,153 and the FDA154 have all 
concluded that pregnant women can be appropriately included in clinical research.  
                                                 
148Mastroianni, A.C., Faden, R., & Federman, D. (Eds). (1994). Women and Health Research: Ethical and Legal 
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Respect for the autonomy of patients, beneficence, and justice in the selection of 
participants are three oft-cited ethical justifications for the inclusion of pregnant women in 
clinical studies.155,156 Denying pregnant women the opportunity to enroll in research studies 
denies them the potential benefits of participation (improved treatment, enhanced medical 
care) and the opportunity to act altruistically and help other pregnant women.157 
"Increasingly, research ethics committees are encouraging researchers not to exclude this 
group of participants from research so long as appropriate safeguards are in place."158 
 In April 2009, subject matter experts in clinical practice, biomedical ethics, NIH, 
FDA, and others participated in a workshop (the Second Wave Consortium) on the topic of 
the inclusion of pregnant women in medical research. Their deliberations concluded, in part, 
with the following statement:159 
                                                                                                                                                       
153Council for International Organizations of Medical Sciences. (2002). International ethical guidelines for 
biomedical research involving human subjects. Retrieved April 17, 2011 from www.cioms.ch. 
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"We believe that the current paucity of research on effective and safe treatment of 
pregnant women's illnesses is unethical. It is unfair and irresponsible to continue a system 
that compels physicians to use therapeutic agents in an uncontrolled experimental situation 
virtually every time they prescribe for pregnant women, and for women and the fetuses they 
carry, to shoulder those risks whenever pregnancy is complicated by illness. As we learned in 
pediatric and geriatric research, if a population is going to use a medication it must be studied 
in that population. Pregnant women and the children they bear are best protected through 
responsible inclusion in research, not broad-based exclusion from it."  
 Chapter 3 
Ethical Framework 
 
 
I. An Ethical Framework for Clinical Research 
Introduction: 
Conceptual or theoretical frameworks attempt to connect all aspects of inquiry160 and 
provide a structure and a common basis upon which to test hypotheses and justify 
conclusions. In this study's area of inquiry, where both the pros and cons of the inclusion of 
pregnant women in research can be argued on the basis of ethical considerations, an ethical 
framework can assist to provide structure to the debate. A common language that is familiar 
to and accepted by health care practitioners, researchers, pregnant women, academics, and 
pharmaceutical industry representatives, will assist stakeholders in the understanding and 
consideration of ideas, opinions, and options. The proposed ethical framework of clinical 
research is based upon moral reasoning and ethical concepts that are common to these 
stakeholders' histories, lived experiences, and values at home and in the workplace.  
                                                 
160Wikipedia contributors. (n.d.). Conceptual Framework. Retrieved June 8, 2011 from 
http://en.wikipedia.org/wiki/Conceptual_framework 
 
 A.  Theoretical approaches 
Medical practice and clinical research are closely related and share Hippocratic roots, 
although important differences have been noted.  Medical practice focuses on the 
improvement of an individual's health and well-being, while clinical research attempts to 
provide knowledge that will improve a population's health and well-being by identifying 
improved methods to treat, cure or prevent disease.  
Medical ethics and research ethics are also closely related and many medical 
practitioners participate in clinical research.  Largent et al. cite technological advances such 
as electronic medical records, increased demand for evidence-based medicine and 
comparative effectiveness research, and the recognition that participation in research allows 
access to new therapies during "evidence development" as reasons for an increased blurring 
of clear boundaries between research and the provision of care.161 It needs to be recognized 
by both the researcher and the participant that, at times, the aims of the research may not 
coincide with the individual interests of the participant. 
To address these and similar issues, the field of research ethics  is devoted to the 
systematic analysis of [ethical and legal] questions to ensure that study participants are 
protected and, ultimately, that clinical research is conducted in a way that serves the needs of 
such participants and of society as a whole."162  
 
                                                 
161Largent, E.A., Joffe, S., & Miller, F.G. Can research and care be ethically integrated? Hastings Center 
Report, 41(4), 37-46, p. 38. 
162 Wendler, D. (Spring, 2009). The Ethics of Clinical Research. In Zalta, E.N. (Ed.), The Stanford 
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1.  Principle-based Ethics 
Principlism is the ethical approach traditionally applied to the fields of clinical 
practice, medical research, epidemiology, and public health. Developed in the second half of 
the 20th century by British physician and ethicist, Raanon Gillon,163 and American ethicists 
Beauchamp and Childress, it invokes four principles: Respect for Autonomy, Beneficence, 
Nonmaleficence, and Justice.164 It is criticized as being too 'Western,' lacking relativity and 
sensitivity to other cultural perspectives on issues such as liberty, social justice, and the value 
of life.165 But it remains the dominant theory applied to clinical practice and research.166 
 
a. The Principle of Respect for Autonomy or Respect for Persons 
Twentieth century legal decisions have determined that the authority and power to 
authorize a health care provider to act on a patient's behalf is vested in the adult, competent 
patient. Health care providers have the obligation to explain their rationale for recommending 
an intervention, the risks and benefits of the proposed procedures, alternative interventions 
they are not recommending, and the reasoning behind these recommendations. The 
competent adult patient is solely responsible for authorizing the initiation of the intervention. 
                                                 
163 Beran, R.G. (2006). The ethics of excluding women who become pregnant while participating in clinical 
trials of anti-epileptic medications. Seizure, 15, 563-570, p. 564, citing Gillon, R., (1985), 
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 58 
 
Each patient brings their "unique configuration and history of particular values and beliefs 
that form the basis for [the] determination of [their] own subjective and deliberative 
interests"167 to the situation.  Thus the patient is the only one who can make decisions that are 
relevant in her own context.  
But with the complexity and multitude of options in today's medical environment, this 
deciding cannot occur in a vacuum. Four models of increasingly respectful doctor-assisted 
patient decision-making were described by Emanuel in 1992: paternalistic, informative, 
interpretative, and deliberative.168 In the preferred deliberative model, the caring health care 
provider teaches the patient about her medical condition and treatment options, discusses 
both in the context of the values held by the HCP and by the patient, and provides a 
recommendation based on these factors. In today's environment of overwhelming access to 
medical information and misinformation, it is imperative that medical providers share 
perspective as well as knowledge. Kukla characterizes the exchange of knowledge and 
context by the patient and health care provider as active collaborative knowledge-building.169 
With this assistance, the patient can then make her informed decision based on the 
consideration of information and value context. Thus respect for autonomy means more than 
just having the patient make the decision. Today it means respecting the patient's capacity for 
learning, for evaluating values and context, and for applying these considerations to arrive at 
a considered decision.  
                                                 
167 McCullough, L.B., & Chervenak, F.A. (1994). Ethics in Obstetrics and Gynecology. New York: Oxford 
University Press, Inc., p. 53.   
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The same principles invoked in the therapeutic environment hold true in the research 
environment. According to McCullough,170 the principle of autonomy is a construct of 
modern Western political philosophy. It is the first principle of the Nuremberg Code,171 and 
the Belmont Report.172 In practical terms, one way of ensuring autonomous choice had been 
through the provision of informed consent.  Spencer defines informed consent as "consent 
given by a competent person in the light of relevant information and without the presence of 
any pressure of coercion."173 Its application to research has been influenced and upheld by 
legal proceedings that address the independent moral status of people and respect for their 
self-determination.  
 
b. The Principles of Nonmaleficence, Beneficence, and the Double Effect 
 Though widely quoted and attributed to Hippocrates, the edict, "primum non nocere 
(first, do no harm)" does not occur in the Hippocratic Oath. A similar statement, "make a 
habit of two things - to help, or at least to do no harm" occurs in an accompanying text and 
combines the principles of beneficence – to do good, and nonmaleficence – to do no harm. 
Nonmaleficence is, according to some ethicists, a corollary of the principle of beneficence 
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and not an independent principle on its own.174 The meaning and import of both principles 
are obvious: the physician commits to seek interventions on the patient's behalf, the 
consequences of which are intended to provide benefit and not cause harm. Adherence to 
these principles in practice encourages the practitioner to utilize her "accumulated scientific 
and clinical knowledge, skill, and experience" to "protect and promote the interests of the 
patient."175 Thus the strength of our beneficence is limited by the "competencies"176 of our 
medical judgment at any point in time.  
In medical and public health practice there are often situations where an action 
intended to provide benefit may result in an inadvertent harm – the harm being intentionally 
less likely to occur or of an acceptable quality or intensity. Examples include mandatory 
vaccinations that cause adverse effects in some children but benefit many, or surgery to 
remove an ectopic pregnancy that saves the woman's life but ends the pregnancy. Patients 
weigh potential benefits against the risk of potential adverse effects when choosing to take 
medication or consenting to surgery.  
The double effect principle recognizes the artificial separation of beneficence from 
nonmaleficence.  It provides criteria to help judge if an intervention is morally acceptable 
including if 1) the action is morally neutral or good, 2) the intention is to invoke the good 
effect and not the bad one, 3) the situation is serious enough that the harmful side effect is 
justifiable, and 4) actions are taken to minimize the potential harmful effects. Originated by 
                                                 
174McCullough, L.B., & Chervenak, F.A. (1994). Ethics in Obstetrics and Gynecology. New York: Oxford 
University Press, Inc., p. 47. 
175 McCullough, L.B., & Chervenak, F.A. (1994). Ethics in Obstetrics and Gynecology. New York: Oxford 
University Press, Inc., p. 37. 
176 McCullough, L.B., & Chervenak, F.A. (1994). Ethics in Obstetrics and Gynecology. New York: Oxford 
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St. Thomas Aquinas in his deliberations about the morality of killing in self-defense, the 
double effect principle is applied in law, medicine, research, and the military to evaluate the 
ethics of actions with good intentions but adverse consequences.177 Complicating the matter 
further, whether an outcome is a benefit (or a harm) can be judged differently by different 
people or by the same person in different contexts. Pregnancy itself is an example of such a 
dependent outcome – a joyfully anticipated occurrence at some times, a burden or even a 
danger to health and well-being in other people, contexts, or times. This lack of objective 
yardstick with which to assess the morality of any decision further necessitates fully 
informed consent and respect for autonomy. 
In research, the principles of beneficence, nonmaleficence, and the double effect are 
operationalized in study design, methodology, and protocol development that minimize risks 
to the study participants. An Institutional Review Board (IRB), also called an independent 
ethics committee or an ethical review board, is responsible for objectively evaluating each 
study for its adherence to these principles, to prospectively assess the study's risks and 
benefits, and to assure potential harms to participants have been minimized. In the U.S., an 
IRB review is required by the FDA and the Office for Human Research Protection for any 
research that receives support either directly or indirectly from the Department of Health and 
Human Services.178  IRBs are guided by The Common Rule (the common name for Subpart 
A, Part 46: Protection of Human Subjects, of Title 45: Public Welfare, in the Code of Federal 
Regulations (46 CFR 45) which contains the basic policy for protection of human research 
                                                 
177 McIntyre, A. (Fall, 2009). Doctrine of Double Effect, The Stanford Encyclopedia of Philosophy, Zalta, 
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subjects) and the international guidance documents that address human subjects research 
(e.g., the Nuremberg Code, the Declaration of Helsinki, the Belmont Report, and CIOMS 
guidelines.)179 
 
c. The Principle of Justice 
Justice was the "guiding ethical principle for the IOM committee" in their evaluation 
of the inclusion of women in clinical research.180 The Belmont Report discusses the principle 
of justice in the research setting as requiring an "equitable distribution of the burdens and 
benefits of research."181 Researchers must not include without good reason eligible 
candidates who may be harmed by participation, i.e. vulnerable persons. Nor can researchers
"exclude without good reason eligible candidates who may benefit from participation."
 
 
                                                
182
When pregnant women do not have access to clinical research studies, they are denied the 
possibility of having the potential for benefit that is available to non-pregnant women - this 
violates the principle of justice.183  
 
179Miller, F.G. & Wertheimer, A. (2007). Facing up to paternalism in research ethics. Hastings Center Report, 
37(3), 24-34. 
180Rothenberg, K. (1996). The Institute of Medicine's report on women and health research: Implications for 
IRBs and the research community. IRB: A Review of Human Subjects Research, 18(2), 1-3. 
181Levine, R.J. (1997). Ethics and Regulation of Clinical Research. New Haven, CT: Yale University Press, pp. 
67-93. In Weijer, C., Dickens, B., & Meslin, E.M. (1997). Bioethics for clinicians: 10. Research ethics. 
Canadian Medical Association Journal, 156(8), 1153-1157, p. 1154. 
182Levine, R.J. (1997). Ethics and Regulation of Clinical Research. New Haven, CT: Yale University Press, pp. 
67-93. In Weijer, C., Dickens, B., & Meslin, E.M. (1997). Bioethics for clinicians: 10. Research ethics. 
Canadian Medical Association Journal, 156(8), 1153-1157, p. 1154. 
183Kass, N.E., Taylor, H.A., & King, P.A. (1996). Harms of excluding pregnant women from clinical research: 
The case of HIV-infected pregnant women. Journal of Law, Medicine & Ethics, 24:36-46, p. 37. 
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Many individuals have been excluded from research as a means to protect them from 
being unfairly burdened by the potential harms of research; some are categorized in federal 
guidelines as “vulnerable.”  Yet Levine et al. warn that the "concept of vulnerability 
stereotypes whole categories of individuals," including pregnant women, as being less than 
capable of making reasoned decisions.184 The label itself may lead to injustice because it 
results in the exclusion of people who indeed have robust decisional capability from the 
opportunity to exercise that capacity in deciding whether their participation in research is in 
their best interests. Justice, state Lyerly et al., "calls into question the de facto summary 
exclusion of pregnant women in research without justification."185 
 
d. Consequentialism 
The question of inclusion/exclusion is at the basis of this study. In addition to 
Principlism, another "action-based" approach to ethics that addresses this issue is 
Consequentialism. This theory holds that the moral status of an action is determined by the 
goodness or badness of its outcomes. The Declaration of Helsinki, in some estimates the 
most influential document governing research world wide,186 includes, in addition to 
autonomy, beneficence, and justice,  an additional moral requirement for ethical research 
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conduct: that patients' participation in research should not put them at a disadvantage with 
respect to medical care. I would argue that this requirement includes and requires its 
converse: that patients' exclusion from research should not put them at a disadvantage with 
respect to medical care. Stakeholders argue that the exclusion of pregnant women from 
medical research puts them decidedly at such a disadvantage. States Lisa Eckenwiler in a 
paper entitled, "Hopes for Helsinki: Reconsidering vulnerability,"…in this contemporary era 
of research, it is essential that codes of ethics move beyond merely protectionist thinking. 
Fair access to research participation should be addressed more explicitly."187 
Eckenweiler takes the access issue a step further and thinks we should "…extend the 
scope of responsibility for ethical research to industry leaders, elected officials, and research 
funders, because they too play a role in ensuring that research endeavours do not create or 
perpetuate vulnerabilities, particularly inequalities in health or relations of power."188 
Inequalities of power are further addressed by the feminist theories that developed in the 
mid-20th Century. 
 
2.  Feminist Ethical Theory 
The modern feminist approaches to ethical analysis arose in the 1970s in response to 
dissatisfaction with "moral" justifications of the status quo.189 Traditional ethics were 
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criticized for promoting culturally masculine traits like "independence, autonomy, intellect, 
will, hierarchy, domination, culture, wariness, war, and death" while dismissing culturally 
feminine traits like "interdependence, community, emotion, sharing, absence of hierarchy, 
connection, nature, trust, peace, and life."190  Traditional ethics was also said to favor "'male' 
ways of moral reasoning that emphasize rules, rights, universality, and impartiality over 
'female' ways of moral reasoning the emphasize relationships, responsibilities, particularity, 
and partiality."191  Feminist perspectives sought to promote the importance of subjective 
experience in moral reasoning.  
Feminist ethics is often linked with the 'ethic of care.'  A term coined by moral 
psychologist Carol Gilligan, the ethic of care highlights certain salient moral considerations 
(context, particularity, relationships) that have not received due attention from traditional 
moral theories.   But the ethic of care is only one of many feminist approaches. Others 
include liberal, radical, Marxist/socialist, multicultural, and ecological ethics where the 
emphasis is on questions of internal and external power, domination and subordination. 
Existentialist, postmodern and Third-Wave approaches focus on the psychological 
consequences of social status. These feminist approaches seek to identify and address the 
ways in which gender, class, and culture affect moral decision-making.  
The feminist ethic of care aims primarily to identify and improve women's conditions 
– and, by extension, to improve circumstances for other vulnerable people like children, 
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elderly, and minorities.192 Its tenets include loving, caring, empathy, sensitivity and an 
emphasis on relationships and responsibilities. As the topic of this research study is the 
pregnant woman's relationships and responsibilities within the research community, with her 
health care provider and, most importantly, with her fetus, the care-oriented approach is, in 
my mind, extremely relevant.  The feminist ethic of care is consistent with, but expands, the 
principlist ethic of beneficence.   
The emphasis on relationships and responsibilities is in contrast to the individualistic 
approach in traditional ethics which are concerned with the rights of the individual. Carol 
Gilligan described moral development as growth from the individualistic perspective of the 
infant and child, to the growing realization of the person in relation to others, and finally to 
the mature person who can balance her individual needs with the needs of others.193 This 
moral maturity results in an acceptance of responsibility for oneself and for the effect of one's 
actions on others.   
In relation to this study, one might see the inclusion/exclusion question about 
pregnant women in clinical research from a traditional (i.e., male) perspective: avoiding harm 
by applying a rule (de jure or de facto) to all clinical studies: no pregnant women (or women 
capable of becoming pregnant) in clinical trials, period. But Gilligan, citing Piaget's findings, 
found that the female perspective encompassed "a greater tolerance, a greater tendency 
toward innovation in solving conflicts, a greater willingness to make exceptions to rules, and 
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a lesser concern with legal elaboration."194 Thus, including the feminist ethic to the 
framework of this study not only promotes the perspective of the primary subject of concern 
(women), but broadens the discussion and opens the deliberation to innovation, flexibility, 
context, and particularity.  
Rather than being dichotomous or contradictory, however, can we find parallels 
between the traditionalist and the feminist approaches? We discussed the principles of 
autonomy, beneficence, and justice as being the foundation of medical and research ethics 
both in theory (see the ethical codes) and in clinical and research practice. Are these 
principles compatible with feminist theory and practice? 
Paternalism – "overriding the [competent person's] wishes or intentional actions [even 
if] for beneficent reasons"195 - is an "offense to the autonomy of [competent] persons"196 and 
would be unacceptable to the principlist's "respect for persons" and to the "ethic of care."   
Beneficent, care-oriented practitioners would embody respect for persons by sharing their 
knowledge, their experience, their preferences and the rationale for those preferences, with 
the woman/patient/potential research subject. They would encourage the woman to include 
her own unique subjective experiences, preferences, and knowledge interpretations in her 
deliberations. Perspective sharing from the woman's own "experts" of choice – her personal 
supporters (e.g., the father of the fetus, family members, friends) – would also be 
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encouraged. The formulation of a decision in this manner is dense with relationships and 
responsibilities. Thus, the care-oriented practitioner, in respectful relationship with her 
patient, enables her autonomy.197,198 This is fully informed consent.  
Parallels exist between the ethic of care and the principle of benficence because both 
seek to induce beneficial outcomes and refrain from causing harm. Nel Noddings suggests 
that the caring behavior we naturally exhibit as children, helping others simply because we 
want to help them, develops into ethical caring as we grow to live in the complex external 
world.199 She further states that "having a robust sense of social justice is predicated on the 
lessons learned in the private sphere." Thus there are parallels between beneficence and 
justice and the ethic of care perspective as well. This suggests that both the principle-based 
approach and the care-oriented approach can, and do, co-exist. Carol Gilligan states that all 
human relationships can be viewed from the justice perspective in terms of equality ("don't 
act unfairly towards others") and from the ethic of care perspective in terms of attachment 
("don't turn away from someone in need").200 Utilizing both perspectives buttresses the 
argument for inclusiveness. Gilligan challenges both men and women to "speak the moral 
language of justice and rights as fluently as the moral language of care and responsibility."201  
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In conjunction with the principle-based ethical framework that is commonly evoked 
by medical and research practitioners, the feminist ethic of care perspective is relevant to this 
research effort. Caring is central to women's experience – not just pregnant women's 
experience. Women may be never pregnant, pre-pregnant, pregnant, or post-pregnant at 
different times in their lives. And many women and men care for and about pregnant women 
– be they their health care providers, their significant others, their parents, their children, or 
their friends. The safety and effectiveness of medical intervention in clinically compromised 
pregnancies impacts, and is of concern to, many people on a fundamentally sensitive loving, 
caring basis. 
Alison Jaggar202 describes the outcomes that all approaches to feminist ethics seek to 
achieve: 
1. to articulate moral critiques of actions and practices that perpetuate women's 
subordination 
2. to prescribe morally justifiable ways of resisting such actions and practices 
3. to envision morally desirable alternatives for such actions and practices 
4. to take women's moral experience seriously, though not uncritically  
 
These aims parallel the aims of this research study: by articulating the views of the U.S. 
pharmaceutical industry, to find common purpose and mutually beneficial approaches to 
including pregnant women, who have historically been excluded, in clinical research studies.  
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3. Business Ethics  
The discovery and development of pharmaceutical agents is a complex and costly 
endeavor. Knowledge of chemistry, pharmacology, biochemistry, microbiology, genomics, 
toxicology, and clinical medicine are required. Once a potentially viable product reaches the 
end of the labyrinth of development, the product then needs manufacture, packaging, 
production, distribution, promotion, ongoing monitoring, fiduciary and legal support. The 
need for all of these highly sophisticated and closely regulated functions requires a complex 
interdisciplinary organization – the pharmaceutical industry.  
In the pharmaceutical industry, medical practitioners work collaboratively with 
research scientists on the design, conduct, and evaluation of clinical studies. The goal to 
obtain objective and definitive scientific data that support the use of preventative or curative 
therapies by people in need satisfies both the clinical and the research agenda. But there is a 
third agent whose needs are also present – the corporate agenda.  
What are the generally acceptable ethical principles for the corporation? I had a hard 
time finding their definition in the literature. Many papers analyzing ethical failures were 
available but I did not find a generally accepted ethical framework for business. I did find a 
description of three potential vantage points from which business ethics could be derived that 
were instructive.203 They are: 
1) Ethics derived from the profit motive – including ‘good ethics result in good business’ 
(i.e., the best interests of a business are served by establishing a trusting relationship with 
the public [resulting in increased product loyalty, and decreased liability claims] and 
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employees [resulting in good morale and productivity]) and its reverse, ‘good business 
results in good ethics’ (i.e., the demand for moral behavior from customers and 
employees will result in proper behavior from companies).  Businesses that meet these 
demands will survive and prosper. 
2) Ethics derived from the legal system – businesses will do the right thing as prescribed by 
the law; any obligation beyond the law is optional.  
3) Ethics derived from general moral obligations -  
• Harm principle: businesses should avoid causing unwarranted harm. 
• Fairness principle: business should be fair in all of their practices. 
• Human rights principle: businesses should respect human rights. 
• Autonomy principle: businesses should not infringe on the rationally reflective 
choices of people. 
• Veracity principle: businesses should not be deceptive in their practices. 
• Stakeholder principle: businesses should consider all stakeholders' interests that 
are affected by a business practice. 
 
Most companies utilize a combination of these three approaches to guide decision-
making and the pharmaceutical companies would be no exception. But medical research is 
fundamental to this industry's ability to discover, produce, and maintain its products. 
Therefore, the ethical framework for medical research must be compatible with the ethical 
framework of the business.  The third approach, ethics derived from general moral 
obligations, is the most compatible with research ethics and the principle-based and feminist 
approaches described above. The Harm and Veracity principles correspond to 
Nonmaleficence, the Fairness principle to Justice, and the Autonomy and Human Rights 
principles to Respect for Persons.  
One could propose that the Stakeholder principle corresponds to the consequentialist 
principle discussed above, i.e., the business practice of excluding pregnant women from 
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research studies may not be in women's best interests.  On the other hand, including pregnant 
women in research studies may not be in the company's best interests.  
The founders of Stakeholder theory, Freeman and Gilbert,204 "view business as a 
connected set of relationships among stakeholders built [not upon the traditionalist] 
principles of competition and justice but [on] cooperation and caring."205 Burton and Dunn206 
propose parallels between stakeholder and feminist theories as these both promote the 
centrality of relationships as the basis upon which knowledge is gained, options are 
considered, and decisions should be made. In individualistic rights-based organizational 
theory, the firm is in competition with other firms and seeks to further its own interests. 
Legal contracts replace trust-based relationships to protect the company in negotiations. In 
stakeholder theory, firms take a more cooperative stance, seeking decisions where all parties 
gain. This can only happen when the company makes the stakeholders interests explicit and 
considers the effects of the proposed decisions on all parties involved. Burton and Dunn 
believe that a rights-based view is inherently problematic when differences of opinion arise. 
If competing parties are trying to get their 'inherent rights' met - but no one's rights supersede 
another one's rights - a stalemate is reached. In Stakeholder theory, companies try to do the 
"right" thing. When differences of opinion arise, Burton and Dunn invoke the ethic of care 
and propose that the company should "care enough for the least advantaged stakeholders that 
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they not be harmed." "A firm following this principle must perform a stakeholder analysis 
not merely to understand which stakeholders have power and which have a stake in the 
decision, but also to understand which stakeholders are most vulnerable to the action."207 
This combination of stakeholder theory and feminist ethics may inform this study's 
conceptual approach to interactions with pharmaceutical company and related or
representatives and to the proposal of procedural change within the industry.  
ganization 
                                                
There are many examples of pharmaceutical company philanthropic activities 
contributing to the public health needs of populations at risk. Some feel that these "good 
deeds have not been given the credit and recognition they deserve."208 They have been 
overshadowed by stories of unlawful marketing practices, unfair pricing practices, 
suppression of safety and efficacy data, and manipulative business practices.209 The challenge 
before the pharmaceutical industry is to find the portfolio of products that maintains 
commercial success (ensuring profitability and shareholder value) while addressing a range 
of unmet medical needs (fulfilling social and political responsibilities).  To do the right thing 
and to overcome negative public perception based on past shortcomings, the successful 
company must maintain corporate integrity by strictly adhering to ethical research and 
business practices.   
 
207Burton, B.K. & Dunn, C.P. (1996). Feminist ethics as moral grounding for stakeholder theory. Business 
Ethics Quarterly, 6(2),133-147, p. 144. 
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 B.   Special Considerations for Pregnancy/Maternal-fetal Ethics 
Vulnerable subjects are those people whose rights need the most protection. These 
groups, according to federal regulations, include children, incapable adults, prisoners, and 
pregnant women. Lupton states that, "While children, incapable adults, and prisoners are 
vulnerable because they lack freedom or autonomy, what distinguishes pregnant women from 
the rest of the population is the prospect of causing harm to vulnerable 'future people' (their 
unborn children)."210 According to him, it is the fetus who is vulnerable to having its consent 
given by a proxy since it is incapable of giving it itself. Do we suspect that a pregnant 
woman might disregard or minimize the risk to her fetus when a study might provide benefit 
to her? In the first place, benefit to the health of the pregnant woman usually provides benefit 
to the fetus as well. Secondly, it is hard to imagine who would care more about protecting 
and enhancing the health of the fetus than the expectant mother.  
Or is the gravid woman vulnerable in her own right? A woman does not lose 
reasoning capacity when she becomes pregnant. Yet her concern for her developing fetus 
might influence her decision-making. Might a pregnant woman accept a higher risk to herself 
in the interests of aiding her fetus? Might it be a risk that would be unacceptable to a non-
pregnant subject? Is this what the FDA research guidelines attempt to address by requiring, 
to the extent possible, that the father of the fetus also provide consent in the case of a 
therapeutic intervention that is beneficial only to the fetus? Is it to protect the woman from 
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herself (her altruism, her love, her compassion)? Or is the regulatory agency implying that 
the woman is less than capable of making the decision herself?  
Is the pregnant research subject more or equally prone to "the therapeutic 
misconception"211 – "the tendency of patient-subjects to mistakenly assume that research 
interventions are designed to benefit them"212 – and thus be more willing to consent to 
participate in a study? Or are they more prone, as research has shown, to overestimate the 
risk of all exposures that inadvertently or purposefully occur during the course of a 
pregnancy213,214 - and thus be less likely to participate in research? 
Is the classification of the pregnant woman as 'vulnerable' to protect her interests or to 
protect the fetus' interests? Is it the pregnant woman who is vulnerable or should we say that 
children, the incompetent, prisoners, and fetuses are vulnerable groups?   
I find that I am not alone in my perplexity about the characterization of pregnant 
women as a vulnerable group. In a paper entitled "The two dimensions of subject 
vulnerability"215 in the Journal of Clinical Research Best Practices, the author, Norman 
Goldfarb, depicts vulnerable groups on a graph. On the x-axis is the Ability to Give Informed 
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Consent and on the y-axis is Resistance to Undue Influence and Coercion with the identified 
groups ranging in placement on scales from low to high on each axis. The 20 vulnerable 
groups depicted include, among others, all of the vulnerable groups defined in the Code of 
Federal Regulation – except pregnant women. It seems Mr. Goldfarb did not know where to 
place pregnant women either. He did, however, include "Unborn" as a vulnerable group, low 
on the x-axis and high on the y-axis. So perhaps he agrees with Lupton and interprets the 
regulations to mean that it is the fetus and not the pregnant woman who is vulnerable.  
Respect for persons requires that the choices of autonomous individuals be respected 
and that people who are incapable of making their own choices be protected (italics mine).216 
This presents a conundrum for the investigator with a pregnant subject. On the one hand, the 
pregnant woman and the fetus are not autonomous in the limited sense of being independent. 
The fetus is wholly dependent on its 'host.' Therefore, the mother's 'choice' should be 
sufficient consent. However, the fetus is an entity who is incapable of making its own choice 
and whose interests, like those of children, deserve extra layers of protection.  
Who speaks for the fetus? According to FDA guidelines, it is sometimes the mother 
and sometimes the mother and the father.  According to American jurisprudence, it is 
sometimes the government. There are cases of government ruling with health care providers 
to force pregnant women to have C-sections for the "good of the fetus." In one notorious 
case, neither the mother nor the infant survived. In that case, the court subsequently ruled that 
                                                 
216Weijer, C., Dickens, B., & Meslin, E.M. Bioethics for clinicians: Research ethics. Canadian Medical 
Association Journal, 156(8), 1153-1157. 
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"neither fetal rights nor state interests on behalf of the fetus supersede women's rights as 
ultimate medical decision maker."217 
The ACOG Committee on Ethics has taken a position on the balancing of the 
mother's and the fetus' interests. The Committee Opinion is that "efforts to use the legal 
system specifically to protect the fetus by constraining women's decision making or 
punishing them for their behavior erode a woman's basic rights to privacy and bodily 
integrity are neither legally nor morally justified."218 They recognize that the intertwined 
interests of the maternal-fetal unit usually "converge rather than diverge"219 but, in either 
case, it is the responsibility of the woman to consent or refuse to participate in medical 
therapy or in clinical research.  
 
C.   Conclusion: Application of the Ethical Framework 
I have reviewed the ethical principles and theories most frequently invoked when 
discussing clinical research, medical practice, women's interests, and business practices.  I 
conclude that an ethical framework for evaluating perspectives about the inclusion of 
pregnant women in clinical research should be based upon the ethical principles of: 
1) Autonomy, or Respect for Persons, including the avoidance of paternalism 
                                                 
217 Harris, L.H. (2003). The status of pregnant women and fetuses in U.S. criminal law. Journal of the American 
Medical Association, 289(13),1697-1699, p. 1698.  
218 American College of Obstetricians and Gynecologists. (2005) Maternal decision making, ethics, and the law. 
ACOG Committee Opinion No. 321. Obstetrics and Gynecology,106, 1127-37, p. 1135. 
219American College of Obstetricians and Gynecologists. (2005) Maternal decision making, ethics, and the law. 
ACOG Committee Opinion No. 321. Obstetrics and Gynecology,106, 1127-37, p. 1135. 
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2) Beneficence, Nonmaleficence, and the Double Principle, including the avoidance 
of causing disadvantage 
3) Justice 
4) Care 
5) Stakeholder Considerations, including as stakeholders both the pregnant woman 
and her caregivers and the drug company and its researchers 
This ethical framework helped in the design of the study and the construction of the 
interview guide. The ethical issues that this study raises are best explored via dialogue – 
hence the qualitative design and the interview approach. It informed the construction of the 
interview guide by helping to identify the relative importance of potential questions and what 
terminology and concepts would be most readily understood by the interviewees.  
This ethical framework will aid the application of ethical principles to potential 
solutions proposed to address the dilemma of whether or not to include pregnant women in 
research studies. As with most ethically-laden situations, no completely "right" or "wrong" 
solutions will likely be obvious. No one solution will be correct in every situation. Just as it 
is would be unethical to require the inclusion of pregnant women in all clinical trials, it is 
unlikely that the exclusion of pregnant women from all clinical trials would be ethically 
permissible either. Having an ethical framework to inform deliberations will facilitate the 
formulation of solutions and exceptions to those solutions upon which stakeholders can 
agree. Table 3.1 illustrates a potential application of this ethical framework to the potential 
solutions proposed by various stakeholders to address the inclusion of pregnant women in 
clinical research. 
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This framework provides a structure and a common basis upon which to justify 
conclusions. In this arena, where both the pros and cons of the inclusion of pregnant women 
in research can be argued on ethical merits (see Chapter 2), a framework in the accepted 
language of medical, research, feminist, and business theory, will assist stakeholders in the 
understanding and consideration of options.  
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Table 3.1 Application of an ethical framework to this study*220 
Each rationale proposed to address pregnant women's inclusion in, or exclusion from 
participation in clinical research can be evaluated using the following ethical analysis: 
 
Autonomy/Respect:  
Does this rationale/solution impinge on anyone's personal autonomy? 
Do all relevant parties consent to this rationale/solution? If not, what are the objections? 
Are all opinions acknowledged and respected? 
 
Beneficence:  
Who benefits from this rationale/solution and in what way? 
Does the rationale/solution use the best of our current knowledge? 
Does the rationale/solution favor the balance of benefit over risk? 
 
Non-maleficence:  
Who may be harmed by this rationale or the implementation of this solution? 
How have the potential harms been minimized? 
Are risks communicated in a truthful, complete, and open manner? 
 
Justice:  
Is the rationale/proposed solution equitable to all stakeholders?  
Can it be made to be more equitable? 
Are the benefits and the burdens fairly distributed among stakeholders? 
 
The Ethic of Care:  
Whose needs are being met by this solution?  
Does the rationale/solution promote cooperation among stakeholders? 
Are relationships identified and maintained or promoted by the action? 
 
Stakeholders:  
Have all parties involved in this rationale/solution been identified? 
What parties are impacted by this rationale/solution and in what way? 
Are all stakeholders' concerns respected and addressed? 
 
*Adapted from Beauchamp and Childress
                                                 
220 Adapted from Beauchamp, T. & Childress, J. (2001). Principles of Biomedical Ethics (5th ed.) Oxford: 
Oxford University Press. In The Office of Public Policy and Ethics (2002), A primer to ethical 
analysis. Retrieved March 6, 2011 from The University of Queensland web site: 
http://www.uq.edu/au/oppe 
 Chapter 4  
Study Design and Methods 
 
 
A. Overall Study Purpose 
There is a dearth of information from the U.S. pharmaceutical industry regarding the 
inclusion of pregnant women in clinical research studies. The extent of pregnant women's 
exclusion has not been quantified, nor has the industry's rationale for their exclusion been 
articulated. The purpose of this concurrent mixed methods study was to better understand the 
U.S. pharmaceutical industry's practices and perspectives about the inclusion of pregnant 
women in clinical research.  
The qualitative and quantitative methodologies were performed concurrently from 
October 2011 through January 2012. The quantitative portion sought to confirm and quantify 
the current practice of excluding pregnant women from clinical studies. It provided a view 
into current practice. The qualitative interviews did not rely upon this information. The 
qualitative study sought to explore the rationale behind current practice and elicit potential 
barriers to, and opportunities for, change. Triangulating information from both portions of 
the overall study provided a broad picture of current practice and resulted in proposals for a 
path forward.
 
 
B. Quantitative Study Design and Methods 
1. Quantitative Study Purpose 
This study quantified the practice of excluding pregnant women by reviewing the 
inclusion/exclusion criteria of all U.S. based, open Phase IV interventional drug studies with 
adult female participants sponsored by industry currently posted on ClinicalTrials.gov.  
As the responsible entity for the cost, conduct, and outcome of clinical trials, 
pharmaceutical companies determine whether pregnant women will be included in or 
excluded from enrollment in each study.  
Clinical trials have traditionally excluded pregnant women to protect their fetuses 
from exposure to experimental medications with unknown safety risks. But this practice has 
contributed to a lack of information about how to treat medical conditions that can 
complicate pregnancies. This does not mean that all studies should include pregnant women. 
Reasons for their exclusion should be considered prior to study initiation. For example, it 
would be reasonable to exclude pregnant women from drug studies for which therapeutic 
benefit is undetermined.  
This study quantified the frequency with which pregnant women are excluded from 
current Phase IV clinical trials evaluating treatments for diseases or conditions that could 
affect a pregnancy. Phase IV trials are conducted using drugs that have already received 
regulatory approval and are currently marketed in the U.S. They evaluate issues about safety, 
concomitant medication interactions, or use in populations other than those for which the 
drug was initially approved. Almost any type of clinical study may be conducted in the post-
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marketing environment.221 Because these drugs have been studied in clinical trials, approved 
by FDA, and are on the market, more safety and efficacy information is available and the 
benefit-risk relationship is better established. These studies are, therefore, some of the most 
appropriate studies in which pregnant women could participate. The exclusion of pregnant 
women from these studies served as a proxy for the practice of exclusion of pregnant women 
from all phases of drug trials.  
For drugs in development, animal studies are performed to predict the potential for 
toxicity and teratogenicity. FDA weighs the pregnancy risk information during the process of 
approval and a pregnancy risk category (see below) is added to the products' label. This risk 
category is available for all drugs being studied in Phase IV trials.  
 
2. Quantitative Question 
What proportion of open U.S. pharmaceutical industry-sponsored Phase IV clinical 
trials currently enrolling women include pregnancy in their exclusion criteria? 
  
3. Quantitative Data source 
Inclusion/exclusion criteria of all U.S.-based, industry-sponsored open Phase IV 
interventional drug studies enrolling women of childbearing potential currently posted on 
www.ClinicalTrials.gov. 
                                                 
221Spilker, B. (1996). Guide to Clinical Trials. Philadephia: Lippincott Raven, p. 44. 
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ClinicalTrials.gov provides public access to the list of federally and privately 
supported clinical trials currently being conducted to investigate experimental treatment for a 
wide range of diseases and conditions. The website was developed to provide public 
information about current clinical trials so that individuals with serious diseases and 
conditions might access experimental treatments and volunteer to participate in the studies. It 
also provides a resource to access the basic results of completed clinical trials.222 
According to its website, ClinicalTrials.gov currently contains 102,470 trials 
sponsored by the National Institutes of Health, other federal agencies, and private industry. 
Studies listed in the database are conducted in all 50 States and in 174 countries. The NIH, 
through its National Library of Medicine, has developed this site in collaboration with the 
FDA, as a result of the FDA Modernization Act, which was passed into law in November 
1997.”223  
This study was limited to the review of open (i.e., currently enrolling) U.S.-based 
Phase IV (i.e. post-marketing) interventional studies (i.e., “trials [to] determine whether 
experimental treatments or new ways of using known therapies are safe and effective under 
controlled environments” as opposed to observational trials that “address health issues in 
large groups of people or populations in natural settings”)224 that include adult (i.e. age 18 to 
65) female participants and are sponsored by a pharmaceutical company. To be included, the 
study must have been evaluating treatment of conditions that may be experienced by, but are 
                                                 
222ClinicalTrials.gov. Protocol Registration System. (2012). Retrieved on Feb. 6, 2012 from 
http://prsinfo.clinicaltrials.gov/ fdaaa.html 
223National Institutes of Health. (2011). About ClinicalTrials.gov. Retrieved Feb. 6, 2011 from  
http://clinicaltrials.gov/ ct2/info/about  
224National Institutes of Health. (2011). About ClinicalTrials.gov. Retrieved Feb. 6, 2011 from  
http://clinicaltrials.gov/ ct2/info/about 
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not limited to, pregnant women and they must not have involved the use of a medication that 
is in the FDA pregnancy categories D or X – those thought to be potentially teratogenic. See 
further description and other restrictions in Limitations, below. 
 
4. Quantitative Methodology  
Analysis of the inclusion/exclusion criteria regarding pregnant women in U.S. clinical 
trial protocols as posted on www.ClinicalTrials.gov resulted in a listing of current studies by 
the following variables and characteristics:  
1. Search criteria: 
a. Open studies 
b. Interventional studies 
c. Included male and female or only female subjects 
d. Adult age group (18-65) 
e. Pharmaceutical company-sponsored 
f. Concern conditions that may be experienced by, but are not limited to, 
pregnant women 
2. Study Phase 
a. Phase IV studies only (n = 348 as of August 1, 2011) 
3. Variables from ClinicalTrials.gov included: Study ID#, Name of Study, Drugs, 
Sponsor, Condition, Estimated enrollment, Inclusion Criteria, and Exclusion Criteria, 
Contact Information, Description  
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4. Variables added included: Disqualification Reason, Pregnancy Category, No mention 
of pregnancy in inclusion or exclusion criteria, Contact Called Y/N, Result of Contact 
– Included/Excluded/Unknown, Notes  
 
Clinical trials were excluded from the analysis if the age (e.g., postmenopausal), 
condition (e.g., amenorrhea), or drugs being tested (e.g., pregnancy risk category D or X) 
would preclude the enrollment of pregnant women. The FDA pregnancy category for all of 
the drugs identified for use in each study was identified by viewing the pregnancy section of 
their prescribing labels on PDR.net. (See Table 4.1 for a description of pregnancy 
categories.) Studies using drugs with FDA pregnancy category D or X were excluded. 
 
                              Table 4.1 FDA Pregnancy Risk Categories225 
Category Description 
A 
Controlled studies show no risk-Adequate, well-controlled 
studies in pregnant women have failed to demonstrate a risk to 
the fetus in any trimester of pregnancy.  
B 
No evidence of risk in humans-Adequate, well controlled 
studies in pregnant women have not shown increased risk of 
fetal abnormalities despite adverse findings in animals, or 
In the absence of adequate human studies, animal studies show 
no fetal risk. The chance of fetal harm is remote, but remains a 
possibility.  
C 
Risk can not be ruled out- Adequate, well-controlled human 
studies are lacking, and animal studies have shown a risk to the 
fetus or are lacking as well. There is a chance of fetal harm if 
the drug is administered during pregnancy; but the potential 
benefits may outweigh the potential risk.  
D 
Positive evidence of Risk-Studies in humans, or 
investigational or post marketing data, have demonstrated fetal 
risk. Nevertheless, potential benefits from the use of the drug 
may outweigh the potential risk. For example, the drug may be 
acceptable if needed in a life threatening situation or serious 
disease for which safer drugs cannot be used or are ineffective. 
                                                 
225American Pregnancy Association. (2006). FDA Drug Category Ratings. Retrieved on Aug. 2, 2011 from 
http://www.americanpregnancy.org/pregnancyhealth/fdadrugratings.html 
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X 
Contraindicated in Pregnancy- Studies in animals or 
humans, or investigational or post-marketing reports, have 
demonstrated positive evidence of fetal abnormalities or risk 
which clearly outweighs any possible benefit to the patient. 
 
5. Analysis Plan: Quantitative Study 
A. Descriptive statistical analysis of data included  
1. Total number of studies included 
2. Total number of studies disqualified 
3. Range of enrollment numbers 
4. Number of studies excluding pregnant women as noted in the inclusion criteria 
5. Number of studies excluding pregnant women as noted in the exclusion criteria 
6. Number of studies inclusion/exclusion criteria that did not mention pregnancy or 
require birth control 
a. Number of these studies contacted 
b. Result of contact – included pregnant women, excluded pregnant women, or 
remained unknown 
7. Total number and proportion of studies that included pregnant women 
8. Total number and proportion of studies that excluded pregnant women 
 
6.  Limitations of Quantitative Analysis 
a. Delimitations – studies were limited to open U.S. Phase IV clinical trials sponsored 
by industry that enrolled women and were posted on ClinicalTrials.gov. ClinicalTrials.gov 
includes all U.S. clinical trials that are approved by FDA and sponsored by the 
pharmaceutical industry.  
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The study was limited to Phase IV trials because they are the most appropriate trials 
in which pregnant women can participate, as described above. In addition, Phase I, II, and III 
trials were excluded because the safety data of the unapproved drugs being evaluated are not 
available in the public domain. Therefore, I would have been unable to evaluate if it would 
be appropriate for pregnant women to be included in such studies.  
b. Limitations – Some of the inclusion and exclusion criteria listed by the study 
sponsors on ClinicalTrials.gov may not have been fully inclusive and may not have 
mentioned pregnancy or pregnancy potential. It may not be accurate to assume that if 
pregnancy was not mentioned as an exclusion criterion then pregnant women were included 
as study subjects. In order to validate the initial findings from the website, any protocols that 
did not mention pregnancy or pregnancy prevention per se were contacted via a phone call or 
email to the study contact to attempt to verify if pregnant women had access to enrollment in 
the trial. 
However, this still may not have addressed de facto exclusion, i.e. the "inadvertent" 
failure to recruit pregnant women (as opposed to exclusion de jure, i.e. the explicit exclusion 
of pregnant women in the protocol).226 In other words, just because a study did not exclude 
pregnant women in the protocol, did not mean that pregnant women would be enrolled. This 
was a point of discussion for the studies that were contacted.   
 
 
 
                                                 
226Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) from 
biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 370. 
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C. Qualitative Study Design and Methods 
1. Qualitative Study Purpose: 
Concurrently with compiling the quantitative data described above,  this study sought 
to understand the perspectives of key opinion leaders in the pharmaceutical industry and 
related organizations, using qualitative key informant interviews to identify key themes 
regarding the rationale for exclusion and the opportunities for  inclusion ones.  
 
2. Qualitative Study Question 
What are the current perspectives of U.S. pharmaceutical industry representatives and 
those of related organizations about the inclusion of pregnant women in clinical research 
studies? 
Key informant interviews provided data to explore why pharmaceutical companies 
may be limiting pregnant women's access to participation in clinical trials and how more 
inclusive practices may be adopted.  
 
3. Qualitative Data Source 
Key Informant Interview data:  semi-structured interviews with subject matter experts in the 
U.S. pharmaceutical industry, professional groups, and related organizations: 
a. Clinical researchers or other staff working in U.S. pharmaceutical companies (n=5) and 
biotech firms (n=3)  
b. Legal representatives from pharmaceutical companies (n=2) and PhRMA (n=1) 
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c. Pharmaceutical Research and Manufacturers of America [PhRMA] representative 
(n=1) 
d. Independent Institutional Review Board members (n=3) who are contracted by 
industry to review their protocols 
e. Food and Drug Administration representative (n=1) 
 
4. Qualitative Methodology  
Key Informant Interviews - I identified key informants by using my past experience 
working on pregnancy registries within the pharmaceutical industry and the relationships I 
built with others working in this field. In qualitative research, participants who will best help 
the researcher address the study questions are purposefully selected (as opposed to the 
random selection used in quantitative research).227 Some informants were known to me and 
others were recommended by them or by others (e.g., committee members)..  
Potential participants were initially contacted by me either via email or by phone. I 
explained the purpose of the study and why I was requesting their participation. The 
qualitative methodology was be described. I clarified that I was seeking their personal 
opinion (not that of their organization) because of their experience in clinical research in the 
pharmaceutical industry or related organizations. If they agreed to participate, I allowed them 
to suggest when and where they would prefer to be interviewed (i.e., during working hours or 
at another time).  
                                                 
227Creswell, J.W. (2003). Research Design: Qualitative, Quantitative, and Mixed Methods Approaches, (2nd ed). 
Thousand Oaks, CA: Sage Publications, p.185.  
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One hour telephone interviews were scheduled with each participant in advance. A 
pre-designed interview protocol was constructed and included an introduction, background 
for the key informants, the key research questions, and probes to follow the research 
questions. The key research questions, a small number of open-ended interview questions 
intended to elicit views and opinions of the participants,228 were utilized for consistency. The 
interview guide was provided to them 2 weeks in advance of the scheduled interview to 
allow the informants time to consider the issues or consult with others within their 
organization. (See Interview Guide, Appendix III.) 
The interviews were tape-recorded with the participant’s permission. Interview 
recordings were transcribed.  
 
5. Qualitative analysis of key informant interview data 
The interview transcripts were systematically manually coded and evaluated to 
identify key themes and issues. Evaluation of the data proceeded from the general (overview, 
high-level ideas, impressions) to the specific (coding similar ideas, clustering similar ideas 
into topics, labeling topics as codes, applying codes to the texts, identifying coded segments 
of text that best describe the concepts).  
Interpretation of the coded data: Codes were evaluated in categories such as expected 
themes (those that relate the findings to the historical information gathered from the 
literature), unexpected themes, and themes that relate to principles in the theoretical 
framework.   
                                                 
228Creswell, J.W. (2003). Research Design: Qualitative, Quantitative, and Mixed Methods Approaches, (2nd ed). 
Thousand Oaks, CA: Sage Publications, p. 188. 
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Confidentiality of key informants' identities is strictly maintained. All informant data 
is presented anonymously with no reference to the informant's name. Interview recordings 
and transcripts are kept in a locked cabinet. Aside from the original documents, all 
subsequent documents are key-coded as to the identity of the informant. The Key code is 
held in a locked cabinet separate from the original documents.  
Themes are identified by type of organization (pharmaceutical or biotech company), 
legal representative, PhRMA representative, IRB representative, or FDA representative. No 
names of individuals are identified. 
Key themes were identified. Multiple perspectives about each theme are presented in 
the Results section (Chapter 6). Specific quotations related to the themes are highlighted. 
Relationships between themes are identified and explored.  
These findings are interpreted and applied to the issues raised by the literature and by 
proponents of the rational inclusion of pregnant women in clinical trials. Where do the 
themes of industry and related organizations agree with and where do they diverge from 
themes identified in the literature and by proponents of the inclusion of pregnant women in 
clinical research trials? Are opportunities or barriers to change identified? Are there 
recommendations that can be promoted to inform discussion, policy, or practice about the 
inclusion of pregnant women in medical research? (See Chapter 6). 
 
6.  Limitations of Qualitative Data 
a. Delimitations – Key informants were limited to 16 participants in the U.S. 
organizations identified above. This does not include informants from all companies or 
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organizations that may potentially be knowledgeable about the subject matter. These 
participants may or may not represent the perspectives of other companies and organizations 
or a consensus on the subject. 
b. Limitations – Telephone interviews were subject to limitations of not being in 
physical proximity to the participant. Visual clues such as body language and facial 
expressions were lost.  
Some of the key informants were chosen by me (convenience sample) based on my 
contacts in the industry and related organizations. Some, but not all, participants were known 
to have worked on pregnancy-related issues in industry. This improved their ability to discuss 
the issue in depth. However, this may have introduced bias as they may have been more 
sensitive to issues about the inclusion of pregnant women than interviewees who have not 
worked on pregnancy-related issues. This may decrease the transferability of the findings. 
Care was taken to include informants who have worked on pregnancy-related issues and 
those who have not. I will consulted with others in the field, including those on my 
dissertation committee, to identify potential qualified candidates. On the other hand, knowing 
me and my work in the industry may have caused participants to view me as an 'insider' and 
improved their comfort in speaking to me about this issue.  
In the interview data analysis, the qualitative findings could be subject to other 
interpretations that may differ from my interpretation.  In choosing participants from within 
and outside of industry, I hoped to add to the validity of the findings by using triangulation – 
examining evidence from different sources to see if similar themes are identified.229 If so, it is 
                                                 
229Creswell, J.W. (2003). Research Design: Qualitative, Quantitative, and Mixed Methods Approaches, (2nd ed). 
Thousand Oaks, CA: Sage Publications, p. 196. 
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likely I have identified valid themes. If not, participant’s views may vary widely among my 
group of subjects or in this field of research. 
c. Bias – As qualitative research is "fundamentally interpretive," personal reflection 
and the identification of the researcher's "biases, values, and interests," at the outset of the 
study is important.230 As someone who has worked as a women's health care provider in 
practice, and as a researcher on pregnancy issues in industry, I bring background knowledge 
but also certain biases to this study. I acknowledge that I agree with proponents who seek a 
more rational and inclusive policy toward pregnant women in research studies. And I 
acknowledge that, while I will strive to maintain objectivity in the data collection and 
analysis, my biases may influence my findings. 
 
D. Plan for use of the combined study results 
1. Improve knowledge: 
As I have been unable to find a source in the literature that quantifies the degree to 
which pregnant women are excluded from studies that might rationally include them, this 
study sought to reveal the extent to which this occurs. By rationally, I mean that the disease 
state being studied occurs in pregnant women and should be treated, and the drugs being 
evaluated are FDA pregnancy risk category A, B, or C. Is it standard practice to exclude 
pregnant women or are they sometimes included and how frequently does that occur? Are 
pregnant women systematically excluded from trials that study medical conditions that might 
occur during a woman’s pregnancy and for which treatment should be administered? How 
                                                 
230Creswell, J.W. (2003). Research Design: Qualitative, Quantitative, and Mixed Methods Approaches, (2nd ed). 
Thousand Oaks, CA: Sage Publications, p. 182. 
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many studies do not mention pregnancy in their exclusion criteria – and does that mean they 
are included or is it simply assumed that they would be excluded?  
The quantitative review of the inclusion and exclusion criteria in clinical protocols 
provided this data. This information will raise awareness and add to our knowledge base in 
the field of obstetrical practice and clinical research. It will provide important information 
about the baseline of exclusionary or inclusionary current practices and make these practices 
explicit.  This information will add weight to the dialogue about whether or not pregnant 
women are, in fact, excluded from participation in clinical research – and whether this should 
change.  
The qualitative analysis will improve our knowledge of the current pharmaceutical 
industry perspective. What are the attitudes, beliefs, and practices of the industry and how do 
each influence company policy? What do representatives from organizations related to the 
pharmaceutical companies think about the issue? Do their opinions concur with or diverge 
from industry representatives? Are there opportunities for change? What are the barriers to 
change? 
 
2.  Improve policy and practice: 
FDA is currently conducting a final review of a draft guidance document that will 
make recommendations to industry about when and how to include pregnant women in 
clinical trials.231 The industry will have the opportunity to provide feedback to the agency's 
plan within a constrained time period. Therefore, discussing the issues and potential solutions 
                                                 
231FDA's Guidance Document To-Do List. (January 3, 2011). "The Pink Sheet". 
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ahead of the document's release for public comment will promote the potential for a reasoned 
and coordinated response.  
As interested parties outside of the pharmaceutical industry deliberate on the risks and 
merits of including pregnant women in medical research, those within the industry may be 
unaware of the debate. Clearly industry needs to be part of this discussion.  
To improve the health of pregnant women and their offspring by providing health 
care providers and pregnant women with accurate information about the risks and benefits of 
medical treatment during pregnancy is a rational goal. In order to do this, some stakeholders 
believe that more and better information is needed about the actual outcomes of pregnancies 
that utilized medications to treat conditions during gestation. In order to obtain this 
information we need to systematically collect the data from exposed pregnancies – in clinical 
trials, in post-marketing studies, or utilizing other methodologies. This study provides the 
perspective of experts working in and with industry about the barriers and facilitators to the 
collection of such data. In doing so, recommendations to company and regulatory policy are 
formulated that may serve to improve pregnancy outcomes.
 Chapter 5 
Quantitative Results 
 
 
Quantitative Study question  
What proportion of open U.S. pharmaceutical industry-sponsored Phase IV clinical trials 
currently enrolling women include pregnancy in their exclusion criteria? 
 
A. Background 
In order to protect the fetus from the potential adverse effects of experimental 
medical interventions and drugs in development, it has been general practice to exclude 
pregnant women from participating in clinical trials. An unintended result of their exclusion 
is that women with medically compromised pregnancies and their health care providers are 
often frustrated by the lack of clinical data available to inform treatment decisions regarding 
obstetric or non-obstetric complications.  
 
 
 
 
 
It has been suggested that including pregnant women in clinical trials would result in 
better information about the safety and efficacy of treatment options during pregnancy by 
experts who are recommending their inclusion.232,233,234,235 How extensive is the practice of 
excluding pregnant women? I was unable to find any documentation in the clinical literature 
of the current proportion of clinical trials that include or exclude pregnant women.  
This study was designed to ascertain the proportion of clinical trials that exclude 
pregnant women by reviewing the inclusion and exclusion criteria of all U.S.-based, 
industry-sponsored open Phase IV interventional studies enrolling women of childbearing 
potential posted on www.ClinicalTrials.gov between October 1, 2011 and January 31, 2012.  
Phase IV trials are conducted using drugs that have already received regulatory 
approval and are currently marketed in the U.S. They evaluate issues about safety, 
concomitant medication interactions, use in populations other than those for which the drug 
was initially approved, etc.236 Because these drugs have been studied in clinical trials, 
approved by FDA, and are on the market, more safety and efficacy information is available 
and the benefit-risk relationship is better established. These studies are, therefore, some of 
                                                 
232Feibus, K. & Goldkind, S.F. (May 17, 2011) Pregnant women and clinical trials: Scientific, regulatory, and 
ethical considerations. Oral presentation at the Pregnancy and Prescription Medication Use 
Symposium, Silver Springs, MD. 
233Mastroianni, A.C., Faden, R., & Federman, D. (Eds). (1994). Women and Health Research: Ethical and Legal 
Issues of Including Women in Clinical Studies. Institute of Medicine. Washington, DC: National 
Academy Press. 
234Council for International Organizations of Medical Sciences. (2002). International ethical guidelines for 
biomedical research involving human subjects. Retrieved April 17, 2011 from www.cioms.ch. 
235American College of Obstetricians and Gynecologists' Committee on Ethics. (2007). ACOG committee 
opinion: Research involving women. Obstetrics & Gynecology, 110(3), 731-736, p. 732. 
236Spilker, B. (1996). Guide to Clinical Trials. Philadephia: Lippincott Raven, p. 44. 
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the most appropriate studies in which pregnant women could participate. The exclusion of 
pregnant women from these studies will serve as a proxy for the practice of exclusion of 
pregnant women from all phases of clinical trials.   
This study quantified the frequency with which pregnant women were excluded from 
current Phase IV clinical trials. To be included, the study must have been evaluating the 
treatment of medical conditions that could be experienced by, but are not limited to, pregnant 
women and they must not have included a medication that was in the FDA pregnancy 
category D (positive evidence of human fetal risk but benefits of use may outweigh the risk) 
or category X (positive evidence of animal or human fetal risk and the risk of use clearly 
outweighs the potential benefit). If there was no mention of pregnancy in the inclusion or 
exclusion criteria of a study, a study coordinator was contacted to confirm that pregnant 
women could be enrolled.   
 
B. Results 
Application of the search criteria above retrieved a total of 559 studies from the 
ClinicalTrials.gov website as of 31Jan2012.237 Of these, 4 were found upon closer 
examination to not meet the criteria specified – one was a trial for hemophilia limited to 
males and three were trials that were not sponsored by industry. This resulted in a total of 
555 clinical trials available for study.  
                                                 
237 ClinicalTrials.gov is an open website, with clinical trials being added or removed on a continuous basis as 
new trials are initiated and completed studies are removed. Therefore, the number of trials retrieved on 
any given day may vary. 
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Of these 555, 103 were excluded from further analysis. Five (5) studies limited 
enrollment to pregnant women and 98 were found to appropriately exclude pregnant women 
based on the following justifications:   
• N = 74 – At least one drug in study was in FDA Pregnancy Category D or X 
• N = 17 – Age criteria excluded childbearing potential 
o 10 studies limited inclusion to men and women age > 60 
o   6 studies limited inclusion to men and women age > 50 
o   1 study limited inclusion to men and postmenopausal women age > 45 
• N = 4 – Study topic was menopause 
• N = 2 – Study topic was contraception 
• N = 1 – Study topic was lactation 
Of the remaining 452 clinical trials that could potentially enroll women of 
childbearing potential, 301 specifically excluded pregnant women, 2 specifically did not 
exclude pregnant women, and 149 made no mention of pregnancy in the inclusion / exclusion 
criteria posted on ClinicalTrials.gov.  
One might expect that, if pregnancy was not mentioned in the exclusion criteria, then 
pregnant women could be included. In order to test that assumption, all 149 of these studies' 
coordinators were contacted by phone, by email, or both. Eighty-four (84) did not respond to 
the request for information. Of the 65 studies for which we obtained clarification about 
whether or not pregnant women could be included, 46 (71%) actually excluded pregnant 
women and 19 (29%) did not exclude them from enrollment in the study. 
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Figure 5.1. Number of studies available for review on ClinicalTrials.gov between 
01Oct2011 and 31Jan2012 and their enrollment of pregnant women 
555 
Studies 
Potentially 
include 
Appropriately 
excluded* 
84  
No Response 
65 
Responded 
46 
Excluded 
     301 
Excluded 
19 
452   98 
2 
Not 
Excluded  
149 
Unknown 
Confirmed criteria  =  368 studies 
Total excluding  =       347 (94%) 
Enrollment limited 
to pregnant  
women
  5 
Total not excluding  =    21 (6%) 
Not 
Excluded 
* Pregnant women were excluded because the drug was in FDA Category D or X, or the 
age or topic (menopause, contraception, lactation) prohibited pregnancy.  
 
Therefore, the overall results of the analysis were that, of the 368 clinical trials for 
which we had specific inclusion/exclusion criteria, 347 (94%) excluded pregnant women and 
21 (6%) did not exclude pregnant women. Therefore, of the 368 Phase IV studies in which 
pregnant women could appropriately participate, we confirmed that 94% excluded and 6% 
did not exclude pregnant women from enrollment. 
A range of medical conditions that could occur in pregnant women was included in 
the Phase IV studies evaluated. These included epilepsy, depression, fungal infection, 
arthritis, heart failure, peripheral artery disease, Von Willebrand disease, aneurysm, HIV, etc. 
None of the conditions were noted to never occur in pregnant women, though treatment of 
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some, like knee replacement, might be safely postponed until the completion of the 
pregnancy.  
A comparison of the studies that were open to the enrollment of pregnant women to 
those that were not yielded little additional insight. In approximately 80% of the studies in 
both groups, the purpose of the trial was to evaluate treatment as opposed to prevention, 
diagnostic, or supportive care. Masking (or blinding) was also similar. The proportion of 
studies that were blinded (subjects and/or researchers do not know what treatment the subject 
is receiving) as compared to those that were 'open-label' (subjects and researchers know what 
treatment the subject is receiving) was also similar – 42% of studies were blinded in the trials 
that excluded pregnant women and 38% were blinded in those that did not.  
The only variable noted to differ between the two groups was allocation – that is, 
whether the studies were randomized trials (in which subjects are randomly assigned to 
different treatment groups) or non-randomized trials (subjects may choose, or are in 
previously chosen treatment groups). In the 297 studies that excluded pregnant women and 
reported allocation on ClinicalTrials.gov, 75% were randomized and 25% were not. In the 
small number of studies (n=19) that reported allocation and did not exclude pregnant women, 
58% of the trials randomized subjects into different treatment categories and 42% were non-
randomized.  
A comparison of the category of treatment being studied can also be made. There 
were six major categories: Drugs (n=245), Devices (n=77), Procedures (n=21), Biological 
Products (n=14), Diet (n=5), and Other (n=6). Excluding the last two categories whose 
numbers are too small to draw conclusions, the percentage of studies in each category that 
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excluded pregnant women was 98% of drug studies, 95% of studies on procedures, 87% of 
device trials, and 79% of biological product studies.    
 
C. Discussion 
The answer to the question, "What proportion of open U.S. pharmaceutical industry-
sponsored Phase IV clinical trials currently enrolling women include pregnancy in their 
exclusion criteria?" was, at first cut of the data, 67%. However, this number did not reflect 
the actual proportion of studies that excluded them. By contacting the study coordinators to 
confirm inclusion or exclusion, it was determined that the inclusion/exclusion criteria posted 
on ClinicalTrials.gov was inaccurate in regards to pregnant women – a key finding of this 
study. Only 2 studies specifically stated in their inclusion criteria that they included pregnant 
women.   
Seventy-one percent (71%) of studies that did not list pregnant women in their 
exclusion criteria posted on ClinicalTrials.gov did, in fact, exclude them. This might infer 
that the practice of excluding pregnant women is so commonplace that it is simply assumed 
to be true and, therefore, did not need to be explicitly stated.  
We contacted study coordinators for the studies that did not address pregnancy in the 
inclusion/exclusion criteria and asked them to clarify the protocol. Could pregnant women be 
included? Comments such as this one supported the assumption of exclusion:  
"We don't have to list every exclusion on ClinicalTrials.gov. No 
glaucoma treatments have been approved for use in pregnant 
women. So this [not to include pregnant women in the exclusion 
criteria] was a no-brainer." 
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Other studies may not have specified pregnancy in the criteria because the condition 
was assumed to have a low prevalence in the treatment group, for example, certain age 
groups (adolescents, women over 40) or medical conditions (cardiomyopathy, dialysis). For 
example, one email response stated, 
"There is no specific pregnancy criteria in this study. The drug is 
mostly used in dialysis pts, who are generally unable (with rare 
exception) to become pregnant anyway. NOTE: Just because not 
excluded doesn't mean they will be included." 
 
This quote addresses the issue of de facto exclusion: pregnancy may not be an 
exclusion criterion, but that doesn't mean pregnant women will be enrolled. Pregnant women 
may not be recruited or accepted for enrollment in the study at the discretion of the Prinicipal 
Investigator (PI).  
But pregnancies do occur in many age groups and conditions so the protocols should 
be more explicit. Two studies addressed the need and the appropriateness of including 
pregnant women. One recognized that pregnancy would rarely occur in women with heart 
failure but had other studies to address that issue: 
"There is not a specific exclusion for pregnant women in [this] 
trial.  However, this would be an extremely rare occurrence. …We 
have other trials for pregnant women with cardiomyopathy." 
 
And the other was one of the two studies that explicitly included pregnant women in 
the inclusion criteria:  
"[Drug] carries a Category B pregnancy risk factor. Since this is a 
minimal pregnancy risk category, no special precautions will be 
taken to determine that the patient is not pregnant."  
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This study found a higher proportion (75%) of the studies that excluded pregnant 
women were randomized trials compared to 58% of the studies that did not exclude pregnant 
women. Because the number of trials that did not exclude pregnant women is small (n=19), 
the strength of this finding is not robust and may be based on chance. But it would make 
sense that, if one were to enroll a pregnant woman in a study, it would have to be one in 
which she would expect to receive therapeutic benefit. In order for it to be ethically 
acceptable for her to enroll, the benefit would need to outweigh the risk to her, her pregnancy 
and her fetus, a somewhat higher hurdle than for non-pregnant subjects.  Therefore, a non-
randomized trial, where the subject was in a therapeutic group prior to the study or could 
choose what treatment group to join, would be preferable. This finding suggests that 
researchers who are conducting non-randomized clinical trials may be more open to the 
inclusion of pregnant women as study subjects.  
It was not surprising to find that drug trials excluded pregnant women at a rate that is 
higher than that for other studies including those that assess procedures, devices, and 
biologics. The precaution against the testing of drugs on pregnant women is very well-
entrenched (see Chapter 6. Qualitative Results for further discussion). However, the 
magnitude of the exclusion (98%) in these Phase IV trials, where pregnancy risk categories 
are defined, is higher than was anticipated by this author.  Also of interest was the finding 
that 21% of the studies on biological agents did not exclude them. This may reflect our 
limited but disquieting recent experience with bioterrorism which has heightened society's 
concern for the protection and treatment of pregnant women in such dreadful scenarios. 
Whether it may also reflect an increased acceptance of the use of vaccines during pregnancy 
may be worth exploring. Two vaccines are currently recommended for administration during 
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pregnancy: H1N1 influenza vaccine and Tdap for tetanus, diphtheria, and pertussis (after 20 
weeks gestation).238   
 
D. Limitations: 
It would be difficult to include an exhaustive list of conditions that would preclude a 
subject from being eligible for enrollment on the ClinicalTrials.gov website. Some study 
protocols addressed this issue by including statements such as "Additional inclusion 
(exclusion) criteria may apply", "Any subject who at the discretion of the Investigator is not 
suitable for inclusion in the study," or "Has any other clinically important abnormalities such 
that risk to patient of participation outweighs the potential benefit of therapy as determined 
by the investigator." Such statements leave the enrollment decision up to the individual PI. 
Contacting the study coordinators or Sponsors to confirm the number of studies that actually 
excluded pregnant women resulted in a more accurate assessment. A 94% exclusion rate 
confirms a very common practice. 
Of course, all clinical studies should not include pregnant women. For example, 
studies for conditions for which treatment could be postponed might recommend deferral of 
enrollment until the conclusion of the pregnancy. This review did not attempt to exclude 
studies for conditions in which treatment can be deferred because, in many instances, that 
conclusion could be determined only by the patient and her health care provider. Severity of 
                                                 
238March of Dimes. (2011). Vaccinations during pregnancy. Retrieved on March 15, 2012 from 
http://www.marchofdimes.com/pregnancy/prenatalcare_vaccinations.html 
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the condition, its effect on the patient's quality of life, and alternative palliative treatment 
options are factors that may need to be considered in that determination.  
A potential limitation of the study is the omission of 84 studies that did not list 
pregnancy in the exclusion criteria and which therefore may have included them. We could 
apply the same ratio of exclusion to inclusion that we found for the 65 with confirmed 
criteria (71% vs 29%) to these 84 studies for which we were unable to obtain confirmation. 
That calculation would have added an additional 60 studies to the number that excluded 
women and 25 to the number that did not. This would result in an estimated total of 407 
studies that excluded pregnant women and 45 that did not. Therefore, of the 452 Phase IV 
studies in which pregnant women could participate, we could estimate that 90% (95% CI = 
82, 99) excluded and 10% (95% CI = 9, 11) did not exclude pregnant women from 
enrollment. Whether the actual proportion is the 90% we would estimate from this 
calculation or the 94% we confirmed - or somewhere in between - does not impact the results 
of the study: the exclusion of pregnant women from clinical research is clearly the norm. 
The study was limited to Phase IV trials. Phase I trials were excluded because they 
only enroll healthy volunteers and would not be appropriate for pregnant women whose 
participation in research should be limited to those studies that potentially provide 
therapeutic benefit. Phase II and III studies were excluded mainly because information on the 
developmental drug's safety during pregnancy was not available in the public domain 
(toxicity study results are proprietary during development) or on the ClinicalTrials.gov 
database (the data source for this question). Therefore, I was unable to evaluate if pregnant 
women could have been appropriately included in such studies.  
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It is the position of this study that the exclusion of pregnant women from Phase IV 
studies of drugs and devices that are not contraindicated during pregnancy could serve as a 
proxy for the practice of the exclusion of pregnant women from all phases of clinical trials. 
This assumption could be challenged. One could ask, "Why would a pregnant woman 
participate in a clinical trial when she could get the drug on the market? Don't people 
participate in clinical trials so that they can access a drug that is not otherwise available?" 
Research has shown that people participate in clinical research studies for many reasons 
including access to otherwise unavailable treatments. Other motivations include: "closer 
monitoring than in routine practice, getting attention for other ailments, better physical and 
laboratory health checks, superior physicians, labs, and testing, more contact with the 
providers,….remuneration, and contributions to society."239  
Of course, since pregnant women have not been included in clinical studies, we don't 
know to what extent they would volunteer to participate. It needs to be re-emphasized that 
pregnant women should only be asked to participate if they are in need of treatment and the 
study would potentially provide therapeutic benefit and if the potential benefits of the study 
exceeded the potential risks. Under those circumstances, participation would be very much 
like treatment in clinical practice with the added benefit of improved informed consent, 
enhanced pregnancy monitoring, and the patient's knowledge that she has contributed her 
experience to the accumulated medical knowledge base to assist other pregnant women.  
However, a limitation of this study is that the exclusion of pregnant women from 
participation in Phase I, II, and III studies was not measured and that their exclusion from 
                                                 
239Iber, F.L., Riley, W.A., & Murray, P.J. (1987). Conducting Clinical Trials, New York: Plenum Press. In 
Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) 
from biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 378. 
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Phase IV studies may not reflect their exclusion from earlier phases of clinical research. In 
addition, the study evaluated studies posted on ClinicalTrials.gov at a specific point in time. 
This time period may not reflect the same prevalence of inclusion/exclusion at other points in 
time.  
This study does not address whether pregnant women would be willing to enroll in 
clinical studies, nor if they would be more or less likely to enroll in Phase IV studies than in 
Phase I, II, or III studies. More research should be done on this topic. Studies have shown 
that pregnant women tend to overestimate the risk of environmental exposures (including 
drug exposures), which suggests they would be less inclined to participate in clinical 
research. However, some pregnant women would likely participate in Phase IV studies for 
the same reasons that some non-pregnant people would: to help others by advancing 
scientific knowledge, to improve their own health care treatment and monitoring, to gain 
access to affordable treatment, etc. One small study found that 95% of pregnant women 
interviewed said that they would participate "if there is a chance that participation in a 
clinical trial would help their pregnancy and improve their baby's health."240 Further research 
is needed to confirm or refute this finding. 
 
E. Conclusion: 
Phase IV trials are conducted using drugs, devices, and other treatments that have 
received regulatory approval and are currently marketed in the U.S.  Phase IV studies are 
                                                 
240Rodger MA, Makropoulos D, Walker M, Keely E, Karovitch A, and Wells, PS. Participation of pregnant 
women in clinical trials: Will they participate and why? American Journal of Perinatology 2003; 
20(2):69-76.  
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conducted for various purposes including, but not limited to, evaluating safety issues, long-
term effects, cost-effectiveness, and use in populations or for conditions other than those for 
which the drug was initially approved. Because these drugs and devices have been studied in 
clinical trials, were approved by FDA, and are on the market, safety, efficacy, and the 
benefit-risk relationship are better established. These studies, therefore, are some of the most 
appropriate studies in which pregnant women could participate.  
Women with medically compromised pregnancies and their health care providers can 
be frustrated by a lack of clinical data available to inform treatment decisions. Subject matter 
experts state that including pregnant women in clinical trials would result in better 
information about treatment options during pregnancy. The clinical literature did not provide 
any documentation or estimate of the current proportion of clinical trials that exclude 
pregnant women.  
Obtaining a measure of the extent of their exclusion is complicated by the fact that it 
would be inappropriate to include pregnant women in some trials because the drug being 
tested may be harmful to the woman, her pregnancy, or her fetus. During drug development, 
the toxicology data on safety of use during pregnancy is proprietary and is known only to the 
drug developer. So the number of Phase I, II, and III trials that exclude pregnant women on 
ClinicalTrials.gov would not take into account whether it was appropriate to do so. In order 
to estimate the proportion of clinical trials that exclude pregnant women but could include 
them, this analysis was limited to Phase IV studies, where the impact of the intervention on 
pregnancy has been evaluated during the FDA approval process. Studies of drugs, devices, 
and procedures that are not contraindicated during pregnancy would be those most 
appropriate to include pregnant women.  
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It is the position of this study that the exclusion of pregnant women from Phase IV 
studies of drugs and devices that are not contraindicated during pregnancy can serve as a 
proxy for the practice of the exclusion of pregnant women from all phases of clinical trials.  
This study establishes that approximately 6% of current industry-sponsored trials include 
pregnant women among the populations eligible for enrollment. However, the overwhelming 
proportion (94%) of studies that exclude pregnant women suggests that, even when it may be 
appropriate to include them, the practice of excluding them is very well-established.  
 Chapter 6 
Qualitative Results and Discussion 
 
 
QUALITATIVE RESULTS 
This study sought to isolate the perspectives of key informants within the 
pharmaceutical industry and related organizations, using qualitative key informant interviews 
to identify rationales for the exclusion of pregnant women from clinical research and to 
discover opportunities for their inclusion.  
 
Qualitative Study Question 
What are the current perspectives of U.S. pharmaceutical industry representatives and 
those of related organizations about the inclusion of pregnant women in clinical research 
studies? 
 
A. BACKGROUND 
To obtain Key Informant information, 16 semi-structured interviews were conducted 
with subject matter experts in the U.S. pharmaceutical industry, and related organizations: 
1. Staff from clinical development, safety, regulatory, and epidemiology departments 
in U.S. pharmaceutical companies (n=5) and biotech firms (n=3)  
2. Legal counsel from pharmaceutical companies (n=2) and PhRMA (n=1)
 
 3. Pharmaceutical Research and Manufacturers of America [PhRMA] (industry 
professional association) representative (n=1) 
4. Independent Institutional Review Board members who are contracted by industry 
to review clinical research protocols (n=3) 
5. Food and Drug Administration representative (n=1) 
Note: BIO, the biotechnology industry association, was invited but declined to participate in 
the interviews. 
Interviews were conducted by telephone. Study questions were provided prior to the 
interviews which were scheduled at the participant's convenience. It is important to note that 
study participants were speaking on behalf of themselves and were not representing the 
position of their companies or organizations. I provided assurance that their names would be 
kept confidential. With their permission, 14 of the 16 interviews were recorded (2 lawyers 
declined). The recordings were then transcribed using Dragon Naturally Speaking® voice 
recognition software. Transcripts of the interviews were copied into the Centers for Disease 
Control and Prevention (CDC) EZ-Text® software which is utilized for the management and 
analysis of semi-structured qualitative data sets. Coding was applied to the interview data to 
facilitate recognition and retrieval of common themes.  
The most pertinent findings from the interviews are presented below. For more 
information on these findings see Appendix IV. Qualitative Study Results: Key Findings 
from Key Informant Interviews.  
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B. STUDY RESULTS AND DISCUSSION 
The primary purpose of this study was to identify from key informants in the 
pharmaceutical industry and related organizations their perceived rationales for the exclusion 
of pregnant women from clinical research and to discover opportunities for their broader 
inclusion. In addition, the 2009 Second Wave Consortium workshop had identified two key 
missing pieces of information for which this study sought clarification: "What is the strength 
of industry's role in affecting the outcome of the debate on the inclusion of pregnant women 
in clinical trials?" and "How influential is the industry's perceived risk of litigation – and is it 
a real risk?" The key informants provided insights on each issue as discussed below.  
The results of the quantitative study (see Chapter 5) revealed, as was expected, that 
most clinical research in the U.S. today excludes pregnant women from participation. 
Participants in the qualitative study agreed that excluding pregnant women from clinical 
studies was the well-established norm. 
The key informants perceived that, of the three primary stakeholders - the 
pharmaceutical industry, IRBs, and FDA - the pharmaceutical industry has the most control 
over whether or not pregnant women are included as study subjects because they: 
• decide if they want to sponsor the trial or not 
• are the owner of the protocol and makes the initial eligibility criteria decisions 
• are the driver of what is to be accomplished by the study 
• know the science behind the drug in development 
• are the responsible party and bear the burden for any "drug exposure-perceived 
injury" 
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Four stakeholders were identified by key informants as having the power to veto a 
clinical trial: the trial's sponsor, the FDA, the IRB, and the institution at which the trial is to 
take place. All of these stakeholders were perceived to be resistant to the idea of including 
pregnant women in clinical trials.  FDA was found to have the least influence as there is no 
regulatory statute that requires the exclusion of all pregnant women from all clinical trials 
(they may be included under certain circumstances). IRBs were felt to be a potential barrier 
to inclusion based on their cautious nature, their patient-centric focus, and the variability of 
decisions from one IRB to the next. 
Having established that the pharmaceutical industry is one of the most important 
stakeholders in the effort to increase the participation of pregnant women in clinical research, 
the participants were asked to discuss the reasons why the industry may and may not want to 
include them.  
 
1. Reasons for Exclusion / Barriers to Inclusion 
Rationales against the inclusion of pregnant women in clinical trials identified in the 
Literature (see Chapter 2: Literature Review) overlapped with the concerns raised by the 
industry stakeholders: non-maleficence and litigation, enrollment issues, business concerns, 
and the lack of a regulatory mandate for their inclusion were all cited as rationales for 
exclusion in both the literature and in this study. Non-maleficence and litigation were the 
most-cited rationales from both sources.  
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Can you give me 3 or 4 reasons why a Company or organization would not want to 
include pregnant women in clinical trials? 
 
"I can't think of 3 or 4 reasons why you'd want to include pregnant 
women."                            -- pharma company lawyer 
 
By far, the two predominant answers to this question were the desire to do no harm 
and the risk of litigation. Most participants mentioned one or both. Other commonly cited 
reasons to avoid including pregnant women were scientific validity issues, risks to drug 
approval and to company reputation, and the increased complexity of conducting such trials. 
Other reasons mentioned by one or two participants were the lack of advocacy for – or even 
awareness of – the need for their inclusion, the lack of a regulatory requirement or 
recommendation, and that it is the historically acceptable way to conduct research.  
 
Table 6.1 Participants' reasons why pregnant women are not included in clinical trials 
Most Cited 
Do No Harm 
Litigation Risk* 
Commonly Cited Occasionally Cited 
Scientific validity issues Lack of advocacy for/awareness of issue 
Risk to drug approval Risk to drug market 
Risk to company reputation/negative publicity Lack of regulatory requirement or 
recommendation  
Increased complexity of the study Not the norm/never been done 
Business concerns Lack of fetal consent 
Areas of confusion 
Are there regulations against inclusion? 
What is the extent of, and what are reasons for, medication use by pregnant women? 
What are the risks of research, in general, and are pregnant women more vulnerable? 
*Litigation concern is addressed in the Section 3. 
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a. Do no harm: beneficence and non-maleficence 
 
"the risk to the fetus... is a historically insurmountable hurdle."                                      
     -- pharma company lawyer 
 
The interviewees agreed that the most important deterrent to the inclusion of pregnant 
women in clinical trials is the fear of doing harm to a developing fetus. Most other 
considerations stemmed from that fear. Being overly cautious was a position that the industry 
has been comfortable with.  
From a company lawyer – 
 "I think it's first and foremost the ethical considerations of 
enrolling a woman when you presumptively don't have a clear 
sense of the potential teratogenic effect of product. So, historically, 
there's been a very strong reluctance to enroll pregnant women for 
fear of causing harm to the unborn fetus. That's the primary 
[reason]. I think that would be far and away the most important."  
 
 Another company lawyer agreed,  
 
"the risk to the fetus… is a historically insurmountable hurdle." 
 
 Three pre-requisites to drug testing in pregnant women were identified by the 
participants:   
• Prior knowledge of the drug's safety for use during pregnancy  
• Prior knowledge of its efficacy against the medical condition in question 
• Prior knowledge of the proper dosing to achieve therapeutic benefit 
 
"The problem lies in the fact that during a clinical trial, we don't 
know the safety of the drug, that's why we're doing the clinical 
trial. That's why we're doing the trial. So, under this kind of legal 
susceptibility, this volatile field, in the context of not knowing the 
benefit of the drug yet and not knowing the safety of the drug yet, 
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then it makes sense that we would exclude this very susceptible 
population until at least the benefits are known. And we will not 
know the benefits of the drugs until the end of the phase 3 trials. 
We may think we know them but until we do the big clinical studies 
we don’t really know the benefits of the drug, the true efficacy and 
benefits."                                                            -- pharma physician 
 
"It's not just congenital anomalies or the effect on the pregnancy, 
the question is, what's the proper dose? Pregnant women get 
increased blood flow and hemodynamic changes that take place in 
pregnancy. I think we need to do some pharmacokinetic studies to 
make sure that the dose is the correct dose for pregnant women. If 
I expect efficacy, I want to make sure I have the correct blood 
levels to get that efficacy."                                 -- pharma physician 
 
b. Scientific validity: Data interpretation 
 
"Pregnancy is just an outlier." 
                            -- biotech physician 
 
Drugs are tested in clinical trials to gain data from experience in enough people to 
result in statistically significant information to draw conclusions about the drug's efficacy, 
safety, and dosage for use in a general population. The people who are eligible to be included 
in the studies are fairly closely proscribed to exclude people who may make analyzing the 
data more difficult – people who have other medical conditions than the illness the drug is 
intended to treat, people who are taking other medications that may interact or interfere with 
the study drug, etc. A rationale for the exclusion of pregnant women articulated by the 
participants in this study was that pregnant women may complicate the interpretation of data 
if they were included in studies of drugs for the general population.  
"…they are so much of an outlier in terms of the normal 
physiology so they just exclude them. They exclude patients who 
have got too complicated a medical history, or who are taking too 
many concomitant meds. That's really basic." Another participant 
said, "It's the same thing that honestly drives really narrow patient 
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populations in the studies they do anyway… pregnancy is just an 
outlier on that spectrum."            -- biotech physician 
 
Pregnant women were cited as having a unique physiology that could impact drug 
studies in two ways: 
• Drugs may affect pregnant women differently than non-pregnant women. 
(pharmacodynamics) 
• Pregnant women may affect drugs differently than non-pregnant women. 
(pharmacokinetics) 
 
It was felt that these factors need to be considered and that they should be evaluated 
in the context of a study designed for pregnant women rather than including pregnant women 
in a study designed for the general population. Also, if pregnant women were included in 
general population studies, the numbers enrolled would likely be low and would probably 
result in a lack of interpretable data to make recommendations for use of the drug in 
pregnancy. 
"We want to make sure that research is always scientifically valid. 
If not, then you're putting people into research that does not have a 
possibility of having some benefit in the future, so then it's not 
ethical to include people in such a trial."        -- IRB representative 
 
Therefore, one of the key findings of this study is that industry perceives it to be 
preferable to design studies that specifically target pregnant women rather than include 
pregnant women in clinical studies designed for the general population. These studies would 
best be conducted after initial testing has established low risk of toxicity and teratogenicity in 
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animal tests, efficacy in the general population, and proper dosing in each trimester of 
pregnancy.  
 
c. Evaluating teratogenicity: 
 
"Thalidomide has really scared a lot of companies" 
                                                          -- pharma physician 
 
Enrolling pregnant women in research studies was seen by the participants as a 
complex and ill-defined process complicated by the fact that between 2% to 4% of 
pregnancies in the background population result in an infant with a major congenital 
anomaly. That percentage rises to about 15% when you include minor anomalies – those with 
no medical or only minor cosmetic significance. The causes of these anomalies are, in the 
great majority of cases, unknown. Those attributed to chemical exposures, including but not 
limited to drug exposures, are very low (about 1%).241,242  
Therefore, if you include pregnant women in studies, a certain number of infants will 
be born with birth defects just by chance or background occurrence. The risk cited by the 
study participants is that a spontaneous birth defect could be erroneously attributed to the 
drug exposure. The evaluation of the potential teratogenic effect of a drug on a fetus follows 
a well-defined scientific analysis that includes factors such as the gestational timing of the 
exposure in relation to the fetal development of the organ system affected, the effect in 
                                                 
241U.S. Department of Health and Human Services, Food and Drug Administration. (2005). Reviewer guidance: 
Evaluating the risks of drug exposure in human pregnancies. Retrieved from http://www.fda.gov/ 
cder/guidance/index.htm; citing Koren G, Pastuszak A, and Ito S. (1998). Drugs in pregnancy. New 
England Journal of Medicine, 338(16), 1128-1137. 
242Brent, R.L. (2007). How does a physician avoid prescribing drugs and medical procedures that have 
reproductive and developmental risks? Clinics in Perinatology 2007; 34:233-232, p. 234. 
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relation to the dosage, the consistency of the effect, etc. A teratologist will be able to provide 
a detailed analysis of the strength of the association between the drug exposure and the birth 
defect, but, especially when there are only a few cases, it is difficult to have certainty of 
causation. In fact, certainty of causation is easier to assure than certainty of non-causation.  
And despite the scientific evidence, causation could be attributed to the drug in the mind of 
the public, sometimes assisted by the legal community. This is what happened with the drug 
Bendectin (discussed in Chapter 1), an effective and non-teratogenic drug that was removed 
from the American market because of litigation costs. The participants in this study disclosed 
that pharmaceutical companies are cautious about testing a new drug in pregnant women and 
risking its reputation in the marketplace if there is no mandate to do so. 
 
"Because, as you well know, bad things happen sometimes in 
pregnancies even when no drugs have been taken. So having one of 
those rare, but not clearly drug-related events happening could 
cast a negative shadow on a drug forever and even prevent 
approval. So having one or two birth defects occur, even if they 
were background, you wouldn't have enough data to clearly say it 
was background, and it could really kill the drug."  
                    -- pharma physician 
 
"I would not want the drug I was trying to develop to be tagged as 
being harmful to women who might become pregnant, [or] being 
blamed for spontaneous abortions or congenital anomalies. Part of 
the problem with enrolling just a couple hundred people is that you 
don't know how to interpret the data. You don't know if there's an 
association or not. The drug could be blamed for it one way or the 
other and I think that's unfortunate."                 -- pharma physician 
 
d. Regulatory rationales: 
 
"It's just like a black hole." 
                     -- biotech physician 
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There appeared to be some confusion about what local and international regulations 
allow and don't allow. Some respondents thought that FDA regulations barred the inclusion 
of pregnant women in clinical trials, others thought that European regulations did so. Some 
thought the human rights documents like the Belmont Report or the Declaration of Helsinki 
prohibited their inclusion. A biotech physician cited "different regulations from the time of 
the Helsinki Declaration until now not allowing…the participation of pregnant women in 
clinical studies" as the reason for their being excluded.  
Some participants stated that pregnant women were not included because FDA, or 
other regulatory bodies, do not require – or even recommend – that developmental drugs be 
tested for use in pregnancy. Few participants even knew that there was a draft FDA guidance 
being developed on this subject.   
An FDA employee predicted that the companies are  
"not going to go there, quite frankly, because they're not regulated 
to go there and there are other special populations, like kids, that 
they're going to have to go to first."  
 
One physician, who has worked at two 'Big Pharma' companies and a biotech firm 
stated,  
"Nobody even talks about it in your planning a study. It's just like a 
black hole. These days when you go [to FDA] for scientific advice 
when you're doing a program, you're looking at pediatric patients, 
they're pushing a lot for elderly patients, and it's not even on the 
radar screen about pregnant women." 
 
Another regulatory issue raised was product labeling. Currently, because most drugs 
on the U.S. market are not tested on pregnant women and animal study results may be 
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ambiguous, they are labeled FDA Pregnancy Category C, which states that, 'human studies 
are lacking, animal studies have shown a risk or are lacking as well, but the potential benefit 
may outweigh the potential risk.' Because pregnancy data are not collected for the purpose of 
adding information to the label, even when products have been on the market for years, most 
remain a Category C for the lifetime of the product. One respondent questioned the quality 
and usefulness of the data in the current labels and inferred that data collected from actually 
studying pregnant women would improve the information in the label and the ability to treat 
medically compromised pregnancies more efficaciously.  
 
e. Business concerns: 
 
"I'm glad this is anonymous." 
                        -- pharma physician 
 
Pharmaceutical companies are for-profit entities whose mission is to create and 
market drugs, biologics, and medical devices that prevent, treat, or suppress the adverse 
medical conditions that plague humanity. That mission includes making a profit in order to 
compensate the people who work to achieve the mission and to spur the continued research 
required to sustain innovation and grow profitability.  
For the pharmaceutical company, the ultimate purpose of the clinical trial is to 
confirm the efficacy and the safety of the new compound in order to get their product 
approved as quickly as possible. Years of research and millions of dollars have already been 
spent in shepherding the potential product to the clinical trial stage. 
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"Companies want to get their studies approved as fast as possible, 
they don't want any extraneous issues that could go wrong."                                              
          -- biotech physician 
 
"Industry constantly thinks about the risk to the drug." 
                              -- pharma physician 
 
Populations that are peripheral to the primary target population are a secondary 
concern. On this topic, key informants stated that,  
"They're not going to go there until they know this drug is going to 
make money for them,"                                   -- FDA representative 
 
"[T]hey don't want to put their drug in a position where the drug 
may receive an unfavorable review from the FDA or any 
regulatory party."                                               -- pharma physician 
 
New drug approvals are based upon the results of Phase I through Phase III trials in 
the general population. Delaying testing in pregnant women until the conclusion of the Phase 
III trials was perceived to be a potential solution to the risk of having a chance finding or a 
false association with a birth defect interfere with an effective product's initial approval.  
In the context of business, several participants named adverse notoriety for the 
company as a reason to avoid testing the drug in pregnant women. An IRB representative 
said, "[I]f something were to go wrong and people found out, 'wow, you were testing this 
drug on pregnant women…'" the impact to the company's reputation could be significant and 
difficult from which to recover. 
"It's not just the fear that something can go wrong – I'm glad this 
is anonymous – [but] when you consider that things can go wrong 
in a clinical trial and the most published news about clinical trials 
is the negative information… You conducted a clinical trial and 
something goes horribly wrong, the name of the facility is put out 
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there, the name of the physician that conducted it is put out there, 
the IRB that reviewed and approved it is put out there…even as 
careful as you can be.."                                      -- pharma physician 
 
f. The risks of research and pregnancy 
 
"It's risky research." 
                        -- IRB representative 
 
Some interviewees gave me the impression that they perceived the risk to the 
pregnant woman and the fetus from participation in any clinical trial to be extremely high. 
They did not consider it on a case-by-case or a trial-by-trial basis, but thought the risk to be 
very high across the board, e.g.,  
"Extreme safety risks – for the mother and the unborn child." "It's 
risky research. I consider it risky research."        -- PhRMA lawyer 
 
And they suggested that pregnancy itself was a high risk condition,  
"Not only is the woman's body different, [but it is] potentially more 
vulnerable healthwise while pregnant…"        -- IRB representative  
 
Research has shown that pregnant women and health care providers overestimate the 
teratogenic risk of drugs and environmental factors. Do we also overestimate the risk of 
participation in clinical trials by pregnant women? Also, are women less healthy and more 
vulnerable when pregnant? Is pregnancy a disease state or a healthy state? Are pregnant 
women, as the Common Rule suggests, a vulnerable population? 
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g. The informed consent of the fetus 
 
"The child has no voice." 
                  -- IRB representative 
 
A couple of the participants suggested that one of the reasons why pregnant women 
are not included in clinical trials is because it is impossible to consent the fetus. IRB 
informants stated: 
"There's not just one person, there's two people at risk. You have 
your second person at risk that has no voice whatsoever. You have 
the mother who can say, yeah, I think I want to do this, but when 
she says that, she's speaking for a child as well, and the child has 
no voice. I think that's the hardest part."         -- IRB representative 
 
"Whatever you think of the moral status of the unborn human life, 
medicine can treat the fetus…as a patient and the law tends to as 
well. So in practice there's a human being there, who in terms of 
human subjects protection is by definition vulnerable."                     
        -- IRB representative 
 
The status of the fetus as an entity whose needs, it was suggested, should be 
considered as independent from the pregnant woman was raised in the responses to this study 
and could be considered to be a barrier to the inclusion of pregnant women in clinical trials.  
 
h. Limit testing to drugs indicated for use by pregnant women 
 
"[T]here's actually a risk of non-treatment to the fetus as well." 
                                                   -- pharma company lawyer 
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"I can't think of 3 or 4 reasons why you'd want to include pregnant 
women - unless it's a situation where you have a specific case 
where you need to study your intervention in the setting of 
pregnancy because pregnant women are going to get your drug in 
the (post-marketing environment)."        -- pharma company lawyer 
 
This response suggests that pregnant women will only use a drug that is intended for 
use by pregnant women. We know that many exposures in pregnant women are unintended – 
the use of medication by women who do not yet know that they are pregnant. We also know 
that many medical conditions are not specific to pregnancy but may occur in pregnant 
women. Therefore, it is difficult to determine with any specificity, which drugs in 
development will or will not be used by pregnant women. The prudent assumption would be 
that most drugs, if they are effective, will be used by pregnant women.  
Since it would be impossible to know what drugs may be used by pregnant women in 
the market place, are there others ways to target research for pregnant women?  
 
I doubt that there's going to be much interest in sponsoring clinical 
trials for the use of chronic meds for non-life-threatening 
conditions or where there is a reasonably well-established 
treatment paradigm. I mean, you have insulin for diabetes, you 
have 'suffer with your symptoms' for allergic rhinitis, etc.  A lot of 
these, you can kind of manage through, but there's others that as a 
pregnant woman you can't always wait. And there's actually a risk 
of non-treatment to the fetus as well. Then I think you have a much 
more compelling ethical argument for experimentation. 
                   -- pharma physician 
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i. Lack of advocacy 
 
 "[T]here's just been no interest in looking at this. There's not been 
anyone to advocate for it…It's not very high up in the 
consciousness of most people conducting clinical studies."                                                  
          -- biotech physician 
 
There has been no push for a change, no pressure on industry to do this. The lack of 
experience, the perceived hassle, the increased complexity of the study design, IRB 
resistance, legal considerations, all conspire to maintain the status quo. One participant 
summed it up in this way,  
"I think there's a long history of not doing it, so trying to get over 
the inertia of doing that is very difficult."          -- biotech physician 
 
And yet, there are suggestions, like the draft FDA guidance and the Second Wave 
Consortium, that advocacy has begun. From the FDA representative –  
"they have to get over the sort of natural reaction of, 'oh, boy, we 
really can't do this' and then get down to the fact that, 'yes, we can 
do it, how are we going to do it?'" 
 
 
Key Findings for Section B.1.: Reasons for Exclusion / Barriers to Inclusion 
One of the aims of this study was to isolate the concerns that are articulated by the 
pharmaceutical industry and their IRB and FDA colleagues regarding the inclusion of 
pregnant women in clinical trials. A better understanding of the potential barriers perceived 
by these powerful stakeholders can contribute to the formulation of a plan for change. 
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Key finding #1: The fear of causing harm to a fetus is the most important concern limiting 
the inclusion of pregnant women in clinical trials.  
 
Key finding #2: The fear of litigation is one of the major concerns that is limiting the 
inclusion of pregnant women in clinical trials.  
 
Key finding #3: The efficacy, safety, and proper dose of a medication must be known to 
some extent prior to testing the drug in pregnant women. 
 
Key finding #4: Industry has little experience designing clinical trials that include pregnant 
women. More information is needed to assist with the design of such studies. 
 
Key finding #5: National and international regulations regarding the inclusion of pregnant 
women in clinical studies are not well understood.  
 
Key finding #6: Studying drugs in pregnant women would provide valuable information for 
the label, which would improve the treatment of pregnant women. 
 
Key finding #7: Industry is reluctant to risk the approval of a drug for the non-pregnant 
population or the reputation of its company by testing drugs on pregnant women.  
 
Key finding #8: A sufficient number of pregnant women must be included in a study of 
pregnant women to ensure that the data collected is interpretable.  
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 Key finding #9: Industry perceives little motivation or advocacy for the study of its products 
in pregnant women.  
 
2. Litigation 
2a. Litigation Risk 
Do we know that allowing pregnant women in clinical trials would result in litigation or 
are we presuming it would?  
 
"The elephant in the room is litigation."  
                                        -- biotech physician 
 
Most of the participants raised the issue of litigation during the course of the 
interview. Most of the respondents to this question stated that they presumed that liability 
would increase if we conducted clinical trials in pregnant women, but they were not sure that 
it would increase. Since we have little experience with trials in this population, we really do 
not know.  
"…when you talk to the OB people,… I hear that there are a lot of 
malpractice suits concerning congenital anomalies…" 
          -- pharma physician 
 
Of the two participants who said they know that litigation would increase, one biotech 
physician said he knew it because of reports in the media and the other, a pharma company 
epidemiologist knew it from personal experience at her company. The latter's experience was 
in regards to a product that was on the market for years and was subsequently found to raise 
the risk for certain birth defects. 
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The biotech company physician said, "people are suing already when we are 
excluding them." When asked to explain, he said that his company has been involved in 
litigation  concerning the exclusion of a woman from a trial during which she became 
pregnant and one concerning a pregnant woman who was excluded from enrolling in a 
clinical trial, because they are "not providing them with the drug that they think is 
necessary."  
A representative from PhRMA stated that, "there are not a lot of lawsuits filed with 
respect to clinical trials" in general. This is corroborated by the literature which indicates 
that, "the risk of incurring liability during the early stages of drug investigation is actually 
quite small whereas the potential for substantial liability is much greater once a fetotoxic 
drug enters widespread use."243 
The issue of informed consent was raised by several participants such as this pharma 
company lawyer who said,  
"if they had informed consent, I can't really see a huge risk of 
litigation versus other studies that we do."  
 
An IRB lawyer responded that,  
"you're following the regulations, you obtained IRB approval so 
it's been considered from an ethics perspective, the person's been 
informed about it, the risks have been minimized as much as 
possible, and you're doing it to help pregnant women right there in 
the trial or in the future." A potential increase in litigation, he said, 
"should not be a reason to stop people from including pregnant 
women in clinical trials. I don't think there's going to be that much 
of a boom in litigation for the industry." 
                                                 
243Clayton, E.W. Liability exposure when offspring are injured because of their parents' participation in clinical 
trials. (1994). In Mastroianni, A.C., Faden, R.R., & Federman, D.D., Women and Health Research: 
Workshop and Commissioned Papers (pp. 102-112). Washington, DC: National Academies Press. 
Retrieved March 11, 2012 from http://www.nap.edu/ openbook/0309050405/gifmid/103.gif 
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 Citing the anthrax study, an IRB lawyer stated that, "pregnant women are being 
included in this trial for a very important reason just like people who are not pregnant are 
included in clinical trials." But not everyone agreed. A pharma company lawyer said that  
"the decision to sue is something that the Company can't control. I 
would make sure the informed consent is as strong as it can be and 
Investigator's Brochure contains disclosures of all data to date 
about risks. It would be a benefit/risk analysis. We can defend on 
causation," he continued, "bring in experts, particularly to discuss 
the science behind the defect. But when playing to a jury – I have 
[children] – any juror might see the case as a parent with a child 
[would]. So I think the litigation risks are higher." 
 
Key Findings for Section 2a. Litigation Risk 
Because birth defects occur at a rate of 3 to 4% in the general population, birth 
defects would therefore be likely to occur in 3 to 4% of the infants born to women who 
participated in clinical trials. The expectation among many participants was that litigation 
would follow these adverse events. But, upon further discussion, it was acknowledged that, 
since we have little experience with pregnant women in clinical trials, we really don't know. 
 
Key Finding #1: There is a perception that the risk of lawsuits against a company would be 
higher if drugs were being tested on pregnant women. But, because we have little experience 
in this area, we don't know if the litigation risks would be higher in clinical trials of pregnant 
women than in clinical trials in general. 
 
Key Finding #2: There is also a perception that excluding pregnant women from clinical 
research could result in litigation due to adverse pregnancy outcomes caused by denying 
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pregnant women access to a developmental drug they needed, or caused by a drug that was 
not fully evaluated before entering the market. 
 
Key Finding #3: Thorough informed consent, complete disclosure in the Investigator's 
Brochure, FDA approval, IRB review, risk minimization activities, and the disclosure that the 
trial is intended to help pregnant women now and in the future, could help protect the 
company from lawsuits in clinical trials of pregnant women.  
 
Key Finding #4: Our litigious society, the emotional component in jury trials, and increased 
litigation risk in the obstetrical community in general could increase the risk of litigation in 
clinical trials of pregnant women.  
 
Key Finding #5: The risk of liability for injuries that occur during research in general is low. 
Some respondents, including company lawyers, believed that the increased risk would be 
minimal and should not be a deciding factor in whether or not to conduct trials in pregnant 
women.  
 
2b. Litigation Environment 
Do you think litigation is higher in the clinical trial environment or in the post-
marketing environment? 
 
"We're risk averse…to anything that has to do with a potential 
lawsuit."                                                             -- biotech physician 
 
The participants of this study expressed concerns about the potential for litigation 
against the pharmaceutical companies and how it could impact research and product 
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availability. Most respondents thought that the risk of litigation was lower in the clinical trial 
environment than in the post-marketing environment, followed closely by those who 
answered, "I don't know."  
Only three participants thought that the risk of being sued was lower in the post-
marketing environment. The concept of the 'learned intermediary' was mentioned by a 
pharma physician who said, "in the post-marketing environment the prescribing physician 
has the decision-making responsibility," and a pharma lawyer who said that for marketed 
products, "you're going to have a labeled statement about use in pregnancy…and the 
prescribing physician will have made the judgment about that in light of the known risks." 
The third respondent, a biotech physician, thought the risks were higher during clinical trials 
because you know less about the safety of the drug at that point in time. He felt that the drug 
being studied could be associated with spontaneous abortions or birth defects that occurred 
during the trial by chance. The pharma physician stated that, "as soon as the Company is 
involved, automatically you assume that there is a greater risk," but, he acknowledged, "It's 
a guess." 
 
 
Table 6.2 Factors that increase the risk of litigation by environment 
Factors that increase the risk in the post-
marketing environment 
Factors that increase the risk in clinical 
trials 
No informed consent Little knowledge about the safety of the drug being studied 
Lack of adequate testing / due diligence in 
clinical trials prior to marketing 
No regulatory statement about safety (like the 
drug label) 
No learned intermediary prescribing the 
product 
Many more pregnant women will be taking the 
drug in an uncontrolled, uninformed manner. 
They may have concurrent medical conditions 
or be taking concomitant medications; have 
less instruction on the proper use of the product 
and less monitoring for safety and efficacy. 
Current standard of care is exclusion – why 
were they testing pregnant women? 
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Table 6.3 Factors that decrease the risk of litigation by environment 
Factors that decrease the risk in post-
marketing environment 
Factors that decrease the risk in clinical 
trials 
Learned intermediary (prescribing physician) Informed consent 
Drug label Drug is known to be experimental 
Drug was approved by FDA Study conducted according to regulations  
IRB acknowledgement that risks were 
minimized and study design is ethical 
Study is conducted for the benefit of pregnant 
women 
Legal scrutiny of the protocol prior to 
implementation 
Select population in trials 
 
Historical precedent – it is harder to succeed 
with litigation in the clinical trial setting than in 
the post-marketing setting 
 
Most of the interviewees thought that the risk of litigation was higher in the post-
marketing environment for the reasons shown in Tables 6.2 and 6.3. They felt somewhat 
protected by the assumption that people participating in clinical trials were aware that the 
drug was experimental. When the drug is on the market, the felt that the public assumption is 
that the drug has been shown to be safe and effective and it is used by a larger and more 
diverse group of people. These factors could increase the risk for adverse pregnancy 
outcomes that could result in litigation.  
"I actually think the litigation risk would be higher in the post-
marketing environment. The clinical trials are being conducted 
according to regulations, being reviewed by an IRB, people are 
going into the study being informed about potential risks, and 
people are in the trials being conducted for the benefit of the 
specific people or…pregnant women. It'll be much more difficult to 
make a case [for] the mother or the fetus who was harmed in the 
clinical trial setting. Now if you take that in the post-marketing 
setting, where you have this drug that’s been approved by the FDA 
and now it has some deleterious effect on the pregnant woman or 
it's not effective, everyone's going to come down and say, "how, 
FDA, could you let this be approved?" and also, "how, Sponsor, 
can you allow this to go to the market? You didn't do your due 
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diligence, you didn't do your research to see if it would affect 
pregnant women, to see if it would be safe." I think now you have 
much more firepower to say you didn't do everything you should 
have, you didn't do due diligence, you breached your duty, 
therefore we can make a good case against you."     -- IRB lawyer 
 
"Litigation risk seems to be higher in the post-marketing stage, 
because of the fact that in clinical trials, you have a very select 
population. You have a smaller population... in order to get a drug 
approved. And [when] they're using the drug in post-marketing 
and it goes into widespread use there – many, many, many more 
patients – and patients who don't necessarily… fit the profile of a 
select population for a clinical trial. They may have comorbidities, 
it's not controlled, it's not under a proscribed set of instructions as 
to how to take the drug. So you have much more risk. The risk goes 
up because the proportion of patients taking the drug increases." 
      -- pharma physician 
 
The informed consent document and process were mentioned by many participants as 
protecting the companies against allegations of research-related injury.  
 
From a doctor: "I would think, not being a lawyer, if in fact the 
consent forms were designed properly for clinical trials, and if the 
woman had a real opportunity to talk about the pros and cons of 
the disease, of the drug, and the possible outcomes, I would think 
litigation in the clinical trials might actually be less than in the 
post-marketing environment. Because in post-marketing, many 
people don't get the true, broad benefit/risk analysis of the drug 
before they start taking it." One of the lawyers agreed, 
"Historically,…it's hard for a plaintiff to succeed if there was 
informed consent." 
 
In spite of this, pharmaceutical company interviewees confirmed a real concern about 
the potential for litigation. They disclosed the litigation can result in high costs to the 
company, and damage to a company's reputation.  
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"Obviously, pregnant women and children or babies are hot button 
emotional topics for juries and so it's not just, 'what is the risk of 
being sued?' but if you lose, 'how much is the risk for damages?'"  
        -- pharma physician 
 
 One pharma physician in clinical development described society's reaction to birth 
defects by saying that "squeamish is too benign a term. Apoplectic is more like it." He went 
on to say that, "A new chemical entity or an unregistered chemical entity would be an easy 
target."  
 
From a company lawyer: 
 
"Liability – this is an emotional, sensitive subject. I can see how in 
a lawsuit, any harm to a mom or a fetus could play well to a jury. 
There would be unknown damages, speaking objectively. 
Therefore, I would caution any sponsor in enrolling pregnant 
women especially in the absence of data that says it is safe or if it 
may not be effective – the potential harm would give us pause." 
 
In a similar vein, one of the participants referred to another company that has a strong 
reputation for conducting pregnancy registries for their products that are intended for use by 
women of childbearing potential. For one such product, the company had identified an 
increased risk for a certain birth defect. Subsequent to this finding, the company was the 
subject of television and internet advertisements encouraging women who had used the 
product to call the law firms in the ads. Her concern was that the lesson learned was that a 
company might be at higher risk for having done a study and found a correlation than if they 
had not done the study at all.  
A pharma physician cautioned that a little knowledge can be a dangerous thing. It 
may not be unusual to find a random birth defect in a small sample of pregnant women. 
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"This," he says, could be "suggested as [having] prior knowledge" and could be used against 
the Company in litigation. Another respondent agreed,  
"there are just not enough pregnant women who are exposed until 
the medications are on the market. Some of these things can't be 
studied and can't be evaluated until they are on the market and 
then you are dealing with…a less controlled, and more real-world 
environment."           -- pharma epidemiologist 
 
Whether or not the risk of litigation is higher in the clinical or the post-marketing 
arenas, the fear of such litigation is real and may have other consequences. One respondent 
described its impact saying,  
"It's very tough. I can tell you that within major Pharma, there are 
drugs that can be very useful and that address a very clear unmet 
medical need that are being given thumbs down by senior 
management because of the spector of endless litigation." 
      -- pharma physician 
 
In the end, the advice of a company attorney was that, "I'm not sure either way that the 
litigation issues ought to drive you either to do or not to do trials [in pregnant women]." 
 Stated another, "you never know if you'll lessen the litigation risk, but you know, we accept 
litigation as the risk of doing business."  
 
Key Findings for Section 2b.: Litigation Environment 
My perception was that this question had not been widely considered by the study 
participants. But the issue is raised in the literature: pregnant women are using marketed 
medication that has not been studied in pregnant women. The result of not testing the 
products on pregnant women in the controlled clinical trial environment is that pregnant 
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women take medication in the post-marketing environment usually without the benefit of 
informed consent, risk minimization considerations, and the enhanced monitoring of her 
pregnancy and the fetus that would be available in a study. Consider the difference in the 
number of birth defects that occurred when thalidomide was on the market (>10,000) 
compared to the number of defects that might have occurred in a clinical trial before the 
teratogenic effect was identified (I would estimate 3 or 4).  
 
Key Finding #1: Pharmaceutical companies are concerned about litigation risks associated 
with testing products on pregnant women in both the clinical trial and the post-marketing 
environment.  
 
Key Finding #2: Fear of litigation about birth defects may be deterring the development of 
potential pharmaceutical interventions that address unmet medical needs of the general 
population.  
 
Key Finding #3: The risk of litigation is perceived to be higher in the post-marketing 
environment than in the clinical trial setting.  
 
3. Reasons for Inclusion / Opportunities to Include 
 After discussing the reasons that pregnant women are currently excluded from 
participating in clinical studies, the converse question was asked to ascertain if, despite 
understanding why they are excluded, they might also understand why they should be 
included?  
 140 
 
Aside from studies that are specifically about conditions of pregnancy, can you give me 
3 or 4 reasons why a Company (or an IRB) should or might want to include pregnant 
women in clinical trials? 
 
 Finding that the key informants could list many reasons why pregnant women should 
be included in clinical research, one can extrapolate that to suggest that there are many others 
within industry who feel the same way. The reasons they cited are summarized in Table 6.4. 
 
Table 6.4 Key informants' reasons for including pregnant women in clinical trials 
Reasons to include pregnant women in clinical research 
It's the right thing to do When the benefit exceeds the risk 
There is medical need To aid the company reputation 
To assist health care providers To inform the product label 
To fully evaluate the product's safety profile To develop medicines that treat the population 
To improve insurance coverage for medications As a competitive advantage 
To emulate best practices in other special populations like the elderly and pediatrics 
 
 These reasons are very similar to those cited in the literature (see Literature Review, 
Chapter 2) with additional attention to the benefits that might accrue to the product and to the 
company.  
 Having established that people within industry and related organizations see the need 
for improved knowledge on how to treat medically compromised pregnancies, the next step 
was to ask for their input on how to do that. The participants in this study were very  
experienced in their respective areas and so would likely represent current thinking on the 
topic and/or could provide suggestions based on experience within their companies and 
organizations.  
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 "What would it take to have companies open (or IRBs approve) relevant clinical 
trials to pregnant women? Would a guidance document be strong enough or would it 
need to be by regulation?"  
 
"I think it would take a woman CEO." -- biotech physician 
 
"I think it would take a woman CEO. People who have had issues 
with (pregnancy), people who have wanted information and have 
had to make difficult decisions with the pregnancy are more 
conscious of these issues than people who haven't."  
      -- biotech physician 
 
"I think it would require FDA to have a strong position. And then I 
think you'd need patient groups that would be pushing. And then I 
think you would need enlightened researchers in the company that 
are willing to take the next step for research in the 21st century. I 
think we still very far from it."  -- biotech physician 
 
 A pharma industry lawyer reasoned that, because there is no regulatory impediment 
to the inclusion of pregnant women, there is no need for a guidance or regulation. However, 
most of the interviewees thought a guidance document would be an effective tool to get the 
dialogue started, to get stakeholders to take notice of the issue, to raise consciousness.  
"[A guidance] would be your first step to actually having sponsors 
not be fearful to include pregnant women in clinical trials. And it 
would be a huge step for the IRB." "It is the FDA standing up and 
saying, 'we support this.'"  
 
Respondents considered a guidance to be "a favorable fact in litigation," and "a sanction for 
enrollment." Without a guidance document, most thought that very little would happen. Said 
one IRB representative, "…if they're not providing guidance, believe me, IRB's aren't going 
to want to touch it." 
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 However, many felt that a guidance document would not be enough for companies to 
change their practice of excluding pregnant women from the drug development process.  
"Certainly a good, thoughtful guidance document would be helpful 
for the really altruistic company or one where this is the nuts and 
bolts of their indication to treat non-pregnant related illnesses that 
occur during pregnancy. But my guess is, unless told to do so, most 
companies would not."        -- pharma physician 
 
 
 
Another participant concurred, "The experience with studies in 
children suggests that a regulation would be necessary." 
         -- pharma physician 
 
 Another agreed, "If we want a universal way of doing it, then I 
think there needs to be a regulation. Otherwise it will depend on 
the goodwill and the interests of companies and will be very 
uneven."         -- biotech physician 
 
 But not all were convinced that a regulation is the answer either.  
"From a litigation perspective, it would be a good defense. But I 
can't see them saying you have to do it - it would pose a risk for the 
FDA."               -- pharma lawyer 
 
 Study participants expressed hope that a regulation would not be required.  
"I personally have this philosophy of, 'don't give me a rule if I 
don't need a rule.' Or a law. And while I applaud the success that 
the pediatric laws have had driving people to the right space, I 
would just love to think that we could get this just by the force of 
public need without having to think about regulation. Goodness 
knows we've got enough of them as it is."  -- FDA representative 
 
"I also realize that these large business enterprises called 
pharmaceutical companies have so much going on that sometimes 
they don't pay attention unless there's a rule. I'd hate to think we 
have to go there. I really would love to see this take root without 
having to go much beyond guidance."            -- FDA representative 
 
 Others agreed that guidance documents, while non-binding, are difficult for 
companies to ignore, and, for the most part, "companies conform." With guidance 
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documents, said a PhRMA lawyer, "you get additional clarity that is quick and adaptable, 
easier. Regs are too vague, guidance can be more detailed." Another physician observed that 
guidance recommendations "can be achieved more easily and harmonized more easily" 
across institutions, states, and even across countries. 
 
 Additional follow-on questions were asked to solicit more specific information. 
"Would Company indemnification be necessary? Is that a realistic option?" 
 
"…if you're not doing things properly, you're going to be sued, I 
don't care what the indemnification says."       -- pharma physician 
 
 Because the perceived risk of company liability was high among industry and IRB 
participants, the question of Company indemnification was explored. Most respondents did 
not think that Company indemnification was a realistic option. 
"I think there are instances where clearly things were not done 
properly and then indemnification doesn't matter to me anymore. 
Indemnification would not [persuade] me one way or the other. I'm 
not sure it really works in the final analysis because if you're not 
doing things properly, you're going to be sued, I don't care what 
the indemnification says."                                  -- pharma physician 
 
 But other participants, once prompted to think further about the possibility, voiced 
interest in its potential. An IRB representative was aware of current efforts by a 
governmental committee to explore this issue further.  
"There are people who are pushing for national funds to reimburse 
research injury. The Presidential Commission just recommended 
that in a recent report, following up on the Guatemala issue.‡ 
Recommendations were: improved accountability and expanded 
treatment and support for research subjects injured in the course 
of [a study], because subjects harmed in the course of research 
should not bear the cost." 244              -- IRB 
physician 
                                                 
‡ The "Guatemala issue" refers to a recently uncovered study conducted in 1946-48 by the U.S. Public Health 
Service involving the intentional exposure of subjects to sexually transmitted diseases without their consent.  
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  He continued, "they cite the national Vaccine Injury Compensation Program (VICP) 
as the example here." [The VICP was enacted in 1986 "to reduce the potential financial 
liability of vaccine makers due to vaccine injury claims. The legislation was aimed at 
ensuring a stable market supply, and to provide cost-effective arbitration for vaccine injury 
claims.]245 Other participants disagreed with a parallel between the VICP and potential 
indemnification for studies with pregnant women, citing vaccines' more significant public 
health impact and the absence of a comparable market concern as differentiating factors.  
 
"Well, so a guidance document is interesting but probably would 
not be sufficient to overcome the other concerns that companies 
have. Carrots, like a patent extension, also may not be sufficient to 
overcome if there are serious litigation risks. So, indemnification 
might actually be important. So, for a society and a Congress that 
really wants to foster drug development [in this area], that might 
be the most effective way to do it. So you give a carrot [a patent 
extension] and a safety net for a specific list of conditions. This list 
of conditions should be studied and if there is a bad outcome for a 
pregnant woman enrolled in one of those studies there is indemnity 
for the company and a separate fund for recourse for the injured 
party. That might be good. You could look at vaccines as a model." 
        -- pharma physician 
 
"Would patent extensions, like those implemented for pediatric trials, be a viable 
enticement?"  
 
"Be careful what you wish for." – FDA representative 
 
 Many participants agreed patent extensions were a viable partial solution:  
"We pharmaceutical companies love patent extensions, because it 
takes a lot to get a drug on the market. I think it may be required, 
                                                                                                                                                       
244Presidential Commission for the Study of Bioethical Issues. (2012). Moral Science: Protecting Participants in 
Human Subjects Research. Washington, D.C., 2011. Retrieved from http://www.bioethics.gov/cms/ 
node/558  
245 Wikipedia contributors. (n.d.). National Childhood Injury Act. In Wikipedia, The Free Encyclopedia. 
Retrieved April 1, 2012 from http://en.wikipedia.org/wiki/National_Childhood_Vaccine_Injury_Act. 
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because if you're going to take the risk of doing it, the patent 
extension may make it worth your while."         -- pharma physician 
"Patent extensions have worked for pediatric exclusivity; it could 
possibly work in this particular case."               -- pharma physician 
"A Company is taking extra risks that have monetary value."  
                -- phrma lawyer 
 
 Another suggestion extended the concept of patent extensions to include transferable 
extensions.  
"You could either extend the patents or you could have a certificate 
that allows you to transfer it to another product. So, there the 
statute says that [if] the manufacturer is developing a drug for a 
rare and, I think maybe, neglected disease drug and they get it 
approved, they can transfer the patent extension to another drug. 
So if you've got a multibillion-dollar drug and you are allowed to 
get an extension on that drug by developing a new orphan drug, 
that's a huge incentive. So, [either] extend the patent for the 
product for which it's developed or transfer the extension to 
another product."                                               -- biotech physician 
 
 However, others expressed dissatisfaction with their patent extension experience in 
the pediatric sector.  
"By the time you complete the pediatric program, get through all 
of the hoops and things, you still might turn out to be too late and 
you've lost patent already or they've taken so long that a patent 
extension doesn't add much. Or with the generic challenges to 
patents that come up so frequently, the patent extension may not be 
worth a hoot and holler… [I]t worked out in one of our cases, that 
we got the six-month patent extension followed one month later by 
a patent suit and the judge ruled in favor of the challenger."  
            -- PhRMA representative 
 
 The FDA participant also advised caution stating that, "Patent extensions would be 
tightly linked to the expectation that we have a rule or a law. So if you go that route it means 
that you're conceding that we need some kind of regulation. Be careful what you wish for." 
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 However, there is a downside to patent extension in the public sector. "Patent 
extensions are kind of unpopular among the general public these days," said an IRB 
representative. A pharma lawyer agreed: 
"the last thing that industry would want is to seem like they're 
doing this from a profit motive as opposed to a public health 
concern and certainly they've taken a fair amount of criticism for 
even the pediatric extensions despite a clearer benefit from a 
public health perspective. It's hard to think that would be that 
helpful."  
 
A lawyer at PhRMA also agreed, stating that,  
"Congress is likely not to grant any more patent extension 
approaches. I think there's a feeling now, with policymakers for 
some time now, that it hasn't been a great solution. …there have 
been some perceived cases that… were seen as industry trying to 
get the extra market exclusivity …you will get some backlash." And 
finally, one participant observed that, "the current fiscal 
environment is at odds with providing additional exclusivity." 
 
To open the issue up to the study participants to contribute additional thoughts or ideas on the 
topic, the open-ended question was asked: "Are there other solutions or incentives you can 
think of?" 
"Just put a whole package of things out there and let them 
react to it."      -- biotech physician 
 
 When asked this question, the interviewees responded with a myriad of ideas, 
commentary, and topics for further discussion. Many concluded their comments with a 
pessimistic appraisal such as, '…but I don't think that will work.' I have organized these ideas 
in the table below under targeted headings. 
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Table 6.5 Participants' observations, suggestions, and potential solutions 
Observations and Recommendations from Participants Solutions 
On the Business   
The company….has to adopt it from a very high level. It's got a come down 
from the top, that the company understands the problem and is willing to 
commit the company resources to doing it. It's got to take upper management 
to require it - I don't think the clinical monitors are going to embrace it. 
Establish 
commitment at 
the top 
My hope is that the guidance would at least drive the companies back to 
reviewing their current feelings on this.  
Respond to 
FDA guidance 
I have this vision of, once we get over the hump of the concerns - which 
we've done before, first with women, then with kids, now with pregnant 
women – it should just be part of the normal [drug] development scheme. 
Make routine 
part of drug 
development 
[Companies] have to see that there's good public relations, that it's good for 
the company, good for the industry, good for the sector.  
Public 
Relations 
Opportunity 
They'd have to see more companies doing these trials….they have to see 
success in these trials and then I think they would be more interested in 
perhaps doing it. You'd want benchmarking - the Company would want to be 
in the middle of that bell-shaped curve. Maybe once some Companies start 
doing it and it doesn't result in negative outcomes, more companies might 
start doing it. I don't think there are enough upsides. There's more downside 
risk than upside benefits. 
Benchmark 
practices and 
successes 
You face the obstacle of businesspeople without that [scientific] knowledge 
base. If they would look to their scientific colleagues - but they're looking at 
the business from an entirely different perspective.  
Have science 
drive the 
decision 
In pediatrics, there's a market; with pregnant women,…not very much. So 
from a commercial perspective, it is completely unappealing for the 
Company. 
Define the 
market 
 
On Litigation 
 
I think if they knew the data well enough and knew that the drug could help 
those women without severe consequences to the company, without risk to the 
company, I think they wouldn't get in the way, they wouldn't prevent it from 
being done.  
I think if ….there was some liability for not treating the woman when you 
could save her life or spare her from increased morbidity, I think that might 
persuade them as well.  
Legal 
community 
advisement in 
assessing real 
risks and 
devising 
protections 
 
On FDA  
…more data can potentially get you a better pregnancy category. [I]f the 
company does do studies in pregnant women and that [information] could be 
then included in the label, that might be yet another incentive. Some drugs are 
thought to be better for you in the pregnant population. That being based on 
real scientific data might be an incentive. 
Implement the 
Pregnancy 
Labeling Rule 
FDA needs to have…more pats on the back, it needs to do some things that 
will, you know, [give them] 'Atta Boys.' Once they start thinking outside the 
box with some of these things, they're going to be in the same position they've 
been [in] which is kind of the whipping dog of Congress and every other 
group that wants to criticize them for stuff.  
Strengthen 
public advocacy 
for FDA's 
efforts 
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And there should be a bit of a, "if you don't do this, especially if the drug or 
vaccine has a high likelihood of being used by pregnant women, this may be 
harsh but, it may jeopardize your indication or authorization." We had 
something very similar. [FDA] said if you don't do this elderly study, you are 
not going to get an authorization and now we're doing an elderly study. We 
never would have done it unless they said that in writing. 
Implement 
sanctions for 
not doing 
studies  
Every month the drug's not approved you lose a lot of money, so early 
approval is really an incentive as well. I think what [companies] really want is 
rapid processing of their applications so that it gets reviewed and the FDA 
makes the decision. 
Implement fast 
track review as 
incentive 
I'm not sure there's enough dialogue that takes place between pharmaceutical 
companies and regulatory agencies throughout drug development. I think 
these issues need to be discussed early and they need to get some real strong 
guidelines from the regulatory agency. These agencies have a lot of power 
and pharmaceutical companies really have to listen to them to get the drug 
approved. Part of the problem too, is when you try to make an appointment to 
see some of the people in the regulatory agency, they don't have the time and 
they push back. And I think you really have to be able to talk with them so 
that you know what they're thinking and they know what you're thinking. 
Release the new 
guidance 
document; 
Improve access 
to dialogue 
between FDA 
and Sponsors 
I do think however that some sort of financial break has to be taken into 
consideration. Our pediatric studies are extremely expensive, high risk, and 
you may or may not gain any financial benefit from it, which is OK in a way, 
but then a generic company comes along a month later and benefits… 
Provide some 
financial 
incentive to 
Sponsors of 
studies 
 
On Advocacy  
I think it needs to be on the agenda of PhRMA and Bio. It takes having a 
number of position papers out there, white papers, symposia, soliciting 
interest from professional groups, ACOG, AAP, and other groups. It really 
takes a concerted effort so that they can all write supportive statements and 
documentation. The point is that it gets into the collective consciousness. 
Involve 
professional, 
industry, and 
medical groups 
It comes back to advocacy. You need a think tank to be behind you in this, 
you need a Washington think tank. The Second Wave coalition might be the 
group you need so that they can develop position papers, they can be in 
contact with the different stakeholders. You have to get stakeholders onboard. 
And you have to be in this for the long haul, this is not a one-off. …So you 
really need to be developing those discussions now in order to have any 
chance of getting on the [PDUFA] agenda for 2017. 
Sustained work 
by central 
advocacy 
group; develop 
position; 
involve 
stakeholders  
For policy advocacy, use anecdotes. They work. The anthrax example is a 
good one. 
Use anecdotes 
for advocacy 
Starting off with the regulation or guidance, if they're having groups of 
experts or an advisory committee to the federal government; if you have more 
and more respected academics, clinicians proposing why it's important to 
include pregnant women in clinical trials; if you get all of those things out 
there; use professional organizations proposing guidelines, anything like that, 
that's going to help pave the way. Or maybe even include pregnant women…; 
the more and more support you have for that, the more and more it can catch 
on and you'll get an okay to include them for various conditions. 
Involve 
stakeholders: 
academics, 
clinicians, 
pregnant 
women; 
professional 
organizations 
[This is] going to take a whole lot of work on the outside of getting folks 
together in those spaces where we all gather professionally, that have these 
Bring 
stakeholders 
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debates around what's needed and how the best to do it. Not under the shadow 
of impending law. So that was my idealist speech. I don't think that will 
happen but it would be nice. 
together in 
public forums 
I think historically pregnant women are classed in.…the category of 
vulnerable patient populations and to the extent that there's a push to say, 
we're not vulnerable, in fact, we're patients who need to understand the 
implications of taking different treatments. It's almost like a cultural change 
rather than a regulatory change.  
Remove the 
vulnerable 
population 
label from 
pregnant 
women 
I don't think that you will have a lobby of pregnant women because it's 
different [than pediatrics].  Lobby 
Is the pregnant population as compelling as the pediatric population? I think 
the perception is that the pediatric population is more underserved. 
Advocate for 
pregnant 
women's needs 
This is where I think the change is going to come - when companies are 
consistently asked what their position is. And that could be by the agencies, 
by the IRB's, could be by the public. They're going to have to hear multiple 
voices, but particularly IRBs and FDA. 
Have 
companies 
clarify their 
position 
I think what would help if [there was] more talk about this ethic. If you could 
get patient groups talking about it, get onto TV, and if people, if it became an 
actual issue that society cared about. I feel as though it isn't at the moment. 
Involve patient 
groups, 
advocate in 
public arena 
Is there a quantitative assessment that could be done?  If pregnant women 
were not protected [from anthrax], what was that cost? Compare mortality and 
health costs with the risk of birth defects. 
Quantify the 
cost of 
exclusion 
 
On Stakeholders 
 
Personally I'd like to see partnerships between a group like the NIH, industry 
and maybe even third-party payers, to supporting this effort.  
Mitigate the risk by building better relationships and partnerships for a trial. 
One would hope that the first company that's going to be really brave to come 
in and say, 'we want to do this,' will come in…to speak to NIH or FDA or 
whoever, and say, 'here's the trial we want to lay out,' and [they] will not [be 
hearing] of this for the first time. And they'll be willing to work with each 
other to make it happen. 
Build 
Partnerships 
So to some degree I think the financial responsibility of undertaking…. things 
which may be largely of public health interest and not necessarily the 
pharmaceutical interest, but to support public health interest and science, 
should really be shared more broadly by a wider group of people. Not 
necessarily government but maybe the generic companies, public health 
groups, NIH and those sorts of organizations.  
Share 
responsibility 
for public 
health 
 
 In summary, participants in the study suggested that increasing the inclusion of 
pregnant women in clinical studies is such a difficult and controversial undertaking that any 
and all suggestions for how to make it happen should be on the table for consideration.  
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 Key Findings to Section 3. Reasons for their Inclusion / Opportunities to Include 
Key Finding #1. Most of the participants believe that a guidance document from FDA on the 
topic of including pregnant women in clinical trials will increase awareness and discussion 
within and outside of the pharmaceutical companies, but that it may not be enough to cause a 
change in current practices.  
 
Key finding #2. Company indemnification should be included when considering all the 
potential solutions to improving knowledge of pharmaceutical therapy for pregnant women. 
 
Key finding #3. Patent extensions and transferable extensions should be considered 
cautiously due to negative industry and public perception.  
 
Key finding #4. Stakeholders within and external to the pharmaceutical industry have 
suggestions on how to improve the inclusion of pregnant women in clinical research. 
 
C. ETHICAL CONSIDERATIONS 
 One of the challenges in doing research with pregnant women is addressing the 
ethical issues it raises.  The study participants were asked, 
 What ethical problems do you think are most challenging or important? 
"You've got disenfranchised women basically. They're truly 
disenfranchised."         -- biotech physician 
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In response, they expressed a number of concerns regarding the ethical issues raised 
by the subject matter. Traditional medical ethics –  non-maleficence, justice, and autonomy – 
were raised, along with a suggestion that perhaps feminist ethics could make a contribution 
to the debate. They struggled with issues like society's uneasy relationship with fetal 
protection, abortion, informed consent, and the difficulties in considering and balancing both 
maternal and fetal benefits and risks. Some passionately described their feelings about the 
dichotomy inherent in the pharmaceutical industry's mission. Does the company's 
responsibility to provide medical products to improve the health of the population supercede 
or follow the corporation's mandate to at least remain solvent or, preferably, generate and 
increase profit?  
While most participants felt that pharmaceutical companies had an ethical 
responsibility to obtain safety and efficacy information for products that would be used by 
pregnant women, many acknowledged that business considerations might be the deciding 
factors in whether such research would be conducted. The attitude of senior management and 
regulatory agency guidance were recognized as factors that could influence such decisions.  
 
D. CONCLUSION 
The participants in this qualitative study provided insightful, thought-provoking, and 
sensitive responses to the issue of the inclusion of pregnant women in clinical research. 
Having joined the pharmaceutical industry, an IRB, or the FDA in order to help humanity by 
assisting in efforts to prevent, treat, or eradicate disease, these key informants grasped the 
implications of treating pregnant women with interventions that have not been tested on 
pregnant women.  And they grappled with potential solutions to address the problem.  
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There were 55 key findings generated by the interviews with key informants (see 
Appendix IV. Qualitative Study Results). Of these, several deserve attention as indicators of 
the strength of the current status and as measures of the potential for change. 
1. The pharmaceutical industry has excluded pregnant women from participating in 
clinical research based primarily on the ethical principle of beneficence. The sincere 
perception, in keeping with the perceived attitude of the general public, is that the inclusion 
of pregnant women in the study of developmental drugs is too risky for the fetus and that 
exclusion is the safest approach. 
2. The adverse consequences of pregnant women's absence from research are largely 
unrecognized by the industry. They are also unaware of stakeholders' desires to increase their 
inclusion, and the impending release of the FDA draft guidance on this subject.  
3. Individuals within pharmaceutical companies and IRBs, when engaged in dialogue 
on this issue, recognize the attendant, though unintended, adverse consequences of pregnant 
women's exclusion from clinical research and agree with the need to change current practice.  
4. Experienced researchers within the pharmaceutical companies – experts on clinical 
trial design and conduct – can readily provide practical solutions to overcome the perceived 
barriers to pregnant women's inclusion in clinical research studies.  
5. Pharmaceutical company researchers and lawyers, and colleagues in associated 
organizations like IRBs and trade associations, think that change to the current practice of 
excluding pregnant women from clinical research studies will be difficult to implement. They 
believe that, aside from safety issues, valid business concerns must be recognized and 
addressed before change will be considered. These include: the additional time and financial 
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costs with little return on investment, potential delays and threats to product approval, 
litigation risks – both financial and reputational, and challenges in study design and validity. 
Therefore, change to current practice, if initiated, will likely be incremental. 
6. Inducing change in the well-entrenched practice of excluding pregnant women 
from clinical research studies will require regulatory directives, financial incentives, and 
legal protections.  
  
 Table 6.6 summarizes some of the most common concerns the participants raised 
with some of the potential solutions they suggested to address the issues. 
 
Table 6.6 Barriers and solutions identified by key informants 
Key Concerns / Barriers Key Potential Solutions 
Causing harm to the fetus Study design, scientific advances in modeling and animal testing 
Litigation Standardized study design, guidance/regulation, improved awareness of issue in public domain 
Scientific concerns 
Initiate study after animal testing and general population 
results, PK testing, data from inadvertent exposures and 
post-marketing surveillance 
Negative impact on initial approval Post-approval studies 
Lack of regulatory agency support FDA Guidance document, international harmonization 
Unclear regulations FDA Guidance document, international harmonization 
Potential negative reputational 
impact 
Data interpretation standardization, FDA guidance; 
improved awareness of issue in public domain 
Lack of advocacy from stakeholders Increase awareness of issue  
Lack of experience and know-how Collaboration, innovation, science 
 Chapter 7 
The Plan for Change 
 
 
 
A. Conceptual Framework 
In 1995, John Kingdon proposed a "Policy Window" theory of change in his book, 
Agendas, Alternatives, and Public Policies.246 In it, he identified three relatively independent 
issue workstreams whose interactions are required to advance social change. Kingdon called 
the participants in the workstreams "policy entrepreneurs," people who are "willing to invest 
their resources in return for future policies they favor." 
The three issue "streams," Problem (recognition), Policy (proposals), and Political 
(influence), can move along independently until a point in time when they "converge," often 
due to external forces. This convergence allows the issue and its potential solutions to be 
recognized across parties. The "window of opportunity," if capitalized on by the 
entrepreneurs, can put the issue on the political agenda for resolution by the parties involved. 
The result is the advancement of social policy. 
Entrepreneurs in the problem recognition stream identify, describe, and frame an 
issue as a problem when it may not have been recognized as such before. Problem
                                                 
246Kingdon, J. (1995). Agendas, Alternatives, and Public Policies, 2nd ed. New York: Harper Collins College. 
 
definitions often have an emotional values component which helps them to get on the agenda 
for change. 
Entrepreneurs in the policy stream contribute potential solutions to a "primeval soup" 
in which "ideas confront, compete, and combine with each other" and eventually result in 
policy formulation.247 The process relies on groups of interested and knowledgeable parties 
to propose multiple solutions that are both "technically feasible and consistent with 
policymaker and public values."248 These policy entrepreneurs "must possess know
time, relationships, and good reputations
ledge, 
."249 
                                                
The political stream is critical to getting the issue on the agenda for solution. The 
policy entrepreneur "recognizes the problem, attaches an appropriate policy proposal to it, 
and floats the policy proposal in various forums"250 to bring it to the attention of the people 
with the power to place it on the agenda for change. Political events may occur unrelated to 
the issue at hand. Astute policy entrepreneurs can recognize the relationships among the 
event, the problem, and its proposed solutions and connect the streams. The result of the 
 
247Lieberman, J.M. (2002). Three streams and four policy entrepreneurs converge: A policy window opens. 
Education and Urban Society, 34(4), 445. 
248Stachowiak, S. (2009). Pathways for change: Theories about how policy change happens. Organizational 
Research Services. Retrieved from http://www.organizationalresearch.com/ 
publications_and_resources_featured.aspx 
249Stachowiak, S. (2009). Pathways for change: Theories about how policy change happens. Organizational 
Research Services. Retrieved from http://www.organizationalresearch.com/ 
publications_and_resources_featured.aspx 
250Lieberman, J.M. (2002). Three streams and four policy entrepreneurs converge: A policy window opens. 
Education and Urban Society, 34(4), 445. 
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convergence of two or three of the streams is that "a compelling problem is linked to a 
plausible solution that meets the test of political feasibility."251  
Kingdon's Policy Window theory of change is most useful when "capacity exists to 
act on policy windows."252 He recommended special studies of the social issue to 1) provide 
indicators of the existence and magnitude of the issue and to 2) promote constituent 
feedback. This study used quantitative methodology to provide such indicators and 
qualitative methodology to collect such feedback. The next step was to bring these study 
findings to the policy window that I believe is about to open to facilitate a correction in the 
lack of reliable information about the safety and efficacy of the medications we use to treat 
medically compromised pregnancies.  
 
B. Application of the Study Results to a Plan for Change 
1.  PROBLEM STREAM 
This study sought to isolate the perceptions of the pharmaceutical industry about the 
barriers to and opportunities for a broader inclusion of pregnant women in clinical research. 
In a 2010 conference on maternal and pediatric drug safety, a speaker suggested that it was 
time for the industry to be brought into dialogue on this issue. The role and perceptions of 
industry had been identified as a gap in knowledge among advocates. As an industry 
                                                 
251Boussaguet, L., Jacquot, S., & Revinet, P. (2004). Dictionnaire des Politiques Publiques, Presses de la 
Fondation Nationale des Science Politiques, p. 217-225. Retrieved Oct. 12, 2011 from 
www.metagora.org/training/ encyclopedia/Kingdon.html 
252Stachowiak, S. (2009). Pathways for change: Theories about how policy change happens. Organizational 
Research Services. Retrieved from http://www.organizationalresearch.com/ 
publications_and_resources_featured.aspx 
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"insider," I felt uniquely well-positioned to initiate a conversation from within. The focus of 
my study and my Plan for Change are change within the pharmaceutical industry. 
 In 2000, a multidisciplinary conference was convened by the University of Texas 
Medical Branch to "address the national problem of underrepresentation of pregnant women 
in clinical trials." In 2009, the Second Wave Consortium held an invitation-only workshop to 
address the issue. Despite being one of the major stakeholders in the design and conduct of 
clinical trials, no one from the pharmaceutical industry was in attendance at either forum. 
This study found that pharmaceutical company employees, IRB members, and PhRMA 
representatives were unaware that the exclusion of pregnant women from clinical research 
was perceived to be a problem. Study participants believed that they were doing the right 
thing by not including pregnant women in clinical trials based on the ethical injunction to "do 
no harm."  
Kingdon found that "problems…are matters of interpretation and social definition"253 
and that issues are only perceived to be problems when there is pressure to do something 
about them.254 It was clear from my interviews that no one in industry was working on a 
solution to this problem because they had not perceived it to be a problem in the first place. 
Nor did they feel any pressure from external stakeholders – health care providers, pregnant 
women, professional groups, or support organizations – to address the issue. "There's just 
been no interest in looking at this…" stated one study participant. "Who's really advocated 
                                                 
253 Rochefort, D. A., & Cobb, R. W. (1993). Problem Definition, Agenda Access, and Policy Choice. Policy 
Studies Journal, 21(1), 57. 
254Reddington, L. (2009). The Orphan Drug Act of 1983: A case study of issue framing and the failure to effect 
policy change from 1990-1994. (Unpublished doctoral dissertation). University of North Carolina, 
Chapel Hill, NC, p. 14. 
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for clinical trials in pregnant women?" The key informants suggested that the lack of interest 
from within and outside of the companies provided little incentive to initiate change.  
However, during the course of the interviews, all of the participants expressed an 
understanding of the potential problems associated with the exclusion of pregnant women 
from research studies and they were able to suggest potential solutions. I found that the 
anthrax/amoxicillin PK study provided a "persuasive and compelling" problem illustration 
and it was all that was needed to shift the perception from exclusion being a normal and 
ethical practice to it being a practice in need of re-evaluation in light of its potential harms. 
These key informants did not think that change would be easy (one referred to the 
"seachange that we have to have here," another suggested that the general public is 
"apoplectic" about issues involving the fetus), but they did see the need for further thought 
on the topic. This study's results identified the need for broader problem recognition among 
the stakeholders.  
Very few key informants had heard of the Second Wave Consortium. Likewise, very 
few were aware that FDA had a guidance document (Pregnant Women and Clinical Trials: 
Scientific and Ethical Considerations) on the 2011 docket for development. Obviously, this 
lack of awareness precluded work on a solution.  
The study also found that the industry is perceived to be a powerful decision-maker in 
control of the inclusion and exclusion parameters of a clinical trial. While the FDA, the IRBs, 
and the institutions at which the research is conducted were all perceived to have "veto 
power" – that is, they could reject a study protocol proposed by the industry – participants 
agreed that they had little power to demand that pregnant women be included if the company 
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was not in favor. Therefore, targeted advocacy to industry will be important to change the 
current status.  
These findings suggest that improved awareness of the problem is needed both within 
and outside of the pharmaceutical industry. To ensure focus and feasibility, this dissertation 
and plan for change is targeted to industry. But the work of advocacy groups is recognized as 
being essential to the effort to broaden the inclusion of pregnant women in clinical research. 
See White Paper (Appendix VI) for suggestions from the study for advocacy groups external 
to industry.  In addition, I intend to share the results of this study – a copy of the dissertation 
and the White Paper – with advocates in the Second Wave Coalition.  
 
a. The Plan for Change in the Problem Stream: 
The release of the FDA guidance document will provide the impetus to move from 
little or no internal discussion of the issue to dialogue and collaboration across industry. 
Once the document is released, industry will have to respond. The release of the document 
will be the opening of the policy window. Therefore, advocates will need to lay the ground 
work now and get ready to move when the document is released into the public domain with 
a 60 to 90-day period for public comment. 
I was advised by one of the key informants that  
"It takes having a number of position papers out there, 
white papers, symposia, soliciting interest from 
professional groups, ACOG, AAP, and other groups. It 
really takes a concerted effort… The point is that it gets 
into the collective consciousness. At the moment there is 
nothing." He continued, And you have to be in this for the 
long haul…"  
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Kingdon agreed. "Of all the attributes of successful policy entrepreneurs that I could name, 
sheer persistence is probably the most important."255 
 
Table 7.1 Plan for Change in the Problem Stream: Understanding the Problem* 
Plan # Goal Target Intervention 
1 
Increase awareness of the 
current practice of including 
pregnant women in, or excluding 
them from, clinical research 
Industry, 
Stakeholders, 
General Public 
Published paper on 
extent of exclusion in 
scientific literature 
2 
Increase awareness of the 'issue 
as a problem' among individuals 
in industry, IRBs, and industry 
associations 
Industry colleagues, 
Senior management 
White Paper† to key 
informants, PhRMA and 
BIO; Conference 
presentations 
*See Complete Plan for Change in Appendix V. 
† See White Paper in Appendix VI. 
 
Plan for Change Proposals 
a.  Increase awareness of the current practice of including pregnant women in, or 
excluding them from clinical research  
Goal: Raise awareness and add to the public knowledge base. The current practice of 
including or excluding pregnant women from clinical research is not quantified in the 
literature. Results of the quantitative study will make the current practice explicit to improve 
understanding of the extent of current practice. It will also provide a benchmark against 
which to measure change. 
Target:  Industry stakeholders, General Public, Academia 
Intervention: I will submit a paper using the findings of the quantitative analysis of 
clinical trials for publication in a professional journal. (See Chapter 5. Quantitative Results 
                                                 
255Kingdon, J. (2005). The reality of public policy making. Chapter 6. In Danis, M., Clancy, C., & Churchill, 
H.R. Ethical Dimensions of Health Policy. New York: Oxford University Press, p. 101.  
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which is a draft of the paper.) The paper will not only share information to initiate discussion, 
it will also provide a baseline against which to evaluate the impact of efforts to improve the 
inclusion of pregnant women in clinical trials. The finding that only 6% of Phase IV studies 
currently include pregnant women will provide a baseline to benchmark against. 
b.  Increase awareness of 'the issue as a problem' among individuals within the 
pharmaceutical industry, the IRBs, and the industry associations.  
Goal: To facilitate potential change, raise awareness among industry researchers and 
associated key stakeholders involved in the issue.  
Target: Company employees and senior leaders, industry associations (PhRMA and 
BIO), IRBs. Company employees participate in dialogue and strategy sessions and influence 
company positions.  These are the subject matter experts on whom senior leaders rely for 
information, issue evaluation, and problem solutions. At the same time, target senior 
management; these are the decision-makers and the allocators of the funding required to 
conduct research. One key informant stated, "The company has to adopt it from a very high 
level. It's got to come down from the top, that the company understands the problem and is 
willing to commit the company resources to doing it." 
Interventions:  
1) To facilitate laying the groundwork, I will submit a white paper to PhRMA and 
BIO, the pharmaceutical and biotechnology industry organizations, articulating the problem 
and sharing the results of the qualitative study.  
 
A White Paper is an authoritative report or guide that helps solve a 
problem. White papers are used to educate readers and help people make 
decisions, and are often requested and used in politics, policy, business, 
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and technical fields. Policy makers frequently request white papers from 
universities or academic personnel to assist policy developers with expert 
opinions or relevant research.256 
 
My intent is to provide industry with a better understanding of the issue, a prelude to 
what the FDA draft guidelines will likely contain, and – based on the results of this study – a 
set of potential solutions to a problem they have not, as yet, recognized but to which they will 
have to respond quickly following the release of the FDA guidance. 
2) A second target for the White Paper are the key informants who participated in this 
study. Many expressed interest in learning of my results and are well-positioned within their 
respective companies and organizations to initiate a dialogue with others there. My 
suggestion will be that they share it within their company in anticipation of the release of the 
FDA guidance. This process will reach four pharmaceutical companies and one Clinical 
Research Organization, three biotech companies, and three people within independent IRBs.  
3) Finally, I am prepared to speak on this topic at industry and clinical conferences 
and workshops. Because of my longtime work on pregnancy registries, I am recognized as a 
subject matter expert and have published and presented widely on the topic of drug safety in 
pregnancy. I was recently invited to speak at the World Drug Safety conference in London in 
September 2012 at which I am prepared to speak on this issue. I will seek other opportunities 
to present on the topic in the U.S.  
 
 
                                                 
256Wikipedia contributors. (n.d.). White Paper. In Wikipedia, The Free Encyclopedia. Retrieved July 15, 2011 
from http://en.wikipedia.org/ wiki/White_Paper 
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b. Public Health in the Problem Stream 
When I tell people that my dissertation topic is on the subject of including pregnant 
women in clinical trials, the usual and immediate response is, "you can't do that." People 
associate pregnant women and medication with thalidomide. I have found it to be a challenge 
to explain the issue in a way that allows them to see the benefits as well as the risks of 
participation in research. In addition, protection of the fetus is a prominent and sometimes 
volatile issue in current U.S. society. Even the 2000 conference on the issue stated that "the 
topic is controversial" and limited participants to invited guests because of what they termed, 
the "perceived sensitive nature of the topic."  
The APHA Legislative Advocacy Handbook states that public health advocates 
should "use data and the public health human interest stories that you encounter in your 
workplace to further your advocacy efforts."257 One key informant advised me, "For policy 
advocacy, use anecdotes. They work. The anthrax example is a good one." Public health 
advocates have learned to use experience and imagery to communicate facts in a way that 
captures the audience's imagination and helps the message to stick in the recipients' mind. In 
'framing an issue,' advocates “select some aspects of a perceived reality and make them more 
salient in a communicating text, in such a way as to promote a particular problem definition, 
causal interpretation, moral evaluation, and/or treatment recommendation for the item 
                                                 
257American Public Health Association. (n.d.). APHA legislative advocacy handbook: A guide for effective 
public health advocacy. Washington, DC: Author. Retrieved March 24, 2012 from 
http://www.apha.org/NR/ rdonlyres/256C8E98-AC70-4CD0-87BA-
6EDC048DB0E8/0/RulesandGuidelinesPHAdvocates.pdf  
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described.”258 Communicating about and supporting the position of increasing the number of 
pregnant women in clinical research can be a challenge.  
To address that challenge, I found the anthrax treatment example to be helpful in 
conveying the seriousness of the lack of evidence-based treatment guidelines. In the 
examples below, bioterrorism, death, and abortion provide context for the consequences of 
underrepresentation of pregnant women in research. The use of such frames can assist 
advocacy efforts during periods of policy change.   
• At the time of the anthrax scare in 2002, 500 mg amoxicillin three times a day for 60 
days was a recommended treatment for anthrax-exposed pregnant women. 
Subsequent study, published in 2007, revealed that this dosage and frequency would 
be ineffective against anthrax due to the effects of pregnancy on the pharmacokinetics 
of amoxicillin. The 20007 study recommended "further research…to determine 
appropriate antibiotic regimens for pregnant women in response to a bioterrorism 
attack."259  
• In my work on a pharmaceutical company pregnancy registry, an obstetrician 
reported that a pregnant woman, concerned about the effect that drugs might have on 
her developing fetus, made the decision to stop using her asthma medications. When 
she was 7 months pregnant, she experienced an acute asthmatic episode and died.  
• Pregnant women reporting to the pregnancy registry have told me that they have been 
advised by their doctors to terminate their pregnancies due to their inadvertent 
                                                 
258Entman, R.M. (1993). Framing: Toward clarification of a fractured paradigm. Journal of Communication, 
43(4), 52. 
259Andrew, M.A., Easterling, T.R., Carr, D.B., Shen, D. Buchanan, M., Rutherford, T., Bennet, R., Vicini, P., & 
Hebert, M.F. (2007) Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of 
dosage strategies. Clinical Pharmacology & Therapeutics, 81(4), 547-556.  
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exposure to drugs and vaccines during pregnancy. Whether the advice was given to 
protect the physician or the pregnant women was not determined. 
• In addition to using anecdotes to illustrate issues, Dorfman et al., in their paper on 
Framing Public Health Advocacy to Change Corporate Practices,260 recommend 
articulating "core messages that correspond to shared values." They cite Daniel 
Beauchamp's 1976 recommendation to frame issues using the public health core value 
of social justice.261 The values of social justice include shared responsibility, 
interconnection and cooperation, strong obligation to the collective good, assurance 
of basic benefits, government involvement, and community superceding individual 
well-being. I think these values may particularly resonate with individuals in the 
pharmaceutical industry, many of whom have a background in medicine, nursing, 
pharmacy, and basic sciences - disciplines that promote the discovery and application 
of interventions that improve the public health.  
Examples of messaging using core values of public health and social justice: 
• It was the tragic outcomes from the use of thalidomide by pregnant women that 
triggered the 1962 FDA amendments that require efficacy and safety information be 
obtained from clinical trials prior to drug approval. It is especially ironic then, that 
pregnant women remain systematically excluded from the benefits of inclusion in 
clinical trials.  
                                                 
260Dorfman, L., Wallack, L., & Woodruff, K. (2005). More than a message: Framing public health advocacy to 
change corporate practices. Health Education and Behavior, 32(3), 320-336. 
261Beauchamp, D.E. (1976). Public health as social justice. Inquiry, 13, 101-109. 
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• Pregnant women are the last of the vulnerable populations to be included in clinical 
trials. More children, elderly, and inmates benefit from inclusion in clinical trials than 
pregnant women.  
• It is doubtful that Millenium Development Goal #5 – Reduce Maternal Mortality – 
will be met. This is true in the developing world and in the U.S. where more than two 
women die every day from pregnancy-related causes262 and more than a third of the 
1.7 million women who give birth each year experience some type of adverse 
complication.263 
 
In addition to clinicians and scientists, the pharmaceutical industry, one of the most 
profitable industries in the world, is also composed of business people. "The biggest barrier 
to achieving social justice," state Dorfman et al, "is the competing ethic of market justice." 
The business concerns of the industry were cited by the key informants in this study as 
powerful justifications to continuing to exclude pregnant women from participation in 
clinical trials.  
Former U.S. Surgeon General Antonia Novello said that “one of the fundamental 
paradoxes of market oriented societies is that some entrepreneurs—even acting completely 
within the prescribed rules of business practice—will come into conflict with public health 
goals." That reflects the issue here; there is no mandate or requirement to broaden the 
                                                 
262Heron, M., Hoyert, D.L., Murphy, S.L., Xu, J., Kochanek, K.D., & Tejada-Vera, B. (2009). Deaths: Final 
data for 2006, National Vital Statistics Reports, 57(14), I-136, p. 116. Retrieved from  
http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf 
263 Daniel, I., Berg, C., Johnson, C.H., &  Atrash, H. (2003). Magnitude of maternal morbidity during labor and 
delivery: United States, 1993-1997. American Journal of Public Health, 93(4), 631-634. 
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inclusion of pregnant women – it is simply the right thing to do. Therefore, framing the 
problem from a public health perspective (showing the values behind the reason for change) 
and using anecdotes to illustrate the issue at a fundamental level (making it personal) can 
move the dialogue toward collective solutions rather than entrenched positions. According to 
Kingdon, language, word choice and symbols are important and are used to promote selected 
interpretations, mobilize support, and influence the political environment.264 
 
c. Public Health Leadership in the Problem Stream 
In "Building the Next Generation of Leaders," Joy Phumaphi, former Botswana 
Minister of Health says, "A leader who tries to drive the health agenda alone lacks vision. 
Every stakeholder needs to feel a part of the solution. To reach this point, all must see the 
problem."265 
This study was done with the intention of bringing a key stakeholder, the 
pharmaceutical industry, into the dialogue on the inclusion of pregnant women in clinical 
research. My research showed that the industry was not aware of the problem, in fact, their 
perception was that the exclusion of pregnant women from clinical research was the ethical 
position and the right thing to do. This research alerts industry stakeholders to the unintended 
consequence of this behavior in an effort to help them "see the problem" – and then work on 
solutions.  
                                                 
264Reddington, L. (2009). The Orphan Drug Act of 1983: A case study of issue framing and the failure to effect 
policy change from 1990-1994. (Unpublished doctoral dissertation). University of North Carolina, 
Chapel Hill, NC, p. 14. 
265 Phumaphi, J. (2005). Building the next generation of leaders. In Foege, W.H., Global Health Leadership and 
Management, San Francisco, CA: Jossey-Bass, p. 190. 
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Martin McKee, professor of public health at the London School of Hygiene and 
Tropical Medicine, states that "Effective public health leaders should not simply wait to be 
asked for their opinion. They should be advocates for health, drawing attention to issues that 
would otherwise be overlooked." He continues that, because "public health is based on social 
justice, …its advocates will often espouse causes that are unpopular."266 I can confirm that 
advocating for the inclusion of pregnant women in clinical studies is not a popular stance to 
take within pharmaceutical companies. However, as a public health leader, I can call upon 
aspects of leadership that come from my experiential knowledge of this issue as a clinician 
who has treated pregnant women and as a researcher who has gathered data in pregnancy 
registries to inform treatment decision-making for pregnant women for many years. My 
position, which was confirmed by the key informants in this study, is that industry can 
"evolve" in the manner in which it considers and addresses the needs of pregnant women and 
their health care providers.   
Advocacy calls upon non-traditional leadership models to promote change. Advocates 
often use 'Transformational Leadership' skills, leading with passion, inspiration and 
relationships267 rather than authoritative leadership practices that are derived from positions 
of power. Advocacy leaders rely upon strong interpersonal skills to explore issues and 
communication skills to add stakeholder voices to the advocacy and problem solving 
                                                 
266McKee, M. (2005). Challenges to health in Easter Europe and the former Soviet Union: A decade of 
experience. In Foege, W.H., Global Health Leadership and Management, San Francisco, CA: Jossey-
Bass, p. 181. 
267London, M. (2008). Leadership and advocacy: Dual roles for corporate social responsibility and social 
entrepreneurship. Organizational Dynamics, 37(4), 313-326. 
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process.268 In the process of this study, I employed interpersonal relationships and 
networking skills to contact and dialogue with key informants. Communication skills and 
connections to influential personnel within the industry, will help me relay my findings in 
various formats and venues to influence key opinion leaders as outlined in this Plan f
Change.   In "Creating the Future of Public Health: Values, Vision, and Leadership,"
or 
rry 
tence." 
                                                
269 Ba
S. Levy advises us to call upon "the values that brought you to public health in the first place 
and not be afraid to articulate them…with passion, with courage, and with persis
 
2. POLICY STREAM 
In this study, the central 'policy' is the proposed FDA Guidance: Pregnant Women in 
Clinical Trials: Scientific and Ethical Considerations. Guidance documents, according to 
FDA,270 
"…represent FDA's current thinking on a topic.  They do 
not create or confer any rights for or on any person and do 
not operate to bind FDA or the public.  You can use an 
alternative approach if the approach satisfies the 
requirements of the applicable statutes and regulations." 
FDA describes the guidance review process:271  
 
 
268Fabrizio, C.S. (2011). Physician's perceptions of the Hong Kong Cervical Screening Program: Implications 
for improving cervical health. (Unpublished doctoral dissertation). University of North Carolina, 
Chapel Hill, NC. 
269Levy, B.S. (1998). Creating the future of public health: Values, vision, and leadership. American Journal of 
Public Health, 88(2), 192. 
270 'Guidances' at http://www.fda.gov/regulatoryinformation/guidances/default.htm; accessed 1Apr2012 
271 U.S. Food and Drug Administration. "Fact sheet: FDA Good Guidance Practices, available at 
http://www.fda.gov/AboutFDA/Transparency/TransparencyInitiative/ucm285282.htm, accessed 
1Apr2012. 
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Release of the FDA Draft Guidance will instigate the pharmaceutical companies to 
consider the inclusion of pregnant women in drug development planning. Changes to the 
current process will ultimately be reflected in internal company policies and procedures. This 
is where change will really happen.  
Kingdon's Policy Window theory has been described as 'an evolutionary model of 
public policy.'272 In the policy formulation stream, Kingdon says that, "Specialists try out and 
revise their ideas by…attending conferences, circulating papers, holding hearings, presenting 
testimony, writing reports, publishing articles, and drafting legislative proposals." The 
resultant 'primeval soup' of policy proposals then go through "the process of policy evolution, 
[where] some ideas fall away, others survive and prosper, and some are selected to become 
serious contenders for adoption."273  
Kingdon's "window of opportunity," if capitalized on by the entrepreneurs, puts the 
problem on the political agenda for resolution. This "agenda" can be either a government 
agenda (key topics on the policy development list) or a decision agenda (developing policies 
that are moving into position for a definitive decision).274 This study is dealing with a 
decision agenda. The FDA draft guidance document has been drafted and is in clearance at 
the agency. It has not yet been released for public consideration. Once it is released – and 
that date is unknown – public comment will be solicited for a 60 to 90-day period and then 
the document will go through a revision process at the agency based on the feedback 
                                                 
272 John P. Is there life after policy streams, advocacy coalitions, and punctuations: Using evolutionary theory to 
explain policy change. Policy Studies Journal 2003:32(4):488. 
273 Kingdon, J. (2005). The reality of public policy making. Chapter 6. In Danis, M., Clancy, C., & Churchill, 
H.R. Ethical Dimensions of Health Policy. New York: Oxford University Press, p. 101.  
274Lieberman, J.M. (2002). Three streams and four policy entrepreneurs converge: A policy window opens. 
Education and Urban Society, 34(4), 445. 
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received. The length of time until the release of a revised draft guidance as a 'final guidance' 
is highly variable. In addition to soliciting written comment, FDA will sometimes hold public 
hearings on the topic. Interested parties can submit a request to speak at the hearing to 
present their position, their concerns, or their recommendations. 
During the period of public comment, interested stakeholders submit their 
perspectives, preferences, and proposals for consideration. In the policy stream the formation 
and refining of policy proposals is a process by which ideas confront, compete, and combine 
with each other, forming combinations and re-combinations.275 Stakeholders (identified in 
Chapter 1), all of whom may respond to the call for public comment, include the general 
public, pregnant women, their families and their health care providers, women's health 
advocates, the obstetrical community, maternal/child health organizations, IRBs, the 
pharmaceutical industry, etc.   
Kingdon recommends that the development of proposals be done before the 
opportunity to submit them arises. One of this study's key informants from PhRMA 
characterized the industry association as being reactive, not proactive. He was, indeed, 
unaware that the FDA guidance on this topic was on the 2011 docket – information that is 
available in the public domain. The White Paper will not only serve to raise awareness of the 
issue, it will also facilitate industry preparation and response to the call for comments on the 
FDA draft guidance document. 
Should pregnant women be included in the drug development process? The issue has 
not yet, but is about to become, a significant subject of concern to industry. The inclusion of 
                                                 
275Kingdon, J. (2005). The reality of public policy making. Chapter 6. In Danis, M., Clancy, C., & Churchill, 
H.R. Ethical Dimensions of Health Policy. New York: Oxford University Press, p. 101.  
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pregnant women in clinical research has serious practical and financial implications for the 
pharmaceutical industry. It has the potential to change the way companies perform their core 
business activity – the development of drug interventions to prevent, ameliorate, or cure 
diseases. Each pharmaceutical and biotechnology company will need to consider the 
implications in the context of their own enterprise. Current internal policies and procedures 
about the drug development process will change; new policies will be implemented. The 
results of this study are intended to assist the companies and their trade associations, PhRMA 
and BIO, consider the implications and formulate their responses to the document - to add 
their voice to the public debate that was going on without their participation.  
 
a. The Plan for Change in the Policy Stream 
To accomplish this goal, the Plan for Change includes multiple means of getting 
information in the hands of industry leaders.  These communications include a number of 
questions, considerations, and recommendations to add to the 'primeval soup' of policy 
proposals. 
Table 7.2 Plan for Change in the Policy Stream: Proposing Solutions* 
Plan # Goal Target Intervention 
3 
Awareness of potential solutions  
for industry consideration in 
guidance responses & internal 
policies 
Industry colleagues, 
Senior management 
White Paper† to FDA, 
PhRMA, BIO, and 
companies 
4 Awareness of potential solutions  
for companies' draft response 
Company 
colleagues & senior 
management 
Participate in drafting my 
company's response to 
FDA 
5 Industry perspective included in 
discussion of the issue 
FDA, Stakeholders, 
Public 
Present study findings at 
FDA hearing, if 
applicable 
*See Complete Plan for Change in Appendix V. 
† See White Paper in Appendix VI. 
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Plan for Change Proposals 
3. Propose potential solutions to the issues for consideration in guidance and guidance 
response. 
Goal: To assist with the identification and adoption of acceptable solutions to the 
underrepresentation of pregnant women in clinical research to enable the evidence-based 
treatment of women with medically compromised pregnancies. 
Target: the agency, the industry, and the companies 
Intervention: Provide a copy of the White Paper to the key informants in this study 
for sharing within their organization and with external colleagues. 
 
4. Provide information and proposed solutions to consider for the company's draft 
response. 
Goal: To provide the broader industry perspective to my company to assist with its 
consideration of the issues and its formulation of a response to the proposed FDA guidance. 
Target: Company colleagues and senior leaders 
Intervention: Provide a copy of the White Paper to my colleagues in various 
departments including Regulatory Affairs, Drug Safety, Medical Affairs, and to the Chief 
Medical Officer; participate in the working group that authors the FDA response.  
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5. Add industry perspective to the discussion in the public domain. 
Goal: Increase awareness of pharmaceutical industry perspectives in the debate about 
the inclusion of pregnant women in clinical research. 
Target: The U.S. Food and Drug Administration, the general public 
Intervention: Present study findings at the FDA hearing, if one is held, and/or share 
study findings with advocates for use in their presentation to FDA, to inform the agency's 
deliberations on this draft guidance. 
 
This study resulted in a number of policy, process, and procedural suggestions from 
the key informants for the three main stakeholders in the debate: FDA, the industry 
association, and the companies (see White Paper, Appendix VI). 
 
b. Public Health in the Policy Stream 
Policy development is one of the three public health core functions identified by the 
Institute of Medicine in its landmark 1988 report on the future of public health276 (the others 
are assessment and assurance). It called upon public health practitioners to promote "the use 
of the scientific knowledge base in decision-making about public health and by leading in 
developing public health policy."277 This study seeks to ensure that there is a scientific 
knowledge base to inform decision making about the treatment of individual pregnant 
                                                 
276Institute of Medicine Committee on the Future of Public Health. (1998). The Future of Public Health, 
Washington DC: National Academies Press. 
277 Turnock, B.J. (2009). Core functions and public health practice. In Public Health: What it is and How it 
Works, 4th ed. Sudbury, MA: Jones and Bartlett Publishers, p.222. 
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women and to encourage the application of the scientific knowledge base to the decision-
making process about when and how to study pregnant women overall. The quantitative 
study adds the benchmark of the proportion of clinical trials that exclude pregnant women to 
the scientific literature. The qualitative study adds the voice of the pharmaceutical industry, a 
key stakeholder, to the public discourse.  
Guidance documents can be viewed as a type of regulatory policy. Although they do 
not mandate behavior, their contents are closely adhered to by the industry. Regulatory 
policies "limit the discretion of individuals and agencies, or otherwise compel certain types 
of behavior. These policies are generally thought to be best applied when good behavior can 
be easily defined and bad behavior can be easily regulated and punished through fines or 
sanctions."278  
The "policy cycle" is a familiar construct in public health279 and is applied to this 
issue in Table 7.3. Knowledge of the cycle assists public health professionals to understand 
problem solving and where in the cycle to intervene to influence policy. 
 
c. Public Health Leadership in the Policy Stream 
"Public health leaders must contribute to national debates; problems that governments 
face in relation to public health are difficult, and they cannot expect to solve them on their 
                                                 
278Wikipedia contributors. (n.d.). Policy. In Wikipedia, The Free Encyclopedia. Retrieved April 1, 2012 from 
http://en.wikipedia.org/w/index.php?title=Policy&oldid=484514172 
279Association of Faculties of Medicine of Canada. (n.d.). Primer on public health population: The policy cycle. 
In Howlett, M., & Ramesh, M. (1995). Studying Public Policy: Policy Cycles and Policy Subsystems. 
Toronto: Oxford University Press. Retrieved from http://phprimer.afmc.ca/Part3PracticeImproving 
Health/Chapter14Decision MakingPoliciesAndEthicsInHealthCareAndPublicHealth/Thepolicycycle 
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own. Public health leaders…contribute to solving these problems. The most successful public 
health leaders have engaged in the policy process…"280 
Table 7.3 Contribution of this study in the policy cycle. 
Stages in 
Policy Cycle  
Phases of 
problem 
solving 
     Description and comments Contribution of Study 
Agenda 
setting 
Problem 
recognition 
FDA creates and releases draft 
guidance to public.  
Notice to stakeholders 
of impending guidance 
release, frames problem 
Policy 
formulation 
Proposal of 
solution 
Stakeholders formulate and 
submit perspectives and policy 
options. 
Potential solutions to 
stakeholders for 
consideration and 
submission 
Decision-
making 
Choice of 
solution 
FDA considers all comments to 
create final guidance.  
Participation in solution 
proposal and adoption 
process 
Policy 
implement-
ation 
Putting solution 
into effect 
Stakeholders consider options, 
formulate internal policies. 
Influence on multiple 
individual company's 
internal policy changes 
Policy 
evaluation 
Monitoring 
results 
Stakeholders monitor 
implementation, intended and 
unintended consequences and 
continue dialogue with FDA. 
Monitoring and 
evaluation activities for 
ongoing workstreams 
 
As a public health professional, my intent is to influence the final version of this 
public policy by contributing the perspective of one major stakeholder to the decision-
making process and by participating in the development of public health policy. 
                                                 
280McKee, M. (2005). Challenges to health in Easter Europe and the former Soviet Union: A decade of 
experience. In Foege, W.H., Global Health Leadership and Management, San Francisco, CA: Jossey-
Bass, p. 181. 
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Beyond identifying the issue as a problem, the results of this study will serve to 
influence my colleagues in industry to consider what industry can do to improve evidence-
based care for women experiencing medically complicated pregnancies. In 1983, a rural 
sociologist, Everett Rogers, published his theory of Diffusion of Innovations281 – how change 
is adopted by individuals and organizations. In it, he called 'diffusion' the process by which a 
new idea or a change in thinking (an innovation) is communicated by members of a social 
system. The diffusion process includes persons becoming knowledgeable about an issue, 
persuading others to make a change, making decisions based on the new thinking, 
implementing the innovation, and then via evaluation, either confirming it as worthwhile or 
discarding it as ineffective. This process takes place over time. By 1) raising the issue with 
industry colleagues, 2) persuading them that the issue is a problem, 3) having them articulate 
potential solutions, 4) providing the proposed solutions to other members of the 
pharmaceutical industry "social system" at a point in time when it is in their best interest to 
respond to the FDA's call for comment, the study should lead to decision-making influenced 
by new thinking. The final FDA guidance document will spur the adoption of the innovation 
and the industry will certainly evaluate its utility and its cost.  
As a participant, rather than a leader, in the industry's social system, I will be using 
'influential power' – the capacity of one person to influence another – as opposed to the 
authority that comes from one’s hierarchical position in an organization282 to stimulate this 
diffusion of innovation. Yukl defines leadership as a “process of influencing others to 
understand and agree about what needs to be done and how to do it, and the process of 
                                                 
281 Rogers, E.M. (1983). Diffusion of Innovations. New York: Free Press. 
282Yukl, G. A. (2005). Leadership in Organizations (6th edition).New Jersey: Prentice Hall, p. 146. 
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facilitating individual and collective efforts to accomplish shared objectives.”283 By 
providing the White Paper to both individuals within the industry and to the collective 
leadership at the industry association, the study findings are intended to stimulate individua
and collective efforts at innovations to benefit pregnant women and th
l 
eir offspring. 
                                                
 
3. POLITICAL STREAM 
"[T]here is…broad agreement that politics and political issues are rarely analyzed and 
frequently ignored at all stages of the policy identification, development, and implementation 
process in the health sector."284  
FDA put the issue in the political stream when it placed "Pregnant Women in Clinical 
Trials: Scientific and Ethical Considerations" on the 2011 docket of proposed guidance 
documents. The government agenda was made clear – regulatory guidance for the 
pharmaceutical industry is coming. Left to be determined is what the final guidance 
document will contain. 
Kingdon recommended special studies of an identified issue to provide indicators of 
the existence and magnitude of the issue. He also advocated for the identification and 
promotion of constituent feedback.285 This study provides both. Papers and publications are 
advocacy tools that provide information to public health activists for use in addressing key 
 
283Yukl, G. A. (2005). Leadership in Organizations (6th edition).New Jersey: Prentice Hall, p. 8. 
284Glassman, A. & Buse, K. (2008). Politics and public health policy reform. In Heggenhougen, K. & Quah, S. 
(Eds.), International Encyclopedia of Public Health, Vol 5. San Diego: Academic Press. pp. 163-170. 
285Stachowiak, S. (2009). Pathways for change: Theories about how policy change happens. Organizational 
Research Services. Retrieved from http://www.organizationalresearch.com/ 
publications_and_resources_featured.aspx 
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legislators and influencing potential guidance and regulation. Other characteristics that 
provide political advantage include, "(a) credible information on social conditions, available 
policy options, and likely impacts; (b) recurrent interactions with policy makers; (c) large and 
geographically dispersed membership; (d ) group cohesion and unified positions on priority 
issues; and (e) organizational resources."286 All three major stakeholders: FDA, PhRMA and 
the Second Wave Consortium, possess these characteristics. This study contributes data for 
item (a) to the stakeholders so that (d) can be achieved. The intent is to increase recognition 
of identifiable commonalities, barriers and opportunities, and shared objectives to assist the 
political process in arriving at acceptable solutions to this issue. 
 
Table 7.4 Plan for Change in the Political Stream: Long-term advocacy* 
Plan # Goal Target Intervention 
6 Increased knowledge of issue in 
public domain 
Advocates, 
Academia, General 
public 
Additional publications 
and presentations 
7 
Personal influence on my 
company's internal deliberations 
on issue 
Company 
colleagues & senior 
management 
Continue involvement in 
issue at my company 
8 
Issue remains in public and 
professional consciousness; 
continued advocacy for 
increased evidence-based 
treatment for pregnant women 
Second Wave 
Consortium, 
PhRMA, other 
organizations 
Continue involvement in 
issue in other 
organizations 
*See Complete Plan for Change in Appendix V. 
 
Plan for Change Proposals 
6. Use the findings of the study to continue to share knowledge of the issue in the 
public domain. 
                                                 
286Thomas, R.O. (2006). The politics of public health policy. Annual Review of Public Health,  27, 195–233. 
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Goal: Keep the issue in the political arena while FDA is considering their policy 
options. This is a sensitive topic for discourse in the public domain. While advocates for 
change are seeking improved health outcomes for both the fetus and the pregnant woman 
(and these two are inextricably linked), women's interests are sometimes characterized as 
being in opposition to fetal protection. It is easy to react to the question of research on 
pregnant women with a resounding "no," "of course not," "that would be unethical." Without 
knowledge of the adverse repercussions, the advantages of such research are counterintuitive. 
To change that mind-set, the adverse consequences of the lack of research for pregnant 
women must be broadly, but carefully, communicated. 
Target: Advocates, academia, the general public 
Intervention: Utilize the findings of the study to create additional publications and 
presentations. The Addendum to the dissertation, which contains my analysis of key 
informant responses to the interview questions, provides additional rich data with which to 
address different perspectives of the issue. For example, the ethics, the costs, and the risks to 
pregnant women of conducting versus not conducting research studies, could all be further 
explored.  Implications for the Institutional Review Boards, the principal investigators, and 
the research institutions at which they conduct studies could be addressed. The willingness of 
pregnant women whose pregnancies are threatened by illness to participate in research 
studies should be explored. Discussing these issues in the public domain would make the 
subtleties of the issue more explicit and refine the possibilities for addressing them.  
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7. Use findings of the study to influence from within. 
Goal: Politics are not confined to the government. Politics exist in all organizations. 
Each pharmaceutical company will consider the potential impact of the FDA guidance within 
their own organization. Dissemination of the study findings to each of the key informants 
that work within the pharmaceutical and biotech industry has the potential to impact the 
decision-making within that institution.  
Targets: Pharmaceutical company colleagues, senior management within industry 
Interventions:  
a) Dissemination of study findings via the White Paper to the key informants in 
this study with instructions to share freely with their colleagues within and outside of 
their companies. 
b) Present the findings of this study in the context of a new maternal health 
initiative at the pharmaceutical company where I work. The goal of the program is to 
apply "scientific and business expertise to making proven solutions more widely 
available, developing new game-changing technologies, and improving public awareness, 
policy efforts, and private sector engagement" for improving maternal health worldwide. 
I will engage the director of the program and other senior leaders in a discussion about 
how the company could improve its support for pregnant women within the company. 
Sharing the results of this study and the recommendations of industry key informants, I 
will suggest that the company, in keeping with its new initiative, could be a forerunner 
and model for the industry in the expansion of the inclusion of pregnant women in 
clinical trials.  
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 8. Use findings of the study to continue to advocate on behalf of pregnant women. 
Goal: To disseminate the findings of the study for use by multiple organizations who 
advocate on behalf of pregnant women 
Targets: Professional organizations, PhRMA, and the Second Wave Coalition 
Interventions:  
a) I have been or am currently involved in several organizations whose mission is the 
improvement of maternal child health (Organization of Teratology Information Specialists, 
the Teratology Society, ISPE [International Society of Pharmacoepidemiologists] 
Medications in Pregnancy special interest group, the Global Health Council, and APHA 
[American Public Health Association] Reproductive Health special interest group]). I will 
continue to work with and within these organizations, and will offer to contribute the 
findings of this study to these groups in the belief that broadening the inclusion of pregnant 
women in clinical studies will improve maternal health.  
b) I have only recently become involved in the Second Wave Consortium but will 
continue to work with them as a contributor in the advancement of their mission. I will, of 
course, offer them my study data for further use, communication, and dissemination. I will 
suggest that they convene a meeting with Consortium members and industry leaders to 
discuss the impending FDA Guidance release.  
c) In further communication with the industry association (in addition to providing 
the White Paper) I will suggest to PhRMA that they create (or recreate, as I believe they used 
to have) a working group on Issues in Maternal Health. 
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 b. Public Health in the Political Stream 
Some participants in the policy stream come to the convergence more prepared than 
others. FDA and the Second Wave Consortium have been working on this issue, often behind 
closed doors, for many years. The pharmaceutical industry, in my mind, comes to this issue 
in the weakest position of the three major players. Unlike its power position in determining 
whether to include pregnant women in individual clinical trials, it appears to be unprepared 
for the debate about the inclusion of pregnant women in clinical research in general.  
Nonetheless, industry is a powerful political constituent with well organized lobbyists 
and a network of connections. It is also the subject matter expert on how to develop drug 
therapies and design clinical trials to test their effectiveness and safety. While the industry 
may be in a weakened position because it has not been paying attention to the issue, it will be 
motivated to respond when the time comes. As Thomas Oliver points out, "Any proposed 
change to policy threatens the existing distribution of benefits and costs, and groups with an 
identifiable stake in the outcome," like the pharmaceutical industry, "will organize 
themselves in the political system" in response. He continues, "The targets of regulatory 
policies can make policy implementation extremely difficult. Organizations… facing 
concentrated costs will likely continue to resist or seek opportunities to renegotiate the 
original policy."287 Therefore, it is important to get information into their hands. Improved 
awareness of the issue, a better understanding of the pervasiveness of the practice, and 
                                                 
287Oliver, T.R. (2006). The politics of public health policy. Annual Review of Public Health, 27, 209-223. 
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potential solutions to the problem – suggested by knowledgeable researchers from within the 
companies – provides the basis upon which to participate in the political process. 
 
c. Public Health Leadership in the Political Stream 
"Public health professional who understand the political dimensions of health policy 
can conduct more realistic research and evaluation, better anticipate opportunities as well as 
constraints on governmental action, and design more effective policies and programs."288 The 
topic of this study has obvious – and difficult – political implications. From the involvement 
of a powerful and highly regulated industry to the publicly debated (and privately held) 
opinions regarding fetal protection and women's reproductive health, the subject of this study 
is controversial and politically charged. This study provides quantitative and qualitative data 
to ground the debate in information and policy proposals from a key, and previously absent, 
stakeholder so that all voices can be represented at the table.   
"Public policy is not a single act of government but a course of action that involves 
individuals and institutions in both the public and private sectors, and encompasses both 
voluntary activities and legal injunctions."289 Currently, pharmaceutical companies can make 
voluntary and individual decisions as to the inclusion of pregnant women in the clinical trial 
process. While an FDA Guidance does not mandate action, the industry usually adopts its 
recommendations. And sometimes, when the industry has been slow to adopt initiatives 
                                                 
288Oliver, T.R. (2006). The politics of public health policy. Annual Review of Public Health, 27, 209- 223, p. 
195.  
289Oliver, T.R. (2006). The politics of public health policy. Annual Review of Public Health, 27, 209- 223, p. 
219. 
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voluntarily, regulations will follow – as was seen with the pediatric drug testing initiatives. 
With the release of the new guidance on the inclusion of pregnant women in clinical trials, 
the industry will have to weigh the pros and cons of adopting new innovations in the 
assessment of drug safety and efficacy in pregnant women. And other stakeholders will 
monitor whether those efforts are enough to improve the evidence-base for treatment 
decisions – or if legislative action will be needed.  
One of the key informants in this study, who has significant political insight and 
experience, encouraged me to pursue this issue via the legislative process: 
"Politically," he said, "I think it needs to be on the agenda of 
Pharma and Bio. It's got to get on their agenda so that the industry 
or the sector as a whole can be supportive to varying degrees. This 
is the kind of thing that can show up in the next PDUFA 
(Prescription Drug User Fee Act)[renewal]. It could be on the 
legislative agenda for 2017. Remember, that starts in 2015 -  
there's a fair lead time. So you really need to be developing those 
discussions now in order to have any chance of getting on [the 
PDUFA] agenda for 2017. 
 
PDUFA, first passed in 2002 and renewed every 5 years since, allows FDA to collect 
user fees from the companies who are applying for a new drug approval to help pay for the 
resources required to perform the application's review. In response to complaints of 
prolonged reviews restricting access to new treatments, especially for HIV, the Act 
significantly improved the number of reviewers at FDA and decreased the amount of time it 
takes for a drug – or device or biologic – to get through the approval process. FDA, PhRMA, 
and the general public all in favored of the regulation. In 2007, the PDUFA renewal was part 
of the Food and Drug Administration Amendments Act which included initiatives like 
requiring pediatric drug testing, rewarding developers of treatments for neglected diseases, 
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and mandating the posting of clinical research studies on ClinicalTrials.gov. The key 
informant is suggesting that continuing advocacy, research, and leadership on this issue could 
lead to regulation that will provide incentives, encouragement, or requirements to include 
pregnant women in clinical research in the 2017 PDUFA renewal.  
Pharmaceutical companies participate in this process through PhRMA. Conducting 
this study, talking to members of PhRMA, and providing them with a white paper on the 
topic establishes my credibility as a subject matter expert in the field. If my persuasion 
results in the establishment of a working group on Issues in Maternal Health, I may continue 
to be involved in the legislative process.  
Whether legislation will be needed or whether the voluntary approach will provide 
enough positive change to be acceptable to the stakeholders will be decided by the impact of 
the guidance formation, implementation, and evaluation process. Adoption of innovation by 
the pharmaceutical industry may be the determining factor as to whether legislative reform 
will be required. Additional research, monitoring, and evaluation will be needed. And 
ongoing leadership via advocacy, communication, persuasion, bargaining, positional power, 
and political pressure will be required.  
 
C. Evaluation 
1. Evaluation of the Impact of the Plan for Change 
When the FDA Guidance is final, the pharmaceutical industry will implement its 
recommendations. While guidance documents are non-binding, their recommendations are 
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difficult to ignore and companies usually conform. Table 7.5 presents the measures of 
success for the Plan for Change. 
 
Table 7.5 Evaluation of the Plan for Change 
Problem Intervention Evaluation method Measure of success 
Lack of 
awareness of 
issue as problem 
White Paper 
frames issue 
Lack of 
awareness of 
current practice 
Publication on 
current practice 
An increase in publications, 
articles, conference sessions on 
this topic 
 
Lack of potential 
solutions 
White Paper 
contains solutions
Monitor literature 
and industry 
publications and 
workshops on topic 
Publications, sessions discuss 
solutions 
Industry need to 
respond to draft 
guidance 
Work with 
Company and 
PhRMA on draft 
responses 
Review content of 
submitted PhRMA 
and company 
responses  
Content of response documents 
reflect awareness of issue and 
recommendations for change 
from current practice 
FDA need to 
determine final 
guidelines 
Participation in 
FDA hearing (if 
applicable) 
Monitor content of 
stakeholder 
presentations 
Final guidance includes 
recommendations to include 
pregnant women in clinical 
research 
Implementation 
of guidance 
within companies 
White Paper 
contains 
recommendations 
Changes in 
companies' policies 
and procedures 
Changes in company policies 
that increase the potential for 
the participation of pregnant 
women in studies 
Evaluation of 
impact on 
inclusion of 
pregnant women 
in clinical 
research 
Ongoing 
involvement as 
SME 
Repeat quantitative 
study; monitor 
literature; 
participate in 
interest groups 
Actual increase in proportion of 
clinical trials that do not 
exclude pregnant women or that 
are designed for pregnant 
women 
Evaluation of 
impact on 
treatment of 
pregnant women 
Ongoing 
involvement as 
SME 
Repeat qualitative 
study, including 
HCPs; review drug 
labels for use in 
pregnancy  
Key informants indicate an 
improvement in evidence-based 
practices; Increased proportion 
of drug labels include evidence-
based guidelines for use in 
pregnancy 
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2. Evaluation of the Impact of the FDA guidance 
There are a number of evaluations that were published following the implementation 
of the pediatric rule requiring clinical trials for the pediatric population. These include, for 
example, Improving Pediatric Dosing through Pediatric Initiatives: What We Have 
Learned;290 Assessing the Effects of Federal Pediatric Drug Safety Policies;291 and Economic 
Return of Clinical Trials Performed under the Pediatric Exclusivity Program,292 etc. The 
methodology these authors used is easily transferable to the evaluation of advances in the 
study of pregnant women. Such measures include evaluating changes to drug labeling that 
include information specific to use during pregnancy including: pregnancy indications, 
dosing changes in pregnancy, pharmacokinetic information, new safety information, and 
information concerning efficacy or lack thereof. Cost savings can be calculated from change 
to current costs for maternal and neonatal hospitalizations, morbidity from adverse drug 
reactions, and maternal illness-induced decreased productivity. However, these calculations 
would have to wait until drug testing in pregnant women was widely implemented.  
These cost calculations could actually get at the public health impact of the guidance, 
which would be extremely important to know. I anticipate that the return on investment of 
this initiative may be difficult to measure in cost savings alone because the market for 
individual drugs used in medically compromised pregnancies is low and the recipients are 
                                                 
290Rodriguez, W., Selen, A., Avant, D., Chaurasia, C., Crescenzi, T., Gieser, G.,…Uppoor, R.S. (2008). 
Improving pediatric dosing through pediatric initiatives: What we have learned. Pediatrics, 121(3), 
530-539. 
291Dor, A., Burke, T., & Whittington, R. (June, 2007). Assessing the effects of federal pediatric drug safety 
policies. The George Washington University Medical Center Newsletter, pp. 1-16. 
292 Li, J., Eisenstein, E.L., Grabowski, H.G., Reid, E.D., Mangum, B, Schulman, K.A. …& Benjamin, D.K. 
(2007). Economic return of clinical trials performed under the Pediatric Exclusivity Program. Journal 
of the American Medical Association, 297(5), 480-487. 
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geographically dispersed. I would refer back to the experts in advocacy and communication 
who recommended the use of framing issues in social justice terms and the use of anecdotes 
to convey meaning. Could we ask clinicians in the obstetric field to collect stories on how the 
information has impacted their practice of medicine and the lives of the pregnant women and 
their babies who participated in clinical trials or benefitted from the use of a dose-adjusted 
therapy in pregnancy? That's where the real impact would be found and its collection and 
communication will rely upon professional organizations and patient advocacy groups.  
Evaluation of potential negative impact and unintended consequences should also be 
undertaken. Estimating the cost of conducting the trials in pregnant women, increased 
litigation due to adverse outcomes, and birth defects or other morbidity attributed to drug 
exposures in clinical trials would be at the top of the list. The industry would certainly 
monitor the impact of the guidance on the pharmaceutical company – the costs of conducting 
the trials and the related infrastructure and administration of them - against any financial 
returns (which would be expected to be small).  
How does one measure the return on investment (ROI) for corporate responsibility 
(CR) measures? Customer and employee satisfaction scores are suggested as potential "soft-
indicators" of impact on corporate responsibility scores. These scores are not to be 
underestimated – pharmaceutical companies compete to get higher ratings on CR indicator 
scales such as the Corporate Social Responsibility Index, the Access to Medicines Index, and 
the Human Rights Impact Assessment score. An effort to get a question about the inclusion 
of pregnant women in clinical studies on a pharmaceutical industry-focused measurement 
scale would focus attention on the issue. How one achieves that goal would be worthwhile 
exploring. 
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New policy implementation and evaluation necessitates the need to monitor and 
measure both intended and unintended outcomes. Based on the outcomes of these 
measurements, policy modifications can be made for improvement in both the process and 
the intended outcomes. 
 
D. Conclusion 
John Kingdon's "Policy Window" theory of change provided the conceptual 
framework for the planning, implementation, and application of findings of the study. The 
participation of pregnant women in clinical research has advocacy, policy, and political 
implications, therefore the plan for change can be framed within Kingdon's constructs. In 
order to elicit change in social issues, he recommended obtaining constituent feedback and 
indicators of the existence and magnitude of the issue via research. The results of this 
research study provide this factual information that was missing from the literature and from 
prior discourse. Problem recognition, policy solutions, and political participation are enabled 
and the pharmaceutical industry can join into the debate. While identifying opportunities and 
ideas for implementing change, the study also identified perceived barriers that must be 
overcome – in clinical research design, in perceptions of ethical conduct, in economic 
impact, in public support, and in litigation risk. Much effort will need to be sustained over 
many years to make the inclusion of pregnant women in clinical research a reality. (See 
Chapter 8 for suggestions for future research.) 
 Chapter 8 
Discussion 
 
 
A. Impact on public health 
In the U.S., more than a third of the 1.7 million women who give birth each year experience 
some type of adverse complication293 - and two women die every day from pregnancy-related 
causes.294 Over 60 percent of pregnant women are prescribed one or more medications (not 
including vitamins) 295,296 but the safety of their use during pregnancy is largely unknown.297  
Also unknown, and equally important, are the negative consequences of not taking a 
medication, taking less of a medication, taking a different medication, or discontinuing a 
medication. I am personally aware of adverse consequences such as the recommendation of 
ineffective treatment to pregnant women exposed to anthrax, the termination of wanted 
                                                 
293Daniel, I., Berg, C., Johnson, C.H., & Atrash, H. (2003). Magnitude of maternal morbidity during labor and 
delivery: United States, 1993-1997. American Journal of Public Health, 93(4), 631-634. 
294Heron, M., Hoyert, D.L., Murphy, S.L., Xu, J., Kochanek, K.D., & Tejada-Vera, B. (2009). Deaths: Final 
data for 2006, National Vital Statistics Reports, 57(14), I-136, p. 116. Retrieved from  
http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf 
295 Andrade, S.E., Gurwitz, J.H. & Davis, R.L. (2004) Prescription drug use in pregnancy. American Journal of 
Obstetrics and Gynecology, 191, 398-407. 
296Glover, D.D., Amonkar, M., Rybeck, B.F. & Tracy, T.S. (2003). Prescription, over-the-counter, and herbal 
medicine use in a rural obstetric population. American Journal of Obstetrics & Gynecology, 188(4), 
1039-1045.  
297 Lo, W.Y. & Friedman, J.M. (2002). Teratogenicity of recently introduced medication in human pregnancy. 
Obstetrics & Gynecology, 100, 465-473. 
 
pregnancies due to unfounded fears of birth defects from exposure to a vaccine, and the death 
of a pregnant woman who ceased taking her asthma medication due to an unwarranted fear 
that the medication would cause harm to her fetus. 
In any pregnancy, there is an overall approximate 3 per cent risk of delivering a baby 
with a birth defect.298 Most of the causes of these congenital anomalies are unknown  and 
medication exposures are known to induce a very small percent of these defects.299 In fact, 
the vast majority of drugs and vaccines do not cause fetal harm.300  
Pregnant women get sick. In addition to pregnancy-specific complications like 
gestational diabetes and pre-term labor, medical conditions that occur in non-pregnant 
women occur in pregnant ones as well, including psychiatric illness, cancer, and infectious 
diseases. These conditions can have a devastating impact on the health of the pregnant 
woman and on the well-being of her fetus. Women's health care practitioners lament that the 
"current evidence base for the care of pregnant women facing illness is widely regarded as 
deplorable."301 
To discover the most effective therapeutic interventions to treat illness, the scientific 
community conducts systematic research. But pregnant women are largely excluded from 
                                                 
298Centers for Disease Control and Prevention. (2011). Birth defects. Washington, DC: Author. Retrieved Oct. 
28, 2011 from http://www.cdc.gov/ncbddd/birthdefects/data.html 
299Brent, R.L. (2004). Environmental causes of human congenital malformations: The pediatrician’s role in 
dealing with these complex clinical problems caused by a multiplicity of environmental and genetic 
factors. Pediatrics, 113(4), 957-968, p. 958. 
300Koren, G., Pastuszak, A., & Ito, S. (1998). Drugs in pregnancy. New England Journal of Medicine. 338, 
1128-1137, p. 1131. 
301Lyerly, A.D., Little, M.O., & Faden, R.R. (2011). Reframing the Framework: Toward fair inclusion of 
pregnant women as participants in research. The American Journal of Bioethics, 11(5), 50-52,             
p. 51. 
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such research despite the recommendations of subject matter experts like the U.S. Food and 
Drug Administration302, the Institute of Medicine,303 the Council for International 
Organizations of Medical Sciences,304 and The American College of Obstetricians and 
Gynecologists.305  This study's findings confirmed that the pharmaceutical industry excludes 
pregnant women based primarily on the beneficent desire to avoid harming a fetus and the 
economic intent to avoid the financial and reputational risk of potential litigation. But the 
absence of research data on the safety and efficacy of medications compels clinicians and 
their pregnant patients to make treatment decisions based on past practices, educated guesses, 
and gut feelings. We must do better.  
Key informants in the study identified barriers to and opportunities for broadening the 
inclusion of pregnant women in clinical research so that FDA, the pharmaceutical companies, 
and other stakeholders can knowledgeably debate the issue and identify acceptable and 
effective ways to conduct research with and for pregnant women. The primary recipient of 
the outcome of this debate is the FDA draft guidance document, "Pregnant Women in 
Clinical Trials: Scientific and Ethical Considerations" which is scheduled for release in 2012. 
Public comment will follow its release and the pharmaceutical industry will respond with its 
reactions to the proposals in the draft. 
                                                 
302Feibus, K. & Goldkind, S.F. (May 17, 2011) Pregnant women and clinical trials: Scientific, regulatory, and 
ethical considerations. Oral presentation at the Pregnancy and Prescription Medication Use 
Symposium, Silver Springs, MD. 
303Mastroianni, A.C., Faden, R., & Federman, D. (Eds). (1994). Women and Health Research: Ethical and Legal 
Issues of Including Women in Clinical Studies. Institute of Medicine. Washington, DC: National 
Academy Press. 
304Council for International Organizations of Medical Sciences. (2002). International ethical guidelines for 
biomedical research involving human subjects. Retrieved April 17, 2011 from www.cioms.ch. 
305American College of Obstetricians and Gynecologists' Committee on Ethics. (2007). ACOG committee 
opinion: Research involving women. Obstetrics & Gynecology, 110(3), 731-736, p. 732. 
 194 
 
This study identified research methods that can be used so that pregnant women with 
medically compromised pregnancies can receive treatment within research protocols that 
minimize the risks to the mother and the fetus. The benefits of the research studies must 
exceed the risks and the pregnant woman must be receiving therapeutic benefit or the 
protocols would be unethical. Key informants from within the pharmaceutical industry 
identified recommendations for research practices that meet these requirements. This 
information will be shared with multiple recipients within the industry and associated 
stakeholders like IRB members and the FDA. By providing the data to the industry 
association, industry colleagues, and key opinion leaders within my own pharmaceutical 
company, the study results will influence the content of the industry's response to the draft 
guidance. By providing the data to FDA by sharing the results with the agency key informant 
and potentially testifying at the FDA hearing, the study findings will influence deliberations 
on the draft guidance content. Ultimately, both activities will affect the final version of the 
FDA guidance document.  
Practices recommended in agency guidance documents are widely adopted by the 
pharmaceutical industry. Therefore, this study's influence on the content of the guidance will 
impact research practices in the pharmaceutical industry. The broader inclusion of pregnant 
women in clinical research studies will improve clinical knowledge to decrease inadequate 
treatment, reduce maternal morbidity and mortality, and diminish the unnecessary 
termination of wanted pregnancies – all consequences of a lack of information about the 
safety and efficacy of medications used to treat illness during pregnancy.  
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B. Limitations of the Study 
In addition to the limitations of the study methodology articulated in the Methods and 
Results (Chapters 4, 5 and 6), the study assumes that, if invited, pregnant women will 
participate in clinical studies. However, pregnant women's willingness to participate in 
clinical studies is largely unknown. One small study found that 95% of pregnant women 
interviewed said that they would participate "if there is a chance that participation in a 
clinical trial would help their pregnancy and improve their baby's health."306 Further research 
should be done to articulate the voice of this key constituent as patient advocacy will be 
necessary to achieve change. Patient advocates were an important constituency in changing 
clinical trial policies to include women of childbearing potential in clinical studies, to include 
infected women in HIV studies, and to conduct studies on breast cancer treatment. 
This study also assumes that the industry will listen to the many arguments in favor of 
including pregnant women in clinical studies. I think that the primary aversion to inclusion – 
the desire to do no harm to the fetus – can be overcome by innovations in preclinical testing, 
research design, and timing of the studies as discussed earlier in this document. However, the 
economic justifications for the exclusion of pregnant women in clinical research – an actual 
increase in research costs and a perceived risk of litigation – will be harder to overcome. The 
current economic climate is not friendly to potentially costly new initiatives based on 
considerations of social justice, shared responsibility, cooperation, or obligation to the 
collective good. Such proposals are 'nice-to-haves' that don't make the cut during a financial 
                                                 
306Rodger, M.A., Makropoulos, D., Walker, M., Keely, E., Karovitch, A., & Wells, P.S. (2003). Participation of 
pregnant women in clinical trials: Will they participate and why? American Journal of Perinatology, 
20(2), 69-76.  
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downturn. The pharmaceutical industry is currently executing downsizings, mergers, 
outsourcing, and decreases in research and development in an effort to cut costs and maintain 
profit in a recessionary environment. So, while key informants within the companies may 
understand the need to include pregnant women in research and support their inclusion, they 
are not the business leaders who must make the difficult decisions that cut potentially 
promising programs or decline to support corporate responsibility proposals.  
The alternative to broadening the inclusion of pregnant women in clinical studies is to 
continue the current practice of their exclusion. FDA guidelines can be ignored. The OPRU 
sites will conduct PK testing on priority medications for important diseases; pregnancy 
registries will continue to collect exposure outcomes over time; population-based registries in 
European countries will provide data, and electronic health and insurance records will enable 
case-control studies – all of which, however, take years to arrive at informative data. In the 
meantime, pregnant women will continue to be misinformed, undertreated, overdosed, and 
mistreated. I fear that, unless public pressure is applied, significant incentives are offered, 
and/or protection from litigation is devised, the status quo may remain the norm. So, in 
addition to my efforts to bring this study's findings into the hands of individual companies, 
the industry association, and the public domain, advocacy efforts and economic pressures 
from other influential stakeholders will be needed. A new workshop by advocates of broader 
inclusion – health care providers, ethicists, pregnant women, academics, FDA, and this time 
with the pharmaceutical industry invited to participate – should be held to negotiate potential 
solutions, incentives, protections, and results. Change can occur if the problem stream 
convincingly articulates the issue as a problem, the policy stream contributes acceptable 
solutions, and the political stream provides sufficient pressure to induce change. Such a 
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trifecta might then ensure that, when the policy window closes, the new policy behind the 
window will be favorable to pregnant women.  
 
C. Ethical Considerations 
In this study's area of inquiry, where both the pros and cons of the inclusion of 
pregnant women in research can be argued on ethical merits, an ethical framework can assist 
to provide structure to the debate. In Chapter 3, I reviewed the ethical principles and theories 
most frequently invoked when discussing clinical research, medical practice, women's 
interests, and business practices and concluded that guidance for evaluating perspectives 
about the inclusion of pregnant women in clinical research should be based upon the ethical 
principles of Autonomy, Beneficence, Justice, the Ethic of Care, and Stakeholder 
Considerations (including as stakeholders both the pregnant woman and her caregivers and 
the drug company and its researchers).  
These principles are actualized in the Ethical Guidance below. I propose that 
stakeholders in the discussions that will occur following the release of the draft guidance use 
this approach to evaluate the proposals to include pregnant women in clinical research. It 
may be particularly useful in workshops or conference settings where stakeholders meet to 
discuss potential solutions. Following Beauchamp's recommendation to frame issues using 
public health core values,307 the guidance is intended to assist with the understanding and 
consideration of ideas, opinions, and options. Translating the essence of the ethical principle 
                                                 
307Dorfman, L., Wallack, L., & Woodruff, K. (2005). More than a message: Framing public health advocacy to 
change corporate practices. Health Education and Behavior, 32(3), 320-336. 
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into a question format facilitates the application of the principles to the situation. It helps to 
change the ethical debate from a lofty, unreachable ideal, to a concrete application of the 
ethical intent. It can facilitate the recognition and consideration of the impact of the proposal 
from multiple stakeholders' perspectives. 
For example, if there is a proposal to wait until the results of Phase III clinical trials 
are complete before studying a new drug in pregnant women, how does that proposal stand 
up to the questions in the table? If the proposal is to allow women who become pregnant 
during a clinical trial the option to remain in the study, how does that proposal stand up to the 
questions in the table?  
 
Table 8.1 Ethical Guidance: Application of ethical principles to 
proposed solutions 
 
Autonomy/Respect:  
Does this rationale/solution impinge on anyone's personal autonomy? 
Do all relevant parties consent to this rationale/solution? If not, what are the 
objections? 
Are all opinions acknowledged and respected? 
 
Beneficence:  
Who benefits from this rationale/solution and in what way? 
Does the rationale/solution use the best of our current knowledge? 
Does the rationale/solution favor the balance of benefit over risk? 
 
Non-maleficence:  
Who may be harmed by this rationale or the implementation of this solution? 
How have the potential harms been minimized? 
Are risks communicated in a truthful, complete, and open manner? 
 
Justice:  
Is the rationale/proposed solution equitable to all stakeholders?  
Can it be made to be more equitable? 
Are the benefits and the burdens fairly distributed among stakeholders? 
 
Ethic of Care: 
Whose needs are being met by this solution?  
Does the rationale/solution promote cooperation among stakeholders? 
Are relationships identified and maintained or promoted by the action? 
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Stakeholders:  
Have all parties involved in this rationale/solution been identified? 
What parties are impacted by this rationale/solution and in what way? 
Are all stakeholders' concerns respected and addressed?  
Do they agree on the solution? 
Adapted from Beauchamp & Childress, Principles of Biomedical Ethics308 
 
D. Conclusion 
The results of this study support a change in the current practices of the U.S. 
pharmaceutical industry to broaden the inclusion of pregnant women in clinical studies when 
appropriate. The findings indicate that there is support within the industry to modify 
regulatory guidance and clinical research inclusion and exclusion criteria. Alternative 
research designs and other legal, regulatory, and public policy solutions that address 
sustaining beneficence and reducing litigation risk are proposed. Improved maternal-infant 
health outcomes due to the enhanced knowledge of medication efficacy and safety gained 
from clinical studies in human pregnancies is this study's contribution to public health. 
Much as the release of the FDA draft guidance will provoke industry to respond to 
the issue, the findings of the study will challenge industry to confront fundamental 
viewpoints, and spur scientists and researchers to find new ways to contribute to clinical 
knowledge about the safe and effective treatment of pregnant women who need medical 
intervention. The business reservations about implementing the necessary changes will need 
to be addressed. But the wealth of knowledge, passion, and willingness to change that this 
study found within companies to confront this challenge portends an improvement in the 
contribution that industry will make to maternal health.   
                                                 
308Beauchamp, T. & Childress, J. (2001). Principles of Biomedical Ethics (5th ed.) Oxford: Oxford University 
Press. In The Office of Public Policy and Ethics (2002), A primer to ethical analysis. Retrieved March 
6, 2011 from The University of Queensland web site: http://www.uq.edu/au/oppe  
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 E.  Suggestions for Further Research 
This study identified several opportunities for further research that would contribute 
knowledge to the field and provide further incentives to change.  
 
Cost Benefit Analyses 
When addressing senior executives in a business environment, in addition to using 
language and anecdotes that speak to individual and collective values, we can and should 
also speak in the language of 'market justice.' This study identified missing information that 
could be helpful in making the case for change to company officials.  
• A cost-benefit analysis on the lack of efficacy of amoxicillin against anthrax 
o What are the financial and social implications of that finding? 
• A cost-benefit analysis of the exclusion of pregnant women from clinical trials 
o Comparative morbidity and mortality 
o Implications of cost to the health care system 
o Implications of cost to the pharmaceutical industry 
o Social and financial costs (e.g., thalidomide or Bendectin as case studies) 
 
Research priorities for pregnant women 
There is a need to identify what diseases and drug classes would be a priority for 
pregnant women. What are current treatment practices for these conditions and how could 
they be improved? Are "older" interventions being used that could be replaced with "newer" 
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treatments? Case studies that illustrate the implications of this lack of knowledge should be 
accumulated. The evaluation of the impact of the inclusion of pregnant women could then be 
measured against such case studies.    
 
Ex-US Studies for Global Harmonization 
This study limited its focus to the inclusion of pregnant women in clinical trials in the 
United States. But clinical trials are rarely performed in only one country anymore and 
medical product markets are global. It would be informative to review how the other two 
major markets' (EU and Japan) regulations, guidelines, and practices regarding pregnant 
women in research differ from the U.S. Understanding how policy is changed in those 
political constituencies would be helpful to the potential harmonization of research practices 
throughout the world. 
A key informant suggested that: 
"The other place you can have potential impact is in Europe with 
EMA (the European Medicines Agency). EMA may have similar 
interests and it may be possible to explore that. ICH (the 
International Council on Harmonization) is semi-moribund at the 
moment but it's entirely possible that they could open up a whole 
new section to deal with this issue, at least to get the ideas on the 
table."  
 
Potential FDA Incentives 
Identify potential incentives that FDA could use to encourage pharmaceutical 
companies to design and implement studies that include pregnant women. What incentives 
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have been used in the past, under what circumstances, and have they been successful? What 
new incentives might be tried? Do incentives replace the need for regulations?  
 
Litigation and Compensation Protection 
From the UTMB conference report:309 
"There should be a nationally supported mechanism to protect 
private sponsors and industry from excessive or inordinate liability 
claims and to develop incentives to promote industry-supported 
research on this population." 
 
From Moral Science: Protecting Participants in Human Subjects Research:310 
Recommendation 3: Treating and Compensating for Research-Related Injury 
"Because subjects harmed in the course of human research should 
not individually bear the costs of care required to treat harms 
resulting directly from that research, the federal government, 
through the Office of Science and Technology or the Department 
of Health and Human Services, should move expeditiously to study 
the issue of research-related injuries to determine if there is a need 
for a national system of compensation or treatment for research-
related injuries."  
 
What is the current status of the Presidential Commission's recommendation to 
explore a national system of compensation for research-related injury? Is the Commission 
including industry-sponsored research in its scope? Is the Commission aware that the adverse 
health consequences caused by the exclusion of pregnant women from clinical research are 
                                                 
309 Goodrum LA, Hankins GDV, Jermain D, Chanaud CM. Conference report: Complex clinical, legal, and 
ethical issues of pregnant and postpartum women as subjects in clinical trials. Journal of Women's 
Health 2003: 12(9):864. 
310Presidential Commission for the Study of Bioethical Issues. (2012). Moral Science: Protecting Participants in 
Human Subjects Research. Washington, D.C., 2011. Retrieved from http://bioethics.gov/cms/node/558  
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abetted by the pharmaceutical industry's defensible fear of the cost of compensation for 
causal or unproven but associated fetal injury? Might this topic be of interest to the 
Commission? 
What is the history of the Vaccine Injury Compensation Program? How did that 
program come to be established? Has it been successful? What are the benefits, detriments, 
and costs? Could a similar program be established to remove the barrier of litigation risk 
from the decision to include pregnant women in clinical research? 
 
Ethics 
"…extend the scope of responsibility for ethical research to 
industry leaders, elected officials, and research funders, because 
they too play a role in ensuring that research endeavors do not 
create or perpetuate vulnerabilities, particularly inequalities in 
health or relations of power."311 
 
More fully explore the ethical arguments for and against the inclusion of pregnant 
women in clinical research. Explore the application of feminist ethics to the issue. How do 
codes of research ethics change over time? How are they formally and informally adopted by 
constituencies?  
 
 
 
                                                 
311Eckenwiler, L.A., Ells, C., Feinholz, D., & Schoenfeld, T. (2008). Hopes for Helsinki: Reconsidering 
vulnerability. Journal of Medical Ethics, 34(10), 765-766, p. 766. 
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Vulnerable populations: 
• Take each of the vulnerable populations as defined in the Common Rule. What 
impact has the label had on the group? What is the current research practice for each 
group? Has it had a positive or negative impact? Has it impacted all groups in the 
same way? 
• Explore the history of the inclusion of children in clinical research and the 
development of the current regulations (Best Pharmaceuticals for Children Act, 
Pediatric Research Equity Act). What lessons can be learned from that history that 
could be applied to the current controversy over pregnant women in clinical research? 
Are these regulations considered to have been successful? What changes would be 
recommended today? 
 
Pregnant women's participation in research 
Because pregnant women have been routinely excluded from clinical studies we do 
not know to what extent they might volunteer to participate. Of course, pregnant women 
would only be asked to participate if they are in need of treatment and the study would 
potentially provide therapeutic benefit and if the potential benefits of the study exceeded the 
potential risks. Under those circumstances, participation would be very much like treatment 
in clinical practice with the added benefit of improved informed consent, enhanced 
pregnancy monitoring, and the patient's knowledge that she has contributed her experience to 
the accumulated medical knowledge base to assist other pregnant women. Research has 
shown that people participate in clinical research studies for many reasons including access 
to otherwise unavailable treatments. Other motivations include: "closer monitoring than in 
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routine practice, getting attention for other ailments, better physical and laboratory health 
checks, superior physicians, labs, and testing, more contact with the 
providers,….remuneration, and contributions to society."312  
A survey of pregnant women who are participating in clinical studies should be 
conducted to ascertain their motivations – why did they agree to enroll? How much influence 
did making a contribution to medical knowledge contribute to their decision? What were 
their other considerations? This study determined that there were 5 studies currently ongoing 
that were specifically designed for pregnant women and 19 studies that would consider 
enrolling pregnant women. This would constitute a small sample but one that would provide 
much needed information if we hope to encourage the enrollment of pregnant women – or 
overcome the mindset that says that pregnant women would never agree to participate. 
 Finally, the study could be repeated if the enrollment of pregnant women in clinical 
research becomes more widespread. One could then see how attitudes, beliefs, and practices 
have changed over time and if the proportion of clinical trials including or designed for 
pregnant women has improved. 
 
 
                                                 
312Iber, F.L., Riley, W.A., & Murray, P.J. (1987). Conducting Clinical Trials, New York: Plenum Press. In 
Merton, V. (1993). The exclusion of pregnant, pregnable, and once-pregnable people (a.k.a. women) 
from biomedical research. American Journal of Law & Medicine, 19(4), 369-451, p. 378. 
 206 
 
 APPENDIX I 
 
The Ethical Principles Invoked For and Against the Inclusion of Pregnant Women in 
Clinical Research. 
 
 
 
Ethical rationale for the exclusion of pregnant women from clinical research 
Principle Rationale 
Beneficence Act in the best interest of the patient: use treatments and study designs that present the least risk. 
Non-maleficence 
Protect mother and fetus from harm by avoiding experimental drug 
toxicity with no assurance of safety and avoid exposure without 
benefit: uninterpretable data. 
Financial 
stewardship 
Cost outweighs benefit: litigation risk; little return on investment; 
and inclusion, which complicates the study, is not required. 
Avoid the Double 
Effect 
Beneficence and non-maleficence may conflict when, in trying to 
do good, harm may be done. 
Good clinical 
practices standards a 
Use standard, acceptable practices based on current knowledge to 
achieve good outcomes. 
a Good Clinical Practice (GCP) is an international quality standard provided by the 
International Conference on Harmonisation (ICH) that governments use to guide regulations 
about protecting human subjects in clinical trials and assuring the safety and efficacy of new 
compounds. (Wikipedia, GCP, 2/20/11) 
 
 
 
Ethical rationale for the inclusion of pregnant women in medical research 
Principle Rationale 
Beneficence Improve the health and safety of pregnant women and their babies. 
Non-maleficence 
Gain knowledge to evaluate risks and benefits of treatment so that 
you do no harm, avoid exposure of fetus with no benefit to mother, 
and prevent termination of wanted pregnancies due to fear. 
Justice Allow access to the best treatment available to all sectors of society equally; and follow regulations. 
Autonomy The pregnant woman has the right to decide whether to accept risk.
Good clinical 
practice standards 
Follow currently accepted best practices and work to improve 
them. 
Informed consent Cannot have informed consent (balancing risks and benefits)  without information. 
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APPENDIX II 
 
The U.S. Drug Development Process 
 
Potential new drug products (author's note: I will use 
the term "drug" but the process is similar for vaccines, 
biologics, and devices) are evaluated via computer 
modeling, laboratory testing, and animal studies prior to 
being tested on human subjects.  Based on the results of 
these studies, the new drug's pharmaceutical company 
sponsor submits an application to the FDA for approval 
to conduct testing in human subjects. Upon approval, 
the first clinical use of the potential new drug product in 
humans occurs in Phase I studies. These studies are 
conducted on a small number (20-100) of healthy 
volunteers to ascertain the effect of the drug on a 
healthy person. Results may corroborate previous 
findings from pre-clinical (animal) testing. If results are 
favorable, Phase II testing is performed on subjects 
with the condition or disease that the potential new drug 
product is intended to treat.  
Figure from the Global Campaign for Microbicides, 
http://www.global-campaign.org/clinical_testing.htm, 
image available at http://www.global-
campaign.org/clientfiles/ClinicalTrials1.jpg; accessed 
09July2011. 
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The size of these studies varies depending on the frequency of the condition in the population 
but can range from 20 to 300 subjects.  These tests provide information on efficacy, dosing, 
and safety.  Finally, large clinical trials are conducted (Phase III studies) on anywhere from 
300 to 3000 subjects or more, to obtain additional data about effectiveness and safety. These 
study results, in many cases, "aim to change medical practices, for example by comparing a 
new treatment with the best standard treatment."313      
  
                                                 
313Weijer, C. (1999). Selecting subjects for participation in clinical research: One sphere of justice. Journal of 
Medical Ethics, 25, 31-36, p. 34. 
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APPENDIX III 
The Interview Guide 
 
The Participation of Pregnant Women in Clinical Research:  
Implications for Practice within the US Pharmaceutical Industry 
 
INTERVIEW GUIDE FOR KEY INFORMANTS IN INDUSTRY OR IRBs 
Intro: 
Thank you for agreeing to speak with me. As you know, I am here to interview you about 
whether pregnant women can and should be included in clinical trials. I recently learned that 
FDA has a draft guidance in review at the agency on this topic. I also know about a group of 
physicians and academics who are advocating for greater inclusion. Being in industry, I 
wondered what our position is on the subject – or if we even have one. I found that there is 
little information from industry on this topic in the literature so I am exploring the subject 
from the industry perspective for my doctoral dissertation. I am a student in the Executive 
Doctoral Program in Health Leadership at the University of North Carolina at Chapel Hill 
Gillings School of Global Public Health.   
 
I want to remind you that by agreeing to meet with me, you have consented to participate in 
this study. You may decline to participate, decline to answer any question, or stop at any 
time. However, your responses will be valuable to the results of this study. The information 
collected in this study will be kept confidential. Your specific answers will not be attributed 
to you or to your organization. The interview results will only be used in summary form to 
discuss issues related to the inclusion of pregnant women in clinical trials. With your 
permission, I will be both recording this interview and taking notes. 
 
Do you have any questions? Do I have your permission to begin? 
 
 
Background: 
 
My background: I was an OB/GYN nurse practitioner before joining Merck 13 years ago to 
run their Pregnancy Registry program. I worked in Drug Safety for 12 years and I'm 
currently working in the Merck Office of Ethics.  
 
Key Informant background: Can you tell me the position you currently hold at your 
company/organization? How long have you been at the company/organization?  
What is your background – did you come from medicine, pharmaceutical science, business, 
etc? 
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Have you worked on any issues involving pregnant women at your company or organization? 
If yes, please briefly describe: 
 
 
Level-setting background to the interview: 
 
There are two scenarios: 
A. One is women who become pregnant during a clinical trial and 
B. the other is actually enrolling pregnant women in clinical trials 
I am most interested in discussing the enrollment of pregnant women and if we have time we 
can talk about research subjects who inadvertently become pregnant.   
 
When we talk about pregnant women participating in a clinical trial, we can assume that it is 
for a therapeutic purpose not otherwise available. [She may not have responded to other 
therapies or they may be contraindicated, e.g. drug allergy or resistance, etc.] Also, we are 
not talking about clinical trials for pregnancy-related conditions but rather drug intervention 
trials for non-pregnancy-related issues that can occur in pregnant women.  
 
Study Questions: 
 
<Study Aim (SA) #6: influence of industry in the debate> 
1. How much control do you think the industry has over whether pregnant women should be 
allowed to participate in trials? In your experience, who has more control over the inclusion 
and exclusion criteria – the sponsor or the IRB or the FDA?  
 
Awareness  <SA #2: raise the issue> 
FDA has a new guidance draft in clearance entitled, "Pregnant Women in Clinical Trials: 
Scientific and Ethical Considerations." There is also a group of health care providers, 
ethicists, academicians, etc., called the Second Wave consortium, who are encouraging, what 
they call "the rational inclusion of pregnant women in clinical trials."  
 
2. Are you aware of the FDA guidance? and Have you heard of this advocacy group? 
[If no, continue. If yes, do you know if your company is doing anything in connection with 
this issue? If yes, describe.] 
 
 
Current state: <background information; current state> 
3. Does your company (or IRB), to your knowledge, have a policy about whether or not to 
include pregnant women in clinical studies? If yes, describe…  If there is no policy, or if you 
are not aware of a policy, do you know what the current practices of the company (or IRB) 
are? 
 
 
Rationales: <SA #3 and #4: isolate concerns and opportunities> 
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4. Can you give me 3 or 4 reasons why a Company (or an IRB) would not want to include 
pregnant women in clinical trials? (barriers) 
 
If mention litigation: <SA #5: pharma's perception of litigation risk> 
4.a. Do we know that allowing pregnant women in clinical trials would result in 
litigation or are we presuming it would?  
 
4.b. Do you think litigation risk is higher in the clinical trial environment or in the 
post-marketing environment? Why/based on what?  
 
[Interviewer notes: If thalidomide had been tested in clinical trials, thousands of 
deformities would have been avoided. There are few lawsuits about birth defects 
uncovered in a clinical trial, even though there have been pregnant women in studies, 
i.e., AIDS secondary transmission trials; Gardasil trials [almost 3000 inadvertent 
pregnancies among 27000 women of childbearing age]). If equal risk: why do we 
take one risk and not the other?] 
 
5. Aside from studies that are specifically about conditions of pregnancy, can you give me 3 
or 4 reasons why a Company (or an IRB) should or might want to include pregnant women in 
clinical trials? (opportunities) 
 
 
Opportunities: <SA #4: potential opportunities> 
6. If pregnant women were to be enrolled, how do you think we should do that? 
• For example, wait to end of Phase III until have safety and efficacy in non-pregnant 
population, then enroll pregnant women? 
• Other ways? (pk studies, look at toxicity studies, other drugs in class, alternatives) 
 
7. If pregnant women were enrolled, what steps could be taken to safeguard the fetuses and 
the pregnant women who consent to participate?  
 
8. I want to brainstorm about what it would take to have Companies open (or IRBs approve) 
relevant clinical trials to pregnant women. What do you think it would take?   
 
• Would a guidance document be strong enough or would it need to be by regulation?  
 
• Would Company indemnification be necessary? Is that a realistic option? 
 
• Would patent extensions, like those implemented for pediatric trials, be a viable 
enticement?  
 
• Are there other solutions or incentives you can think of?  
 
 
Alternatives <SA #4: potential opportunities> 
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9. If not enrolling in clinical trials, what are alternative ways to get this information? Are 
there alternative study designs or data collection methods that could include pregnant 
women? 
 
• Do you think a pharmaceutical company would support or fund this kind of research? 
Why or why not? 
 
10. One of the challenges in doing research with pregnant women is addressing the ethical 
issues it raises.  What ethical problems do you think are most challenging or important?" 
 
[Prompt: The inclusion of pregnant women in clinical trials raises questions about industry's 
contributions to the good of society vs our contributions to our shareholders. How do we 
reconcile the need for improved knowledge about how to treat pregnant women with the 
costs and risks to the companies?  
 
 
11. What else should be added to this discussion about the inclusion of pregnant women in 
clinical research? 
 
 
 
[If there is time left to discuss] 
B. Women who become pregnant in clinical trials 
 
1. Does your company have a policy about what to do with women who become pregnant 
during a trial?  
 
2. If no policy, what is current practice? Are they always disenrolled and followed to 
outcome? [Can you name a protocol in which women who became pregnant stayed on study 
drug?] 
 
3. Can you think of a situation where a woman who becomes pregnant should remain in the 
study? [e.g., when potential benefits outweigh risks of a) ongoing fetal exposure to study 
drug, b) risk of discontinuing maternal therapy, c) risk of exposing fetus to additional drugs 
if mother must go on alternative therapy.] 
 
4. What would be needed to retain her in the trial? [new informed consent – discuss alt tx and 
comparative tx risks and benefits, incl risk of untreated maternal disease] 
 
Are there any other comments you'd like to add about this or any other topic? 
 
If you would like to contact me after our discussion today, please feel free to do so. I can be 
reached at 267-231-7215 or at kristine_shields@merck.com.  
 
Again, thank you so much for agreeing to this meeting. If you wish to reach me, please 
feel free to call me or send an email. 
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 The Participation of Pregnant Women in Clinical Research:  
Implications for Practice within the US Pharmaceutical Industry 
 
INTERVIEW GUIDE FOR KEY INFORMANTS AT FDA, PhRMA and BIO 
Intro: 
Thank you for agreeing to speak with me. As you know, I am here to interview you about 
whether pregnant women can and should be included in clinical trials. I recently learned that 
FDA has a draft guidance in review at the agency on this topic. I also know about a group of 
physicians and academics who are advocating for greater inclusion. Being in industry, I 
wondered what our position is on the subject – or if we even have one. I found that there is 
little information from industry on this topic in the literature so I am exploring the subject 
from the industry perspective for my doctoral dissertation. I am a student in the Executive 
Doctoral Program in Health Leadership at the University of North Carolina at Chapel Hill 
Gillings School of Global Public Health.   
 
I want to remind you that by agreeing to meet with me, you have consented to participate in 
this study. You may decline to participate, decline to answer any question, or stop at any 
time. However, your responses will be valuable to the results of this study. The information 
collected in this study will be kept confidential. Your specific answers will not be attributed 
to you or to your organization. The interview results will only be used in summary form to 
discuss issues related to the inclusion of pregnant women in clinical trials. I will be both 
recording this interview and taking notes. 
 
Do you have any questions? Do I have your permission to begin? 
 
 
Background: 
 
My background: I was an OB/GYN nurse practitioner before joining Merck 13 years ago to 
run their Pregnancy Registry program. I worked in Drug Safety for 12 years and I'm 
currently working in the Merck Office of Ethics.  
 
Key Informant background: Can you tell me the position you currently hold at 
FDA/PhRMA? How long have you been at the organization?  
 
What is your background – did you come from medicine, pharmaceutical science, business, 
etc? 
 
Do you now or have you worked on any issues involving pregnant women at FDA/PhRMA? 
If yes, please briefly describe: 
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Level-setting background to the interview: 
 
There are two scenarios: 
A. One is women who become pregnant during a clinical trial and 
B. the other is actually enrolling pregnant women in clinical trials 
I am most interested in discussing the enrollment of pregnant women and if we have time we 
can talk about research subjects who inadvertently become pregnant.   
 
When we talk about pregnant women participating in a clinical trial, we can assume that it is 
for a therapeutic purpose not otherwise available. [She may not have responded to other 
therapies or they may be contraindicated, e.g. drug allergy or resistance, etc.] Also, we are 
not talking about clinical trials for pregnancy-related conditions but rather drug intervention 
trials for non-pregnancy-related issues that can occur in pregnant women.  
 
Study Questions: 
 
<SA #6: influence of industry in the debate> 
1. How much control do you think the industry has over whether pregnant women should be 
allowed to participate in trials? In your experience, who has more control over the inclusion 
and exclusion criteria – the sponsor or the IRB or the FDA?  
 
Awareness  <SA #2: raise the issue> 
FDA has a new guidance draft in clearance entitled, "Pregnant Women in Clinical Trials: 
Scientific and Ethical Considerations." There is also a group of health care providers, 
ethicists, academicians, etc., called the Second Wave Consortium, who are encouraging, 
what they call "the rational inclusion of pregnant women in clinical trials."  
 
2P. For PhRMA rep: Are you aware of the new FDA draft guidance entitled, "Pregnant 
Women in Clinical Trials: Scientific and Ethical Consideration"? Was it influenced by 
PhRMA? [If yes, describe, if No continue:] Is PhRMA doing anything in connection with this 
issue? If yes, describe.]  
 
Are you aware of the Second Wave advocacy group? [If yes, describe, if No continue:] 
 
2F. For FDA rep: What is your involvement with the guidance document? What is your 
opinion of the guidance? What is your opinion of how the industry will respond to the 
proposals in the guidance? 
 
Are you aware of the Second Wave advocacy group? [If yes, describe, if No continue:] 
 
 
A. Enrolling pregnant women in clinical trials 
Current state: <background information; current state> 
3. Do most companies, to your knowledge, have a policy about whether or not to include 
pregnant women in clinical studies? If yes, describe…  If there is no policy, or if you are not 
aware of a policy, do you know what the current practices of most companies are? 
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Rationales: <SA #3 and #4: isolate concerns and opportunities> 
4. Can you give me 3 or 4 reasons why a Company would not want to include pregnant 
women in clinical trials? 
 
If don't mention litigation, raise the issue, if mention litigation: <SA #5: pharma's 
perception of litigation risk> 
4.a. Do we know that allowing pregnant women in clinical trials would result in 
litigation or are we presuming it would?  
 
4.b. Do you think litigation risk is higher in the clinical trial environment or in the 
post-marketing environment? Why/based on what?  
 
[Interviewer notes: If thalidomide had been tested in clinical trials, thousands of 
deformities would have been avoided. There are few lawsuits that arose over birth 
defects uncovered in a clinical trial, even though there have been pregnant women in 
studies, i.e., AIDS secondary transmission trials; Gardasil trials [almost 3000 
inadvertent pregnancies among 27000 women of childbearing age]). If equal risk: 
why do we take one risk and not the other?] 
 
5. Aside from studies that are specifically about conditions of pregnancy, can you give me 3 
or 4 reasons why a Company might want to include pregnant women in clinical trials? 
 
 
Opportunities: <SA #4: potential opportunities> 
6. If pregnant women were to be enrolled, how do you think we should do that? 
• For example, wait to end of Phase III until have safety and efficacy in non-pregnant 
population, then enroll pregnant women? 
• Other ways? (pk studies, look at toxicity studies, other drugs in class, alternatives) 
 
7. If pregnant women were enrolled, what steps could be taken to safeguard the fetuses and 
the pregnant women who consent to participate?  
 
 
8. I want to brainstorm about what it would take to have Companies open relevant clinical 
trials to pregnant women. What do you think it would take?   
 
8a. Would a guidance document be strong enough or would it need to be by 
regulation?  
 
8b. Would Company indemnification be necessary?  
 
8c. Would patent extensions, like those implemented for pediatric trials, be a viable 
solution?  
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8d. Are there other solutions?  
 
Alternatives <SA #4: potential opportunities> 
9. If not enrolling in clinical trials, what are alternative ways to get this information? Are 
there alternative study designs or data collection methods that could include pregnant 
women? 
 
9a. Do you think a pharmaceutical company would support or fund this kind of 
research? Why or why not? 
 
10. One of the challenges in doing research with pregnant women is addressing the ethical 
issues it raises.  What ethical problems do you think are most challenging or important?" 
 
11. What else should be added to this discussion about the inclusion of pregnant women in 
clinical research? 
 
 
[If there is time left to discuss] 
B. Women who become pregnant in clinical trials 
 
1. So, first, do you know if companies have policies about what to do with women who 
become pregnant during a trial? If yes, describe: 
 
2. If no (or no policy), what is their current practice? Are pregnant women always disenrolled 
and followed to outcome? [Can you name a protocol in which women who became pregnant 
stayed on study drug?] 
 
3. Can you think of situations where it would be appropriate for a woman who becomes 
pregnant to remain in the study? [when potential benefits outweigh risks of a) ongoing fetal 
exposure to study drug, b) risk of discontinuing maternal therapy, c) risk of exposing fetus to 
additional drugs if mother must go on alternative therapy.] 
 
4. What would be needed to retain her in the trial? [new informed consent – discuss alt tx and 
comparative tx risks and benefits, incl risk of untreated maternal disease] 
 
 
Again, thank you so much for agreeing to this meeting. If you wish to reach me, please 
feel free to call me or send an email.
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Study Aims (SA): 
 
1. Quantify the frequency of the participation of pregnant women in current pharmaceutical 
company-based studies by accessing the inclusion and exclusion criteria via 
ClinicalTrials.gov. (The Food and Drug Modernization Act of 2007 mandates that all 
federally and privately funded clinical trials be posted on the NIH website, 
ClinicalTrials.gov.) 
2. Raise the issue to selected pharmaceutical industry representatives and related 
organizations to heighten their awareness of the issue and the debate. 
3. Isolate the concerns of the pharmaceutical industry representatives about including 
pregnant women in clinical trials to further our understanding of potential barriers to their 
inclusion. 
4. Isolate potential opportunities for inclusion of pregnant women in clinical trials from the 
pharmaceutical industry representatives' perspectives. 
5. Ascertain the pharmaceutical industry and related organizations' representatives' 
perceptions of litigation risk [regarding how influential it is and is it a real risk?].  (This is 
one of two key pieces of missing information identified by the Second Wave Consortium 
workshop.)314 
6. Explore the selected pharmaceutical industry and related organization representatives' 
perspective about the industry's role in affecting the outcome of the debate [how 
influential is it?] (This is the second key piece of missing information identified by the 
Second Wave Consortium workshop.)315 
                                                 
314 Personal communication, AD Lyerly, 12Nov2010. 
315 Personal communication, AD Lyerly, 12Nov2010. 
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APPENDIX IV 
QUALITATIVE STUDY RESULTS 
Key Findings from Key Informant Interviews 
 
Question Key Findings 
 
1 
 
Who has the most control over whether pregnant women are 
included in clinical trials – the pharmaceutical company sponsor, the 
Institutional Review Board (IRB), or the FDA? 
 
1a. Four stakeholders were identified as having the power to veto a 
clinical trial: the trial's sponsor, the FDA, the IRB, and the institution at 
which the trial is to take place. 
  
1b. The Sponsor was perceived to have the most control over whether or 
not pregnant women were included as study subjects. Without proposing 
their inclusion, it was unlikely that the FDA or IRB would suggest it. In 
addition, it was felt that because the company would have the highest risk 
for liability, they had the right to be the decision-makers. 
  
1c. FDA was found to have the least influence as there is no regulatory 
statute that requires their exclusion.  
  
1d. IRBs were felt to be a potential barrier to inclusion based on their 
cautious nature, their patient-centric focus, and the variability of decisions 
from one IRB to the next. 
  
1e. All of these stakeholders were perceived to be resistant to the idea of 
including pregnant women in clinical trials.   
 
2 
 
Are you aware of the FDA Guidance? Have you heard of the Second 
Wave advocacy group? 
 
2a. There is a lack of awareness among industry employees and within 
related organizations about the issue of the inclusion of pregnant women 
in clinical trials, about the impending release of an FDA guidance 
document on the topic, and about the Second Wave Coalition advocacy 
group. The interviewees implied there is also a lack of awareness of the 
issue among the general public. The implication of this dearth of 
awareness at all levels was seen to be a potential barrier to the initiation of 
change and a facilitator of the status quo.  
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 2b. It is critical to get the issue into the public domain in order to change 
current thinking and get stakeholders involved. The work of the Second 
Wave Consortium was important in this regard. 
  
2c. There is opportunity for change utilizing the government's and public's 
current interest in protection against bioterrorism.  
  
2d. There is opportunity for change utilizing the work that has been done 
in clinical trials for HIV treatment and the prevention of vertical 
transmission. 
  
2e. There exist similarities between the exclusion of pregnant women 
from clinical research and the former exclusion of pediatric patients from 
clinical research. There may be lessons learned from the endeavors of the 
pediatric sector that have resulted in mandated pediatric clinical studies.  
 
3 
 
Does your organization have a policy about whether or not to include 
pregnant women in clinical studies? What are the current practices 
there? 
 
3a. Most companies exclude pregnant women from their studies. 
  
3b. IRBs generally have policies regarding the inclusion of pregnant 
women in clinical studies, based on the Code of Federal Regulations 
regarding vulnerable populations. They feel that their policies could be 
improved by an FDA guidance on this topic. 
  
3c. Some companies have experience doing clinical studies that include 
pregnant women. Information on drug safety gathered from other sources 
can be helpful in setting up clinical studies for pregnant women. Some 
women who become pregnant while enrolled in clinical studies may 
remain in some studies on an ad hoc, compassionate use basis. 
  
3d. FDA feels that studies should be done for certain products where the 
need is well established.  
 
4 
 
Can you give me 3 or 4 reasons why a company or organization 
would not want to include pregnant women in clinical trials? 
 
4a. The fear of causing harm to a fetus is the most important concern 
limiting the inclusion of pregnant women in clinical trials.  
  
4b. The fear of litigation is one of the major concerns that is limiting the 
inclusion of pregnant women in clinical trials.  
  
4c. The efficacy, safety, and proper dose of a medication must be known 
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to some extent prior to testing the drug in pregnant women. 
  
4d. Industry has little experience designing clinical trials that include 
pregnant women. More information is needed to assist with the design of 
such studies. 
  
4e. National and international regulations regarding the inclusion of 
pregnant women in clinical studies are not well understood. 
  
4f. Studying drugs in pregnant women would provide valuable 
information for the label, which would improve the treatment of pregnant 
women. 
 
4g. Industry is reluctant to risk the approval of a drug for the non-
pregnant population or the reputation of its company by testing drugs on 
pregnant women.  
  
4h. A sufficient number of pregnant women must be included in a study 
of pregnant women to ensure that the data collected is interpretable.  
  
4i. Industry perceives little motivation or advocacy for the study of its 
products in pregnant women. 
  
4a Do we know that allowing pregnant women in clinical trials would 
result in litigation or are we presuming it would? 
 
4a1. Because we have little actual experience, we presume, but don't 
know, that the litigation risks would be higher in clinical trials of pregnant 
women than in clinical trials in general. 
  
4a2. There is a perceived risk that excluding pregnant women from 
clinical research could result in litigation due to adverse pregnancy 
outcomes caused by restricting pregnant women from getting the drug 
they needed, or caused by a drug that was not fully evaluated was put on 
the market. 
  
4a3. Thorough informed consent, complete disclosure in the Investigator's 
Brochure, FDA approval, IRB review, risk minimization, and the 
disclosure that the trial is intended to help pregnant women now and in 
the future, could help protect the company from lawsuits in clinical trials 
of pregnant women.  
  
4a4. Our litigious society, the emotional component in jury trials, and 
increased litigation risk in the obstetrical community could increase the 
risk of litigation in clinical trials of pregnant women.  
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4a5. The risk of liability for injuries that occur during research in general 
is low. 
  
4a6. Some respondents believed that the increased litigation risk would be 
minimal and should not be a deciding factor in whether or not to conduct 
trials in pregnant women. 
 
4b 
 
Do you think litigation is higher in the clinical trial environment or in 
the post-marketing environment? 
 
4b1. Pharmaceutical companies are concerned about litigation risks 
associated with testing products on pregnant women in both the clinical 
trial and the post-marketing environment. 
  
4b2. Fear of litigation may be deterring pharmaceutical companies from 
testing drugs in pregnant women in clinical trials.  
  
4b3. Fear of litigation about birth defects may be deterring the 
development of potential pharmaceutical interventions that address unmet 
medical needs of the population.   
  
4b4. Evaluating the safety of drug in pregnant women may increase a 
company's risk for litigation.  
  
4b5. The risk of litigation is considered to be higher in the post-marketing 
environment than in the clinical trial setting.  
 
5 
 
Aside from studies that are specifically about conditions of 
pregnancy, can you give me 3 or 4 reasons why a company (or an 
IRB) should or might want to include pregnant women in clinical 
trials? 
 
5a. Members of pharmaceutical companies, IRBs, PhRMA, and FDA, 
physicians, lawyers, and business people, agree that there are compelling 
reasons to conduct clinical trials in pregnant patients based on the need 
for information on how to treat them effectively. 
  
5b. Conducting trials on drug treatments for pregnant women is 
advantageous for the pregnant women, the health care providers, the 
prescribers, the FDA, the pharmaceutical company, and society in 
general. 
  
5c. Pregnant women are at a higher risk if clinical trials are not conducted 
than if they are conducted. 
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6 
 
If pregnant women were to be enrolled, how do you think we should 
do that? 
 
6a. We are already doing clinical trials in pregnant women. Building upon 
this experience, we can start evaluate many more drugs that are or will be 
used by pregnant women to treat their medical conditions. 
 6b. There are new advances being made to evaluate potential drug 
therapies in the preclinical area that will help to identify therapies that are 
appropriate for testing in pregnant women and to monitor the therapies 
being tested. 
  
6c. There are manageable ways to design studies that minimize risk to 
pregnant women, their pregnancies, and their fetuses. 
  
6d. Planning for drug testing in pregnant women should be part of the 
routine drug development process. Evaluation of the drug's use in 
pregnancy should continue after the drug is marketed and be ongoing 
through the lifetime of the product. 
 
7 
 
If pregnant women were enrolled, what steps could be taken to 
safeguard the fetuses and the pregnant women who consent to 
participate? 
 
7a. Data collection and analysis should be applied in an iterative fashion 
so that each pregnant patient entering a study should be benefit from the 
knowledge gained from every patient that has gone before her. 
  
7b. A pregnancy-specific independent data safety monitoring board 
should provide oversight and decision-making functions. 
 
8 
 
What would it take to have companies open (or IRBs approve) 
relevant clinical trials to pregnant women? Would a guidance 
document be strong enough or would it need to be by regulation? 
 
8a. The subjects in this study believe that it would take much work on the 
part of many stakeholders for pregnant women to participate in clinical 
research.  
  
8b. Most of the subjects believe that a guidance document from FDA on 
the topic of including pregnant women in clinical trials will increase 
awareness and discussion within and outside of the pharmaceutical 
companies, but that it may not be enough to cause a change in current 
practices.  
  
8c. Company indemnification should be included when considering all the 
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potential solutions to improving knowledge of pharmaceutical therapy for 
pregnant women. 
  
8d. Patent extensions and transferable extensions should be considered 
cautiously due to negative industry and public perception. 
  
8e. Stakeholders within and external to the pharmaceutical industry have 
suggestions on how to improve the inclusion of pregnant women in 
clinical research.  
 
9 
 
If not enrolling in clinical trials, what are alternative ways to get this 
information? A. Are there alternative study designs or data collection 
methods that could include pregnant women? B. Do you think a 
pharmaceutical company would support or fund this kind of 
research? 
 
9a. There are opportunities to improve our knowledge of the efficacy and 
safety of medication use in pregnancy in pre-clinical techniques and 
analysis, in inadvertent pregnancy exposures during clinical trials, and in 
post-marketing surveillance, pregnancy registries, and epidemiologic 
studies. Current methodologies could be improved and new 
methodologies should be explored. 
  
9b. Regulatory agency support would be helpful to these efforts including 
the release of the pregnancy labeling rule, the guidance on inclusion of 
pregnant women in clinical research, and agency recommendations on the 
analysis of pregnancy data. 
  
9c. Pharmaceutical support and funding for the collection and analysis of 
use-in-pregnancy data would be helped by an articulated medical and 
societal perception of need and by regulatory agency pressure.  
    
10 
 
One of the challenges in doing research with pregnant women is 
addressing the ethical issues it raises. What ethical problems do you 
think are most challenging or important? 
 
10a. Study participants cited ethical principles to both justify and 
condemn the exclusion of pregnant women from clinical research 
including non-maleficence, autonomy, and justice and suggested that 
feminist ethics might make a contribution to the topic. 
  
10b. Informed consent was considered to be an important issue on two 
counts: 1) that a pregnant woman has the opportunity to be given 
informed consent (distributive justice) and that the document is complete, 
honest, and comprehensible; and 2) that the fetus be considered to have an 
interest in the decision to participate in the study.  
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10c. The issue of including pregnant women in clinical research implicitly 
raises issues of fetal rights, abortion, and divergent perceptions of the 
fetus in society.  
  
10d. While most participants felt that pharmaceutical companies had a 
responsibility to provide safety information for products that would be 
used by pregnant women, many also acknowledged that business 
decisions might decide whether research in this area would be conducted. 
The attitude of senior management and regulatory agency guidance were 
recognized as factors that could influence the decision. 
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APPENDIX V 
 
The Plan for Change 
 
 
 
Plan # Goal Target Intervention 
1 
Increase awareness of the 
current practice of including 
pregnant women in, or excluding 
them from, clinical research 
Industry, 
Stakeholders, 
General Public 
Published paper on 
extent of exclusion in 
scientific literature 
2 
Increase awareness of the 'issue 
as a problem' among individuals 
in industry, IRBs, and industry 
associations 
Industry colleagues, 
Senior management 
White Paper to key 
informants, PhRMA and 
BIO; Conference 
presentations 
3 
Provision of potential solutions  
for industry consideration in 
guidance responses & internal 
policies 
Industry colleagues, 
Senior management 
White Paper to FDA, 
PhRMA, BIO, and 
companies 
4 Provision of potential solutions  
for companies' draft response 
Company 
colleagues & senior 
management 
Participate in drafting my 
company's response to 
FDA 
5 Industry perspective included in 
discussion of the issue 
FDA, Stakeholders, 
Public 
Present study findings at 
FDA hearing, if 
applicable 
6 Increased knowledge of issue in 
public domain 
Advocates, 
Academia, General 
public 
Additional publications 
and presentations 
7 
Personal influence on 
companies' internal deliberations 
on issue 
Company 
colleagues & senior 
management 
Continue involvement in 
issue at my company 
8 
Issue remains in public and 
professional consciousness; 
continued advocacy for 
increased evidence-based 
treatment for pregnant women 
Second Wave 
Consortium, 
PhRMA, other 
organizations 
Continue involvement in 
issue in other 
organizations 
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 1. Introduction 
The treatment of medical conditions complicating pregnancy is challenged by a serious lack 
of information about the safety and effectiveness of the medications used by pregnant 
women. To improve our knowledge of what constitutes the most effective therapeutic 
interventions, we conduct systematic research. Research for pregnant women, however, is 
challenging. One study found that, of 368 Phase IV studies in which pregnant women could 
appropriately participate (the drugs were in FDA pregnancy categories A, B, or C and the 
conditions being studied could occur during pregnancy), 94% excluded pregnant women 
from enrollment.(1) (See Addendum I.) Stakeholders like the Second Wave Consortiuma (2) 
are advocating for increased inclusion. In response, the U.S. Food and Drug Administration 
(FDA) will release a draft guidance in 2012 entitled, "Pregnant Women in Clinical Research: 
Scientific and Ethical Considerations." This white paper provides data from key informant 
interviews with industry researchers and lawyers, Institutional Review Board (IRB) 
members, and representatives from FDA and the industry association (the Pharmaceutical 
Research and Manufacturers of America [PhRMA]) (1)b, to assist industry as it prepares a 
considered response to the FDA's call for comment.  
 
2. Background 
In the U.S., more than a third of the 1.7 million women who give birth each year experience 
some type of adverse complication (3) and two women die every day from pregnancy-related 
causes.(4) To treat the morbidity, prevent the mortality, and achieve the optimal pregnancy 
outcome, over 60 percent of pregnant women are prescribed one or more drugs (5,6). 
Because pregnant women are largely excluded from participation in clinical research studies, 
                                                 
a The Second Wave Consortium is "a consortium of physicians, scientists, and bioethicists working to advocate 
for the importance of advancing the evidence base for the treatment of pregnant women facing serious illness." 
b Via key informant interviews, the study, conducted in 2011-2, sought to isolate the perspectives of industry 
and related organizations about pregnant women and clinical research. Participants included research, 
regulatory, and safety staff from pharmaceutical (n=5) and biotech (n=3) companies, legal counsel from 
industry (n=2), an IRB (n=1) and PhRMA (n=1), and other representatives from PhRMA (n=1), IRBs (n=2), 
and FDA (n=1).  
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the efficacy and safety of these medications when used during pregnancy are largely 
unknown.(7)  
 
The potential impact of a lack of data for drug efficacy during pregnancy is illustrated by the 
2002 recommendation by the American College of Obstetricians and Gynecologists (ACOG) 
of the use of amoxicillin by pregnant women for anthrax post-exposure prophylaxis. 
Subsequent study results, published in 2007, showed that the dosage regimen was ineffective 
for the treatment of pregnant and post-partum women.(8) No studies are available for 
ciprofloxacin or doxycycline, the alternative antibiotics. Women's health care providers 
lament that the "current evidence base for the care of pregnant women facing illness is 
widely regarded as deplorable."(9) 
 
The exclusion of pregnant women from participation in drug studies is widely accepted as the 
right thing to do. Thalidomide casts a long shadow.c Unless you are a pregnant woman with 
an illness or her health care provider, the consequences of the lack of research results are 
largely invisible.  
 
Interviews with key informants in industry, IRBs, PhRMA, and FDA found that the exclusion 
of pregnant women from clinical research is primarily based on the ethical principle of 
beneficence - the desire to avoid causing harm to a fetus. Even when the negative 
consequences are recognized, other motives for their exclusion may be difficult to overcome. 
These include the perceived risk of litigation, scientific validity issues, risks to drug approval 
and to company reputation, and the increased complexity of conducting such trials. The lack 
of advocacy for their inclusion, the lack of a regulatory requirement or recommendation, and 
historic precedent are other rationales.  
 
The FDA (10), the Institute of Medicine (11), the Council for International Organizations of 
Medical Sciences (CIOMS) (12), and ACOG (13) recommend the inclusion of pregnant 
                                                 
c In the late 1950s and 1960s, women around the world were prescribed thalidomide to prevent miscarriage, for 
hyperemesis, and for sedation. It took several years, and over 10,000 cases of severe limb defects (phocomelia), 
before its teratogenic properties were recognized.  
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women in research when the benefits outweigh the risks. These recommendations and an 
increase in requests to review clinical protocols that included pregnant women, spurred 
FDA's development of the guidance document. "Pregnant Women in Clinical Research: 
Scientific and Ethical Considerations"(14) is currently in review at the agency and slated for 
release in 2012. It will challenge the industry to increase its inclusion of pregnant women in 
clinical research studies. This White Paper presents research results to inform industry of the 
anticipated recommendations and potential responses to the call for comment following the 
release of the guidance.  
 
3. Anticipated content of the draft guidance 
It is anticipated that the FDA draft guidance will present the following rationale for the 
increased inclusion of pregnant women in clinical research (1,15): 
 
Why should pregnant women be included in clinical research?  
• Controlled studies provide evidence-based guidance on treatment options for application 
in medically compromised pregnancies. 
• The supervision of the patient and the quality of the data acquired in rigorous controlled 
studies is superior to that received in the post-marketing environment. 
• Safety and efficacy information will be obtained sooner and with fewer pregnant women 
and fetuses exposed than if the drug information is obtained following its release on the 
market (recognizing, as with all drugs, that some objectives cannot be met until 
widespread use occurs). 
 
When should pregnant women participate in clinical research? 
When their exclusion cannot be justified by scientific rationale: 
o When participation in a study provides therapeutic benefit and the anticipated benefits 
exceed the anticipated risks 
o When there is medical need to treat a particular pregnant woman or pregnant women in 
general and there is reliable information from animal testing or human experience on the 
teratogenic and developmental risks of the proposed treatment 
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 It is anticipated that the FDA draft guidance will present the following recommendations for 
the increased inclusion of pregnant women in clinical research:  
 
Where in drug development should research include pregnant women? 
• Clinical environment:  
o Pharmacokinetic (PK) testing 
o End of Phase III studies designed to include pregnant women 
• Post-marketing:  
o Phase IV clinical studies designed for pregnant women  
o Enhanced surveillance: pregnancy exposure registries for active surveillance, cohort 
and case control studies for signal evaluation 
 
What pregnant women should be included in clinical research? 
• Pregnant women in need of treatment (whether for pregnancy-related conditions or 
unrelated illness) can be enrolled: 
o in studies that potentially provide therapeutic benefit and whose potential benefits 
exceed the potential risks 
o in studies designed to evaluate safety and/or efficacy during pregnancy  
o in general clinical trials on a compassionate use basis after individual consideration of 
risk/benefit and re-consent 
• Pregnant women already taking approved medications in the post-marketing environment 
• Women who become pregnant during a clinical trial who desire to remain in the study 
after individual consideration of risk/benefit and re-consent 
o Factors for consideration include the risk to the pregnant woman and her fetus from 
continuation of therapy, discontinuation of therapy, and the effectiveness and risks of 
alternative therapies (including risk of fetal exposure to the experimental and the 
alternative therapy).  
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4. Considerations for industry response to FDA draft 
guidance  
When engaged in dialogue on this issue, individuals within pharmaceutical companies and 
IRBs, including their legal counsel, recognized the unintended adverse consequences of 
pregnant women's exclusion from clinical research. While understanding the need for change 
from the current practice of general exclusion, they cautioned that change would be difficult 
and probably incremental (1). Via the key informant interviews, experts on clinical trial 
design and conduct identified barriers to inclusion and provided potential solutions to the 
concerns. These are presented in Table 1 and are further discussed below. 
 
Table 1. Concerns and Solutions identified by Industry Informants 
Key Concerns Key Potential Solutions 
Causing harm to the fetus;   
Scientific concerns 
Study design; scientific advances in modeling and animal 
testing; end of Phase III and post-marketing studies 
Litigation Guidance/regulation; informed consent; indemnification; improved awareness of issue in public domain 
Enrollment concerns PK testing on small numbers; partnerships with OPRU* and obstetrical community, data from multiple sources 
Negative impact on initial approval Post-approval studies 
Lack of regulatory agency support, 
unclear regulations FDA guidance document, international harmonization 
Business concerns Define market; conduct post-approval studies; devise incentives and protections 
Lack of experience and know-how Collaboration, best practices, innovation, science 
*see pg 8 for description of OPRUs 
 
Attitudes towards inclusion: 
• Change from the widespread practice of excluding pregnant women from clinical 
research studies will call for regulatory directives, financial incentives, and legal 
protections.  
• Pharmaceutical companies have a responsibility to provide efficacy and safety 
information for products intended for women of childbearing potential. Prioritizing 
studies for pregnant women by those conditions and drug classes where the need is 
greatest may facilitate acceptance and target resources to where they are needed the most.  
• Consideration of the need for drug testing in pregnant women should be part of routine 
drug development for all new molecular entities.  
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• Evaluation of all products' effects on pregnancy should continue after the drugs are 
marketed and be ongoing through the lifetime of the product. 
 
Clinical concerns: Efficacy and Safety 
• Clinical studies can be designed to minimize risk. Build on the experience we have 
gained from prior studies in pregnant women, e.g., studies in HIV transmission, to plan 
future studies. 
• Data collection and analysis should be applied in an iterative fashion so that each 
pregnant patient entering a study should benefit from the knowledge gained from every 
patient that has gone before her. 
• All pregnancies that occur during clinical trials should be followed to outcome. 
• Consider retaining women who inadvertently become pregnant during clinical trials 
following an individual benefit/risk assessment and re-consent. Consider the risk of the 
exposure vs. the benefit of the treatment, the risk of discontinuing treatment, the efficacy 
and safety - including fetal exposure – of the alternative treatments.  
 
Efficacy 
• Key informants recommended that a treatment's efficacy should be confirmed by 
completing clinical trials in men and non-pregnant women before initiating testing in 
pregnant women.   
• Proper dosing for pregnant women can only be gained by conducting PK testing in 
pregnant women. Such testing can be done on small numbers of women, and could be 
done with pregnant women who are already taking the approved medication in post-
approval studies.  
• Since 2004, four Obstetric-Fetal Pharmacology Research Units (OPRUs) have been 
receiving government funding to conduct pharmacology studies on pregnant women "to 
enhance understanding of obstetrical pharmacokinetics and pharmacodynamics, and 
improve appropriate therapeutics during pregnancy"(16). Pregnancy-induced changes in 
PK and PD have been documented (16). Sponsors should partner with the OPRUs to 
conduct studies that determine correct dosing for pregnant women.  
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 Safety 
• We can improve our knowledge of the safety of medication in pregnancy by innovation 
in pre-clinical techniques and analysis, by systematic learning from inadvertent 
pregnancy exposures during clinical trials, in planned trials for pregnant women, and 
in post-marketing surveillance, pregnancy registries, and epidemiologic studies.  
• Some knowledge of a drug's safety in pregnancy can be obtained from doing careful 
testing in animals. Acknowledging the need to be extremely cautious, it is important to 
note that the majority of drugs are not teratogenic, and all but oned of the drugs known to 
be teratogenic in humans are teratogenic in animals as well (17). Current advances in 
drug modeling, Phase 0 testing, and advancements in animal testing are innovations 
being made by pre-clinical scientists.  
• Once efficacy in non-pregnant subjects and PK parameters in pregnant women have been 
established, studies can be designed specifically for the enrollment of pregnant women in 
late Phase III and Phase IV.   
 
For FDA consideration: If the potential therapeutic benefit to the pregnant woman 
(and fetus) exceeds the risk of including her in a clinical study, then there is no scientific 
justification for her exclusion. At what point does the agency consider that the Sponsor 
has 'enough' pre-clinical and clinical data to perform a benefit/risk assessment? What 
constitutes adequate data? Is there agency guidance on the evaluation of pregnancy 
exposure data on this point? The establishment of best practices for data collection and 
evaluation can provide standardization, improved knowledge, and protection from 
litigation. 
 
 
 
                                                 
d Misoprostol is the exception. 
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Company Oversight 
• Companies should have internal women's health committees composed of subject 
matter experts within the company to consult on pregnancy-related issues – in study 
design and planning, in policy making on inclusion and retention in trials, in post-
approval activities and Risk Evaluation and Mitigation Strategies. 
• An independent pregnancy-specific data safety monitoring board should provide 
oversight and decision-making functions for open trials, similar to other organ-specific 
DSMBs. 
 
Business concerns 
Aside from safety issues, valid business concerns must be recognized and addressed before 
change can be considered. These include: the additional time and financial costs with little 
return on investment, potential delays and threats to product approval, litigation risks – 
both financial and reputational.  
• Business decisions will influence whether research for pregnant women will be 
conducted. The attitude of senior management and regulatory agency guidance are 
recognized as factors that will influence the inclusion/exclusion decision. 
• Business analyses would be helpful to define the market for pharmaceutical use in 
pregnant women 
• To avoid delayed initial approval and access to products with established therapeutic 
benefit for the general population, consider the conduct post-approval studies in 
pregnant women. 
 
Litigation 
• There is no evidence that suggests that designing clinical trials for pregnant women will 
increase the risk of litigation against the company (though experience is limited).  
• There is evidence that discovering teratogenicity post-marketing in therapies not 
evaluated during development raises the risk for litigation (18). 
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• Sponsors should not be punished for following best practices to ascertain if a product is 
teratogenic. The financial and reputational costs of a product that has been inaccurately 
branded teratogenic, e.g., Bendectin,e (19,20) can be substantial. Therefore, best 
practices should be defined and standardized and company indemnification should be 
considered as protections against litigation. (See further discussion of indemnification in 
Addendum II.) 
 
For PhRMA consideration: Consider sponsoring the collection of additional data that 
would be helpful to industry to inform its response to the draft guidance including: 
o Market analysis – what are the expected financial returns – or lack thereof – for 
the approved or off-label use of a product during pregnancy? What are the 
expected costs of conducting additional clinical trials for pregnant women? While 
financial considerations may not be the deciding factors in the decision to conduct 
such studies, the associated costs must be factored into the total research costs of a 
product in development.  
o Legal analysis on the risk of increased litigation if pregnant women are:  
o retained in clinical trials in which they inadvertently became pregnant  
o included in clinical trials designed for testing in pregnancy during 
development (late Phase III) or in the post-marketing environment 
o Legal opinion on potential protections to prevent litigation in clinical and post-
marketing environment, including indemnification. 
 
 
 
 
                                                 
e Bendectin, a combination of vitamin B6 and an antihistamine, which are both available over the counter as 
separate medications, was approved and is effective for the treatment of nausea and vomiting during pregnancy. 
Despite having been extensively studied in animal, clinical, and epidemiologic studies with no findings of 
measureable risk to the developing fetus, the product was withdrawn from the market in 1983 due solely to the 
burdens of litigation. The product remains on the market in the UK and Canada where it is widely used. 
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Regulatory 
A guidance document from FDA on the topic of including pregnant women in clinical trials 
will increase awareness and discussion within and outside of the pharmaceutical companies, 
but it may not be enough to cause a change in current practices. 
• Regulatory agency measures that would promote change include: 
o the release of the Pregnancy Labeling Rule which will enhance the 
communication of use-in-pregnancy information in the product label  
o the release of the draft guidance on Pregnant Women in Clinical Research 
o agency recommendations on the standardized analysis of pregnancy exposure 
data 
• The ability for Sponsors to access FDA reviewers to discuss study design options and 
obtain agency advice was cited as an obstacle to drug development. Communication 
between FDA reviewers and company representatives needs to be substantially improved 
in order to facilitate the planning and conduct of studies in pregnant women. Without 
communication, the voluntary conduct of such studies will be negatively impacted.  
• International harmonization with CIOMS and the International Committee on 
Harmonization would assist global standardization in the current environment where 
many clinical studies are multinational. 
 
Incentives and Protections 
• Patent protections (including transferable extensions), while helpful, should be 
considered but caution should be exercised due to poor industry experience with their 
value and negative public and political perceptions. 
• Would a drug's indication for use in pregnancy, due to the small market, qualify the 
product for orphan drug status? The number of pregnant women being treated for many 
conditions may be <200,000. 
• Consider tax incentives, research subsidies, partnerships with government bodies (e.g., 
NIH, OPRU sites), grants, etc. 
• Consider fast track review for New Drug Applications that include plans for studies in 
pregnancy 
[See Addendum II for commentary on company indemnification.] 
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5. Proposed Industry Response to FDA draft guidance  
 
Proposed recommendations from industry key informants to the FDA "Call for Comment” on 
its draft guidance, "Pregnant Women in Clinical Studies: Scientific and Ethical 
Considerations": 
 
Pharmaceutical companies should consider:  
• Participating in dialogue with stakeholders about increasing the inclusion of pregnant 
women in clinical studies. 
• Designing studies for pregnant women, on an individual product basis, including PK 
studies, pre- and post-approval safety and efficacy studies, pregnancy registries, and other 
methodologies to improve its contribution to best practices for the treatment of pregnant 
women with medically compromised pregnancies. 
• Establishing a policy for including pregnant women in clinical development and post-
marketing studies, and retaining women who inadvertently become pregnant in clinical 
studies if the benefits outweigh the risks and the woman requests and consents to 
continue to participate. 
 
PhRMA should consider: 
• Producing a position paper for industry on the inclusion of pregnant women in clinical 
research. 
• Convening a maternal health working group to consider recommendations for the 
expansion of the inclusion of pregnant women in clinical research. 
• Sponsoring legal and market analyses to inform deliberations on the topic. 
 
6. Proposed FDA actions to support industry's enrollment 
of pregnant women in clinical research 
 
Proposed recommendations from industry key informants to the FDA on its draft guidance, 
"Pregnant Women in Clinical Studies: Scientific and Ethical Considerations": 
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 FDA should consider:  
• Identifying diseases and drug classes that are a priority for drug testing for pregnant 
women; prioritizing these disease and drug categories for studies in pregnant women so 
that resources can be targeted efficiently.  
• Defining the conditions under which Sponsors should consider studies for pregnant 
women, e.g., prevalence of the condition in pregnancy, risk of no or delayed treatment, 
safety and efficacy data available for alternative treatments, etc. 
• Providing a list of considerations that would result in the exclusion of pregnant women, 
e.g. evidence of teratogenicity in preclinical studies or human exposures, conditions that 
would never or rarely occur in pregnant women, treatment of the condition could usually 
be postponed until the conclusion of the pregnancy, etc. 
• Defining the considerations that would support the inclusion of pregnant women in 
clinical studies, e.g., when the benefit outweighs the risk, when there is no evidence of 
teratogenicity in preclinical studies or human exposures, the condition commonly (define 
commonly) occurs in pregnant women and its treatment should not be postponed, etc. 
• Developing an efficient process within the agency for individual review of New Drug 
Applications (NDAs) as to whether they should or should not include testing in pregnant 
women (i.e., do not recommend testing in pregnant women solely by indication and drug 
class). 
• Identifying potential company incentives for the design and implementation of studies 
that include pregnant women. Consider: 
o Fast track review for NDAs that include plans for studies in pregnancy 
o Providing financial incentives to offset costs (patent protections, tax incentives, 
orphan drug status, research subsidization, new incentives)  
o Partnerships with NIH, CDC, OPRUs, and others to conduct studies in pregnancy 
• Recommending that generic companies, where applicable, participate in and contribute to 
the costs of research on marketed, off-patent products used by pregnant women. 
Future Steps 
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Dialogue and Communication 
PhRMA, and FDA, and Industry should consider sponsoring a series of workshops to bring 
together key stakeholders, including the Second Wave Consortium (2), professional 
associations like ACOG and the March of Dimes, women's health advocates, etc., to share 
concerns, discuss issues, and generate and evaluate potential solutions. Understanding each 
other's genuine concerns and the guidance's potential impacts will be key to finding 
solutions. The realization of a comprehensive guidance document that addresses 
stakeholders' perceptions and concerns and results in acceptance of the outcome will rely 
upon dialogue, negotiation, and cooperation. 
 
Evaluation  
The three major stakeholders, PhRMA, industry, and FDA, will need to monitor and evaluate 
the impact of the final guidance on the inclusion of pregnant women in clinical research.  
• The evaluation of the guidance's impact on the inclusion of pregnant women in clinical 
research would be indicated by the actual increase in proportion of clinical trials that a) 
do not exclude pregnant women and b) those that are designed specifically for enrollment 
of pregnant women.  
• The evaluation of impact on treatment of pregnant women would be indicated by an 
increased proportion of drug labels that include evidence-based recommendations for use 
in pregnancy and by case reports or surveys of practical experience in obstetrical practice. 
Labeling changes would include information specific to use during pregnancy including: 
pregnancy indications, dosing changes in pregnancy, pharmacokinetic information, and 
new safety information.  
• The financial costs to industry – the costs of conducting the trials, related infrastructure 
and administration, delays in approvals, experience with litigation, etc., – and their offset 
by the financial impact of any implemented incentives. These will be more difficult to 
measure.  
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Benchmarking / Best Practices 
As the practice of including pregnant women in clinical studies will be new to the research 
community, benchmarking and sharing of best practices will be vital to the continuing 
improvement of clinical research practices involving pregnant women. Sharing lessons 
learned by experience would be facilitated by ongoing participation and monitoring by the 
proposed PhRMA committee on maternal health.  
 
7. Limitations 
Rarely occurring adverse effects, including birth defects, may not be identifiable until a large 
number of people have taken the drug. Safety surveillance compliments clinical research data 
and needs to continue throughout the life-cycle of all products. 
 
Concern has been raised that it may not be possible to enroll enough pregnant women to 
achieve statistical significance. Because pregnant women have been routinely excluded from 
clinical studies we do not know to what extent they might volunteer to participate. Pregnant 
women could only be invited to participate if they are in need of treatment, if the study would 
potentially provide therapeutic benefit, and if the potential benefits exceeded the potential 
risks. In this way, their treatment in a research study would be similar to their treatment in 
clinical practice - with the added benefit of improved informed consent, enhanced pregnancy 
monitoring, and the knowledge that she has contributed her experience to the accumulated 
medical knowledge base to assist other pregnant women. Currently, evidence from pregnant 
women treated in clinical practice is rarely captured at all. One small study found that 95% of 
pregnant women interviewed said that they would participate "if there is a chance that 
participation in a clinical trial would help their pregnancy and improve their baby's 
health."(21) Further research is needed to confirm or refute this finding. 
 
8. Conclusion 
Women's health advocates, medical experts, and key informants within industry and related 
organizations believe that pregnant women and their fetuses are at a higher risk of adverse 
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medical consequences if they are not included in clinical trials than if they are included in 
clinical trials.(1,9,11-13) They believe that conducting trials on drug treatment for pregnant 
women, while ethically, legally, and operationally challenging, is morally required and will 
be advantageous to pregnant women and their fetuses, their health care providers and 
prescribers, and society in general. By issuing the draft guidance on the inclusion of pregnant 
women in clinical research, FDA is challenging industry to confront assumptions and past 
practices and address the obstacles that prevent effective, evidence-based treatment for 
pregnant women and the fetuses they carry.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note on the Author: 
Kristine Shields MSN, DrPH is an OB/GYN Nurse Practitioner with a doctorate in Public 
Health Administration. She joined the industry in 1998 where she developed and managed a 
pharmaceutical company's Pregnancy Registry Program for 12 years. She is currently an 
Ethics Officer at the company. 
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White Paper Addendum I 
Quantitative Study Findings 
 
Results of a study designed to ascertain the proportion of clinical trials that excluded 
pregnant women by reviewing the inclusion and exclusion criteria of all U.S.-based, 
industry-sponsored Phase IV studies enrolling women of childbearing potential posted on 
www.ClinicalTrials.gov between October 1, 2011 and January 31, 2012.f  
 
Number of studies available for review on ClinicalTrials.gov between 01Oct2012 and 
31Jan2012 and their enrollment of pregnant women. 
555 
Studies 
Potentially 
include 
Appropriately 
excluded* 
84  
No Response 
65 
Responded 
46 
Excluded 
     301 
Excluded 
19 
Not 
Excluded 
452   98 
2 
Not 
Excluded  
149 
Unknown^ 
Enrollment limited 
to pregnant  
women
  5 
Confirmed criteria  =  368 studies 
Total excluding  =       347 (94%) 
Total not excluding  =    21 (6%) 
* Pregnant women were excluded because the drug was in FDA Category D or X, or the 
age or topic (menopause, contraception, lactation) prohibited pregnancy.  
^Study coordinators were contacted if enrollment criteria posted did not address pregnancy. 
                                                 
f Shields K. Dissertation: The participation of pregnant women in clinical research: Implications for practice 
within the U.S. pharmaceutical industry; 2012. Chapel Hill, NC: University of North Carolina Gillings 
School of Public Health. 
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White Paper Addendum II 
Company Indemnification 
 
While many of the study participants were doubtful that indemnification was a real 
possibility, several of the pharmaceutical company and IRB participants recommended 
not dismissing the concept of company indemnification outright.  They thought that the 
concept should be included when considering all the potential solutions to improving 
knowledge of pharmaceutical therapy for pregnant women. 
 
Pharmaceutical industry concern about both the cost and the potential harm to a product and 
to a Company's reputation is a legitimate barrier to the implementation of efforts to 
increase the enrollment of pregnant women in clinical research. The following four points 
should be considered: 
• The President's Commission for the Study of Bioethical Issue's recommendation of a 
national compensation system,(22) which states that "Because subjects harmed in the 
course of human research should not individually bear the costs of care required to treat 
harms resulting directly from that research, the federal government, through the Office of 
Science and Technology or the Department of Health and Human Services, should move 
expeditiously to study the issue of research-related injuries to determine if there is a need 
for a national system of compensation or treatment for research-related injuries." 
• One of the conclusions of the 2000 University of Texas Medical Branch conference held 
"to address the national problem of underrepresentation of pregnant women in clinical 
trials" was that "[t]here should be a nationally supported mechanism to protect 
private sponsors and industry from excessive or inordinate liability claims and to 
develop incentives to promote industry-supported research on this population."(23) 
• The success of the Vaccine Injury Compensation Program, and  
• The potential for industry-sponsored group insurance. 
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For FDA and PhRMA consideration: Consider an agency-industry-legal working 
group to explore the feasibility of indemnification. The adoption of the practice of 
designing and conducting studies for pregnant women may rest on the outcome of this 
question. Jury awards for children with birth defects and developmental disabilities – 
rightly or wrongly attributed to drug exposure – can be severe. Litigation costs can 
remove effective products from the market (e.g., Bendectin). Potential break-through 
medications are removed in early development due to this concern. Improvement in 
maternal health and positive pregnancy outcomes relies upon accurate knowledge of the 
safety and efficacy of treatment options during pregnancy. Systematic research is required 
to obtain this knowledge but litigation may prevent it. 
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